



City Research Online

City, University of London Institutional Repository

Citation: Sehmi, R., Smith, N., Nguyen, A. and McManus, S. ORCID: 0000-0003-2711-0819 (2019). Trends in long-term prescribing of dependence forming medicines. London, UK: PHRC/NatCen.

This is the published version of the paper.

This version of the publication may differ from the final published version.

Permanent repository link: <https://openaccess.city.ac.uk/id/eprint/23651/>

Link to published version:

Copyright and reuse: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

City Research Online:

<http://openaccess.city.ac.uk/>

publications@city.ac.uk

NatCen

Social Research that works for society

Trends in long-term prescribing of dependence forming medicines





Public Health Research Consortium

Sehmi R, Nguyen A, McManus S, Smith N. (2019) *Trends in long-term prescribing of dependence forming medicines*. London: PHRC/NatCen.

This is independent research commissioned and funded by the National Institute for Health Research (NIHR) Policy Research Programme (PHPEHF50/14). The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care or its arm's length bodies, or other Government Departments. Information about the wider programme of the Public Health Research Consortium (PHRC) is available from <http://phrc.lshtm.ac.uk/>. Study summary available at: www.natcen.ac.uk/dependence

Cover image by Rosie Rodgers.



NatCen Social Research
35 Northampton Square
London EC1V 0AX
T 020 7250 1866
www.natcen.ac.uk

A Company Limited by Guarantee
Registered in England No.4392418
A Charity registered in England and Wales (1091768) and Scotland (SC038454)
This project was carried out in compliance with ISO20252.

Contents

Executive summary	1
1 Introduction	14
1.1 Background.....	14
1.2 New analyses in this report.....	14
1.3 Objectives	15
2 Methods	17
2.1 Data extraction.....	17
2.2 Estimating length of individual prescriptions	17
2.3 Estimating length of continuous prescribing periods.....	17
2.4 Base population	18
2.5 Analysis	18
2.6 Exclusion criteria.....	19
2.7 Missing data.....	19
2.8 Over-the-counter sales	19
3 Trends in DFM prescribing	20
3.1 Proportion of people prescribed to	20
3.2 Mean average length of prescribing.....	20
3.3 Prescriptions exceeding thresholds	20
3.4 Continuous prescribing periods exceeding thresholds.....	21
3.4.1 Benzodiazepines	22
3.4.2 Z-drugs.....	23
3.4.3 Opioids	24
3.4.4 GABAergic medicines.....	25
4 Trends in gabapentin and pregabalin prescribing	26
4.1 Items prescribed in England 2008-2018	26
4.2 Average length of prescriptions and continuous prescribing periods	26
4.3 Prescriptions exceeding thresholds	28
4.4 Continuous prescribing periods exceeding thresholds.....	29
4.4.1 Gabapentin.....	29
4.4.2 Pregabalin	30
5 Characteristics associated with DFM prescribing in excess of 6 months	31
5.1 Variation in continuous prescribing by age-group	31

5.1.1 Benzodiazepines	31
5.1.2 Z-drugs	32
5.1.3 Opioids	32
5.1.4 GABAergic medicines	33
5.2 Variation in continuous prescribing by gender	34
5.3 Variation in continuous prescribing by area level deprivation	34
5.4 Characteristics associated with long-term prescribing in 2014	36
5.4.1 Gender variations in long-term prescribing	36
5.4.2 Age-group variations in long-term prescribing	36
5.4.3 Area level deprivation variations in long-term prescribing	36
5.4.4 Regional variations in long-term prescribing	36
6 Characteristics associated with gabapentin and pregabalin prescribing in excess of 6 months	41
6.1 Variation in continuous prescribing by age-group	41
6.2 Variation in continuous prescribing by gender	42
6.3 Variation in continuous prescribing by area level deprivation	42
6.4 Characteristics associated with long-term prescribing in 2014	44
6.4.1 Gender variations in long-term prescribing	44
6.4.2 Age-group variations in long-term prescribing	44
6.4.3 Area level deprivation variations in long-term prescribing	44
6.4.4 Regional variations in long-term prescribing	44
7 Time trends in sales of codeine- and dihydrocodeine-containing medications	47
8 Conclusions	48
9 References	49
Appendix A. Data tables	51
Appendix B. Evaluation of published estimates of dependence on prescribed medicine	91
Appendix C. Estimating the minimum proportion of the population prescribed DFM long-term in 2014	95
Appendix D. Clinical Practice Research Datalink	96
Appendix E. Medicines included in the analysis	100

Figures

Figure 1: Proportion of prescriptions exceeding 30 days by DFM type	21
Figure 2: Benzodiazepines: Proportion of continuous prescribing periods exceeding thresholds	22
Figure 3: Benzodiazepines: Proportion of continuous prescribing periods exceeding 6 and 12 months	22
Figure 4: Z-drugs: Proportion of continuous prescribing periods exceeding thresholds.....	23
Figure 5: Z-drugs: Proportion of continuous prescribing periods exceeding 6 and 12 months.....	23
Figure 6: Opioids: Proportion of continuous prescribing periods exceeding thresholds.....	24
Figure 7: Opioids: Proportion of continuous prescribing periods exceeding 6 and 12 months.....	24
Figure 8: GABAergic medicines: Proportion of continuous prescribing periods exceeding thresholds	25
Figure 9: GABAergic medicines: Proportion of continuous prescribing periods exceeding 6 and 12 months	25
Figure 10: Number of GABAergic medicine items dispensed in 2008-2018.....	26
Figure 11: Average number of days of prescriptions by GABAergic medicine type	27
Figure 12: Average number of days of continuous prescribing periods by GABAergic medicine type.....	27
Figure 13: Proportion of prescriptions exceeding 30 days by GABAergic medicine type	28
Figure 14: Gabapentin: Proportion of continuous prescribing periods exceeding thresholds.....	29
Figure 15: Pregabalin: Proportion of continuous prescribing periods exceeding thresholds.....	30
Figure 16: Pregabalin: Proportion of continuous prescribing periods exceeding 6 and 12 months.....	30
Figure 17: Benzodiazepines: Proportion to exceed continuous prescribing threshold of 6 months, by age	31
Figure 18: Z-drug: Proportion to exceed continuous prescribing threshold of 6 months, by age.....	32
Figure 19: Opioid: Proportion to exceed continuous prescribing threshold of 6 months, by age.....	33

Figure 20: GABAergic medicines: Proportion to exceed continuous prescribing threshold of 6 months, by age	33
Figure 21: Proportion of continuous prescribing periods to exceed 6 months among people prescribed DFM and living in the least (Q1) and most (Q5) deprived areas.....	34
Figure 22: Gabapentin: Proportion of continuous prescribing periods to exceed 6 months, by age.....	41
Figure 23: Pregabalin: Proportion of continuous prescribing periods to exceed 6 months, by age.....	42
Figure 24: Proportion of continuous prescribing periods to exceed 6 months among people prescribed gabapentin living in the least (Q1) and most (Q5) deprived areas.....	43
Figure 25: Proportion of continuous prescribing periods exceeding 6 months among people prescribed pregabalin living in the least (Q1) and most (Q5) deprived areas.....	43
Figure 26: Total counts of individual codeine and dihydrocodeine-containing medicines	47

Tables

Table 1: Characteristics of people prescribed benzodiazepines in excess of 6 months and in excess of 12 months, 2014	37
Table 2: Characteristics of people prescribed Z-drugs in excess of 6 months and in excess of 12 months, 2014.....	38
Table 3: Characteristics of people prescribed opioids in excess of 6 months and in excess of 12 months, 2014.....	39
Table 4: Characteristics of people prescribed GABAergic medicines in excess of 6 months and in excess of 12 months, 2014	40
Table 5: Characteristics of people prescribed gabapentin in excess of 6 months and in excess of 12 months, 2014.....	45
Table 6: Characteristics of people prescribed pregabalin in excess of 6 months and in excess of 12 months, 2014.....	46
Table 7: Minimum proportion of the population exceeding DFM continuous prescribing periods in 2014, by length (%)	95
Table A.1: Geographical distribution of patients	98

Executive summary

Concerns about long-term prescribing

There has been concern about levels of prescribing of medicines with the potential to create dependence (BMA, 2015). Most research on trends in the prevalence of prescribing has been based on volume of medicines prescribed. One such study identified that increases in opioid prescribing have been most pronounced for stronger opioids (Curtis et al., 2018).

It is also important, however, to use patient-level data so that the proportion of the population prescribed to, their individual characteristics, and the length of time medicines are prescribed for can be examined (McManus, 2018). While short-term use of potentially dependence forming medicines (DFM) may be clinically appropriate, long-term use - especially for the management of chronic pain - is generally not (FPM, 2019).

Commissioning of the 2017 report

This need to understand trends in long-term DFM prescribing prompted the Department of Health and Social Care (DHSC) to commission an analysis of primary care data at the patient-level. An extract from the Clinical Practice Research Datalink (CPRD; Herrett et al., 2015) was examined to produce trends in the proportion of people prescribed DFM and to calculate the length of continuous prescribing periods.

Continuous prescribing periods here refers to the length of an initial individual prescription, combined with the length of any repeat prescriptions within a particular time frame. The results were published in a report: [*Prescribing Patterns in Dependence Forming Medicines*](#) (Cartagena Farias et al., 2017).¹

Key findings from the 2017 report

The 2017 analysis showed that the proportion of patients prescribed at least one of four types of DFM increased in England from 6.3% in 2000 to 9.5% in 2015. Benzodiazepines were the only type examined to see a reduction in prescribing. The other types all at least doubled in the proportion of the population prescribed to.

The report also showed that the mean number of days that DFM were continuously prescribed for increased. In particular, the length of opioid continuous prescribing periods nearly doubled, from 64 days in 2000 to a peak of 102 days in 2013/2014. In 2015, over half of prescribing periods for GABAergic medicines exceeded 30 days, as did around a third of benzodiazepine, opioid and Z drug prescribing periods.

¹ The full report includes a research of research, detailed CPRD methodology, and can be downloaded here: http://phrc.lshtm.ac.uk/papers/PHRC_014_Final_Report.pdf

The current report builds on and extends the previous analyses

- While the previous report focused on prescribing periods exceeding 30 days, this report presents trends for three thresholds: 30 days, 6 months and 12 months. This addresses a critical gap in knowledge about the extent of very long-term DFM prescribing in England.
- In the previous report people with an epilepsy or cancer diagnosis were analysed separately. In the current analysis those who had ever been diagnosed with cancer were excluded from the sample for opioid prescribing trends only, and those who had ever been diagnosed with epilepsy were excluded for trends in GABAergic medicines only.
- The current analyses additionally examine two individual medicines: gabapentin and pregabalin. It is important to consider trends in these separately as pregabalin was not introduced to the market until 2004.
- This report also includes trends in the volume of sales of over-the-counter (OTC) medicinal products containing codeine and dihydrocodeine (2015-2018).

Aims

- Estimate the proportion of individual prescriptions for each type of DFM to exceed 30 days, 6 months and 12 months each year, 2000 to 2015.
- Estimate the proportion of continuous prescribing periods for each type of DFM to exceed 30 days, 6 months and 12 months each year, 2000 to 2015.
- Compare the demographic and area-level characteristics of people prescribed DFM short- and long-term.
- Explore time trends in sales of OTC medicine products containing codeine and dihydrocodeine, 2015 to 2018.
- Review some published estimates of the number of people in England prescribed DFM long term.

The estimates in this report draw on a relatively small data extract, the descriptive trend lines presented should not be viewed as definitive or exhaustive. This analysis is one of several studies taking place on related topics. Public Health England (PHE) have conducted a fuller review of the evidence, including detailed analyses of other data sources (Tayler et al., 2019).

Methods

The current study reanalysed the same CPRD data extract. The extract consists of a sample of patients prescribed at least one of the four types of DFM between 2000 and 2015. The CPRD contains information about individual prescriptions issued by GPs (including the specific product and number of tablets prescribed) and about the patients prescribed to (such as age, sex, and area).

The length of individual prescriptions was calculated. The length of continuous prescribing periods was estimated by combining the length of the initial prescription with that of all repeat prescriptions for a medicine of the same DFM type within a relatively short period. The estimates presented should be considered conservative. A range of approaches can be used to estimate what proportion of prescribing periods exceeded particular thresholds. The approach taken in this report was to calculate the prevalence of long-term prescribing in all prescribing periods occurring in a given year. This is ideal for understanding temporal trends, maximises the relatively small sample, and is consistent with the approach taken in the previous report.

Time trends for longer-term prescribing periods (6 months or more) are presented for 2001 to 2014. This is because prescribing at the start (2000) and end (2015) of the CPRD data extract period may not fully capture the completed period of continuous prescribing. Data on over the counter (OTC) sales of codeine and dihydrocodeine-containing medicines were acquired from IRI Group Ltd.

Definitions

The following definitions are used in this report:

- **Prescriptions:** individual prescriptions not linked at the patient level.
- **Continuous prescribing periods:** a series of one or more prescriptions (an initial prescription combined with all repeat prescriptions) making up a continuous episode of prescribing.


Key findings

Patterns for the proportions of prescriptions and prescribing periods exceeding 30 days were broadly consistent with the previous report, they are summarised here for completeness. The more nuanced sample inclusion criteria (relating to those with a cancer or epilepsy diagnosis) had relatively minimal effects on the results.

Trends in length of individual prescriptions


A downward trend has been evident for benzodiazepines and - since 2004 - for GABAergic medicines in the proportion of individual prescriptions to exceed 30 days. The rate has been more stable for opioids and Z drugs. As expected, individual prescriptions exceeding 6 months were too rare for trends to be reliably examined with this data extract.

Proportion of individual prescriptions to exceed 30 days, by DFM type



When the two main GABAergic medicines were examined separately, we can see that the overall fall in 2004 in the proportion of prescriptions exceeding 30 days was due to the introduction of pregabalin in that year. The proportion of pregabalin prescriptions to exceed 30 days has remained about half the rate for gabapentin. Trends for GABAergic medicines as a whole are likely to reflect changes in how much of the total prescribing was for pregabalin and how much was for gabapentin widely prescribed (Montastruc et al., 2018).

Proportion of individual prescriptions to exceed 30 days, gabapentin and pregabalin




Trends in length of continuous prescribing periods

Benzodiazepines: continuous prescribing periods


While there has been a steep fall in the proportion of benzodiazepine prescribing periods to exceed 30 days (from about half of prescribing periods in 2001 to a third in 2014), reductions in the proportions of prescribing periods to exceed 6 and 12 months have been less clear.

Benzodiazepines: Proportion of continuous prescribing periods to exceed 30 days



In 2014, 12% of continuous benzodiazepine prescribing periods exceeded 6 months. Half of these (6% of prescribing periods that year) exceeded 12 months. There are indications of a slight downward trend over time. Around 13% of prescribing periods exceeded 6 months in 2001 to 2003, while since 2007 10% to 12% were prescribed at this level.


Benzodiazepine: proportion of continuous prescribing periods to exceed 6 and 12 months



Z drugs: continuous prescribing periods

In 2014, 37% of continuous Z drug prescribing periods exceeded 30 days. The rate has had a slight downward trend over time.

Z-drugs: Proportion of continuous prescribing periods to exceed 30 days



Similar to benzodiazepines, in 2014 13% of Z drug continuous prescribing periods exceeded 6 months, and 6% exceeded a year. While the rate exceeding 30 days appears to have decreased, the rate exceeding these longer thresholds may be increasing.


Z-drugs: proportion of continuous prescribing periods to exceed 6 and 12 months




Opioids: continuous prescribing periods

Similarly, while the proportion of continuous prescribing periods to exceed 30 days reduced (from 38% in 2001 to 34% in 2014) no reduction was evident at the longer thresholds. Rather, the results were indicative of a slight upward trend over time.

Opioids: Proportion of continuous prescribing periods to exceed 30 days




Opioids: proportion of continuous prescribing periods to exceed 6 and 12 months



Gabapentin: continuous prescribing periods


Since 2010, the proportion of gabapentin prescribing periods to exceed 30 days fell from 76% to 60% in 2014.

Gabapentin: Proportion of continuous prescribing periods to exceed 30 days



The rates exceeding 6 and 12 months fluctuate in the data but are not consistent with a pattern of long-time decline.


Gabapentin: proportion of continuous prescribing periods to exceed 6 and 12 months




Pregabalin: continuous prescribing periods

While the proportion of pregabalin prescribing periods to exceed 30 days remained around 60% between 2004 and 2014, the proportion to exceed longer thresholds steadily grew over this period. In 2014, 16% of continuous pregabalin prescribing periods exceed 6 months and 8% exceeded a year.

Pregabalin: Proportion of continuous prescribing thresholds to exceed 30 days



Pregabalin: proportion of continuous prescribing periods to exceed 6 and 12 months




Among those prescribed DFM: characteristics of people prescribed DFM long-term:

Among those patients prescribed DFM, the characteristics of those prescribed to longer-term can be compared with the characteristics of those prescribed to shorter-term. It is important to bear in mind, however, that these comparisons do not take account of the characteristics associated with being prescribed DFM at all.

Older people

For most types of DFM (except opioids), older people prescribed the drug were more likely than younger people to be prescribed it for more than 6 months. For example, in 2014 18.7% of those aged 81 and over who were prescribed Z drugs were prescribed to for more than six months, compared with 5.1% of those prescribed the drug who were 18 to 40-year olds.

Z drugs: proportion of continuous prescribing periods to exceed 6 months, by age



Men

In 2014, for all types of DFM, continuous prescribing periods in excess of 12 months were more likely among men prescribed the drug than among women who were prescribed to. Differences by sex, however, were not evident at other prescribing thresholds or in earlier years.


North of England

The sample was grouped into five regions: North of England, Midlands and East of England, London, South East, and South West. People prescribed DFM and living in the North were more likely than those living in other regions to be prescribed to for periods in excess of 6 and 12 months. This was the case for all classes of DFM.

Deprived neighbourhoods

Among people prescribed DFM, those living in deprived areas were generally more likely to be prescribed to for longer. This association, for example, has remained evident and pronounced among those prescribed opioids in every year of the data extract.


Opioids: proportion of continuous prescribing periods to exceed 6 months, in areas of least (Q1) and most (Q5) deprivation



Trends sales of over the counter (OTC) medicines

There was a small reduction in the volume of OTC sales of medicines containing codeine or dihydrocodeine between 2015/2016 and 2017/2018. Apart from a slight increase in sales of ibuprofen and codeine combinations, all products showed a small fall in sales volume between 2015/6 and 2017/18.

Total counts of sales of individual codeine and dihydrocodeine-containing medicines



Estimates of the prevalence of prescribed medicine dependence

We need to be cautious about drawing conclusions about dependence on prescribed medicines from primary care data, even where the analyses take account of length of prescribing. We discuss three papers that have been used to extrapolate such a prevalence and conclude that they should not be used in this way.

Limitations

The analyses presented in this report have limitations, including that they:

- Examine trends by broad class of medicine, and do not take account of medicine strength or variations in dose.
- Are based on a relatively small sample (<50,000 patients).
- Relate to prescribing practice: these data do not indicate whether medicines were dispensed, whether they were taken, and whether they were taken by the patient they were prescribed to or by someone else.
- Cannot tell us whether long-term prescribing was clinically appropriate in individual cases, nor whether patients were dependent on prescribed medicines.
- Apply strict rules on what constitutes a continuous prescribing period; estimates should be regarded as conservative.
- Do not capture recent trends (since 2015).

Conclusions and implications

Prevalence: Individual DFM prescriptions almost never exceeded 12 months. However, once repeat prescribing is accounted for a sizeable minority of continuous prescribing periods exceed this level: about one in twenty in 2014 lasted more than a year. This ranged from about 4% of prescribing periods for opioids and gabapentin, to 6% for benzodiazepines and gabapentin, and 8% for pregabalin.

Change over time: While the prevalence of continuous prescribing over 30 days tended to show signs of decline, there is little evidence of any decline at longer-term thresholds.

Pregabalin trends: Prescribing for periods in excess of 12 months increased particularly sharply for **pregabalin** since its introduction in 2004. As pregabalin and gabapentin become controlled as class C drugs (Home Office, 2018), it will be important to monitor the impact of reclassification on prescribing practice (Torjesen, 2019). Awareness of this steep increase in long-term pregabalin prescribing is relevant across sectors, and should inform service provision in primary care, specialist services (such as pain management), and psychiatry.

Variation: Those most likely to be prescribed DFM at this level were older, living in deprived neighbourhoods, and living in the North of England. In 2014 being male emerged as associated with prescribing for periods exceeding 12 months. It is possible that changing prescribing practices are not addressing the issue of very long-term prescribing in some groups of men.

Further research

- The current analyses drew on a relatively small extract of data from the CPRD. There is a need for further research with larger CPRD extracts which explore patterns in long-term prescribing for individual medicines.
- In relation to the monitoring of opioid prescribing periods, this should include taking account of oral morphine equivalence (OME) (Curtis et al., 2019).
- Further analyses could draw on other information available in the CPRD, both to more fully profile the extent of DFM prescribing and the characteristics of who is prescribed to long term. As information on diagnoses and symptom recording improves, this could include exploring psychiatric comorbidities in this population.
- Different methods can be used to calculate the length of continuous prescribing periods and to monitor change over time in these. The analyses in this report should be replicated using other approaches.
- OTC sales data can be used to examine trends at the aggregate level. Further work exploring individual level purchasing and use of OTC products containing codeine and dihydrocodeine is needed, and could be achieved with the inclusion of questions on general population surveys such as the Health Survey for England (HSE) and the Adult Psychiatric Morbidity Survey (APMS).
- Up-to-date monitoring of duration of prescribing is essential, in particular review of current trends in the long-term prescribing of pregabalin.
- Alongside monitoring prescribing data, other types of research are also needed to understand the nature and extent of dependence on prescription medicines.

1 Introduction

1.1 Background

There has been concern about levels of prescribing (Curtis et al. 2019), particularly the risks associated with long-term prescribing (McManus, 2018), of medicines with the potential to create dependence. Dependence here refers to the need to continue taking a medicine to maintain a state of feeling normal and to avoid symptoms of withdrawal.

In response to this concern, a report was commissioned through the Public Health Research Consortium (PHRC) by the National Institute for Health Research (NIHR) Policy Research Programme: *Prescribing Patterns in Dependence Forming Medicines* (Cartagena Farias et al., 2017).² The National Centre for Social Research - with clinical and methodological support from the Institute of Psychiatry, Psychology and Neuroscience and University of Bristol - undertook the descriptive study of prescribing trends. This report included a rapid review of literature and should be referred to for details of previous research on the topic. It also included analysis of an extract from the Clinical Practice Research Datalink (CPRD) and methodological details about that extract. The report described:

- Trends (2000-2015) in the proportion of people prescribed medicines known to have the potential to be dependence forming, and prescribing trends for four different types of dependence forming medicines (benzodiazepines, Z-drugs, opioids and GABAergic medicines).
- Trends in the characteristics of prescribing periods: mean number of days prescribed for and the proportion exceeding 30 days.
- Trends in the characteristics of people prescribed dependence forming medicines long term: age, sex, region, health, and area-level deprivation.

The report produced new information at the patient level necessary to understand trends in prescribing practice. It confirmed falls at the patient level in the extent and length of benzodiazepine prescribing, but also found increases in the prescribing of other types of dependence forming medicines (DFM).

The findings raised additional questions at Department of Health and Social Care (DHSC), Public Health England (PHE) and for the All Party Parliamentary Group (APPG) for prescribed drug dependence, specifically around continuous prescribing periods to exceed even longer thresholds.

1.2 New analyses in this report

The following definitions are used in this report:

Prescriptions: individual prescriptions that are not linked at the patient level.

Continuous prescribing periods: a series of one or more prescriptions (an initial prescription combined with all repeat prescriptions) making up a continuous episode of prescribing.

The current study revisits the same data extract as that used in the previous report, but builds on the analysis in several new ways:

² http://phrc.lshtm.ac.uk/papers/PHRC_014_Final_Report.pdf

Different thresholds of long-term prescribing

The previous report presented the proportion of prescriptions and the proportion of continuous prescribing periods of benzodiazepines, Z-drugs, opioids or GABAergic medicines to exceed 30 days (the recommended maximum for some drug classes). The current analyses extend this by presenting the proportion of prescriptions and continuous prescribing periods to exceed three different prescribing length thresholds: 30 days, 6 months, and 12 months.

Differently defined patient population

People with a diagnosis of epilepsy or cancer were analysed separately from other people in the previous analysis. This was done to reduce the inclusion of prescribing linked to the management of epilepsy and cancer-related pain and the use of medicines in community-based palliative care. In the current analysis, however, a more nuanced approach has been taken. Those with a cancer diagnosis were excluded from the analyses of opioid prescribing trends only (and retained in the sample for other drug classes), and those with an epilepsy diagnosis were excluded from the analysis of GABAergic medicines (and retained in the sample for the other drug classes).

Separate focus on gabapentin and pregabalin

The previous report examined prescribing for four classes of drugs: benzodiazepines, Z-drugs, opioids, and GABAergic medicines. The current analyses also examine two individual medicines included in that combined GABAergic medicine grouping - gabapentin and pregabalin – separately. It is important to examine trends in these separately as pregabalin was not introduced to the market until 2004.

Inclusion of separate analysis of over-the-counter (OTC) opioid sales

The previous report drew only on analysis of primary care prescribing data, while this report includes analysis of scale and trends in sales of OTC medicinal products containing codeine and dihydrocodeine (2015-2018).

1.3 Objectives

The main objectives were to examine the extent to which DFM are prescribed long-term and to profile the characteristics of people who are prescribed to long-term. We also include analysis of the sales of over-the-counter medicines containing (dihydro)codeine and evaluate some published estimates of the extent of long-term DFM prescribing (see Appendix B).

Objective 1

Estimate the proportion of individual prescriptions for each type of DFM to exceed 30 days, 6 months and 12 months each year between 2000 and 2015 (Chapters 3 and 4).

Objective 2

Estimate the proportion of continuous prescribing periods for each type of DFM to exceed 30 days, 6 months and 12 months each year between 2000 and 2015 (Chapters 3 and 4).

Objective 3

Describe the demographic (age, sex) and area-level (deprivation and region) characteristics of people prescribed DFMs short- and longer-term each year between 2000 and 2015 (Chapters 5 and 6).

Objective 4

Produce time trends in the volume of annual sales of OTC medicine products containing codeine and dihydrocodeine, between 2015 and 2018 (Chapter 7).

Objective 5

Extrapolate from the proportion of prescribing periods in 2014/5 to estimate the proportion of the population to be prescribed each type of DFM continuously in excess of 30 days, 6 months and 12 months (Chapter 8).

Objective 6

Review some published estimates of the number of people in England who are dependent on prescribed medicines (Appendix B).

Data tables are presented in Appendix A. Methods are described in Chapter 2, with further detail about the CPRD extract in Appendix D and the medicines included in the analysis listed in Appendix E.

2 Methods

2.1 Data extraction

The Clinical Practice Research Datalink (CPRD) contains primary care data for approximately 8% of the UK population (Herrett et al., 2015). A geographically representative random sample of 49,999 individuals living in England and prescribed any benzodiazepine, Z-drug, opioid or GABAergic medicines between 2000 and 2015 was extracted for analysis.

Further detail about the CPRD extract are provided in Appendix D and a list of all medicines included in each of DFM groups examined is provided in Appendix E. A full description of the structure, content and generalisability of the CPRD dataset can also be found in the previous report (Cartagena Farias et al., 2017), including further description of the data extract used for analysis.

2.2 Estimating length of individual prescriptions

The length of an individual prescription was defined as the number of treatment days a drug is prescribed for a specific therapy event on a specific occasion. Each consultation provided information regarding the total dose and numeric daily dose of a particular drug. To calculate the length of each individual prescription, the total quantity of drug prescribed was divided by the numeric daily dose for each given therapy (e.g. 90 tablets / 3 tablets per day = 30 days duration). Variations in dose levels were not accounted for.

2.3 Estimating length of continuous prescribing periods

The number of days for which a particular class of drug was continuously prescribed to a person for was estimated by adding the length of an initial prescription to the length of any repeat prescriptions. A repeat prescription was identified when the same drug (or another drug in the same class) was prescribed to the same person within a period. To identify a series of prescriptions that could reliably be classified as repeat prescriptions, the following rules were applied:

1. The number of days between each consultation is less than or equal to 35 days, or the length of the previous prescription is equal to, or less than, the number of the days between consultations (plus 5 days). This ensured that a repeat prescription was identified, as opposed to multiple prescriptions over a longer period.
2. In some instances, consultation identifiers varied despite being held on the same day; it was assumed that all events that occurred on the same day were part of the same consultation.
3. For analyses of the four major classes of drugs (benzodiazepines, Z-drugs, opioids and GABAergic medicines): if a patient switched from one type of benzodiazepine to another type of benzodiazepine, this still counted as a continuous prescribing period; the same applied to other classes of drug.
4. If two different drugs belonging to the same class of drug were prescribed in the same consultation (e.g. diazepam and lorazepam), the longer of the two derived

prescription lengths was used. Similarly, if two different prescription lengths were prescribed in the same consultation then the longer length was used.

5. The first consultation date when a drug was prescribed was noted as the start date of a continuous prescribing period; this ensured that repeat prescriptions following from one year to the next were counted from the original start date.

When reporting on prescribing periods that span two calendar years, duration length is based on when the prescribing period ends as opposed to curtailing periods at the end of a calendar year. As a result, periods spanning more than one calendar year are effectively reported twice, in both consecutive years. Likewise, periods spanning three years are captured in the data for each of those years. For example, if someone was prescribed opioids from May 2001 to August 2002, that would be counted as a continuous prescribing period exceeding 12 months in both 2001 and 2002. This phenomenon will affect longer prescribing periods more than shorter term prescribing. Because prevalence per year is reported, the validity of rates of longer-term prescribing is maintained as the relevant prescribing period did indeed occur in both consecutive years.

It is important to note that the CPRD data extract is cut off at the end of 2015, so it is likely that a proportion of people had not yet completed their continuous prescribing period. This is an issue when estimating the proportion of prescribing periods exceeding the longer thresholds, such as 6 or 12 months. Because of this, estimates for the final year of data (2015) have not been fully presented, and are given in grey text in the tables. Similarly, a significant proportion of people would not have their full continuous prescribing period captured at the start of the study period. For instance, we would expect low estimates of the proportion of people with a continuous prescribing period of 12 months within the first 12 months of the data as many people would have received their initial prescription before the start date of the extract. This report shows the rates for 2001 to 2014 for continuous prescribing periods exceeding 6 months and 12 months due to concern about the reliability of longer-term estimates for 2000 and 2015; rates for prescriptions, however, include estimates for 2000 as truncation should not affect this estimate.

We use the following conventions in all results tables, ‘-’ denotes no observations (zero value), and ‘0’ denotes non-zero values of less than 0.05% and are thus rounded to zero.

2.4 Base population

The unit of analysis in the tables varied according to the subject being examined and is referred to in the text. Analyses examining trends over time used either prescriptions or continuous prescribing periods, where appropriate, whereas analyses of the characteristics of long-term prescribing in 2014 refers to people. For the latter analyses, prescribing patterns were investigated by area level deprivation of the GP practice, region and by the gender and age of the person prescribed to. When examining the characteristics of people prescribed to for periods in excess of six or 12 months, some age bands were combined due to small base sizes.

2.5 Analysis

The mean length of prescriptions and continuous prescribing periods for each class of DFM and for two types of GABAergic medicines – pregabalin and gabapentin – were derived for each year of the data. The results presenting trends over time in prescriptions and continuous prescribing periods are descriptive, unadjusted, and not tested for statistical significance.

Further analysis estimated the proportion of prescriptions and continuous prescribing periods for each class of DFM which were in excess of 30 days, 6 months, and 12 months. These thresholds are not mutually exclusive, meaning that a continuous prescribing period in excess of 12 months was also counted as a prescribing period in excess of 30 days and in excess of 6 months.

The unit of analysis for the trends described above was prescribing events. These were also used to extrapolate a crude estimate of the proportion of the total population in 2014 to be prescribed each DFM long-term. For example, we know that 5.2% of the total CPRD population were prescribed opioids in 2014. We also know that 33.7% of continuous opioid prescribing periods in 2014 exceeded 30 days. Extrapolating from this, we can estimate that approximately 33.7% of the people prescribed opioids were prescribed long-term (33.7% of 5.2% = 1.8% of the total population). The key assumption here is that there was little association between the number of continuous prescribing periods someone experienced in a year and the length of each of those continuous prescribing periods. The mean number of prescribing periods per person prescribed to was less than 2 for all types of DFM. Because of the uncertainty and scope for systematic undercounting, we recommend that these proportions are viewed as minimum estimates and indicative only.³

2.6 Exclusion criteria

Exclusion criteria differed from those applied in the previous report. Individuals with an epilepsy diagnosis (at any point in the data extract) were excluded from the analysis of GABAergic medicines (including pregabalin- and gabapentin-specific analyses). This was because some GABAergic medicines have been approved for the long-term treatment of epilepsy. People with a cancer diagnosis (at any point in the data extract) were excluded from the analysis of opioid prescribing as the use of opioids in the treatment of severe cancer-related pain is considered standard procedure, although their suitability for treating chronic, non-cancer related pain has been questioned. These exclusion criteria were not applied to the analysis of benzodiazepines and Z-drugs.

2.7 Missing data

Overall, variation in the amount of missing data was not pronounced by gender, age or practice (see previous report). However, bias resulting from missing data could not be ruled out for other characteristics for which we could not make assessments. Therefore, missing data need to be acknowledged as a potential limitation which could have biased the results.

2.8 Over-the-counter sales

Data on the sales of over-the-counter (OTC) medicines containing codeine or dihydrocodeine between February 2015 and February 2018 were acquired from IRI Worldwide. Total counts of individual tablets were derived for each 12-month period from week ending February 28th, 2015. Counts were calculated from the sales volume multiplied by the pack size.

³ These extrapolations are approximate and should be regarded as likely underestimate.

3 Trends in DFM prescribing

This chapter presents trends in the prescribing of four classes of DFM: benzodiazepines, Z-drugs, opioids and GABAergic medicines. Trends for each of gabapentin and pregabalin (subclasses of GABAergic medicine) are presented separately in Chapter 4.

3.1 Proportion of people prescribed to

In the previous report analyses of these data showed that the overall proportion of people prescribed DFM at any point in the year increased from 6.3% in 2000 to a peak of 9.5% in 2012. The pattern varied by type of DFM. Opioids, Z-drugs and GABAergic medicines saw pronounced increases in the proportion of people for whom they were prescribed. The proportion prescribed opioids and Z-drugs doubled between 2000 and 2012. GABAergic medicine prescribing increased even more steeply, from 0.2% of people in 2000 (following approval in October 2000) to 2.1% in 2015. This context should be borne in mind when interpreting trends in the length of time medicines were prescribed for.

3.2 Mean average length of prescribing

The mean average number of days of individual prescriptions and of continuous prescribing periods are presented for each type of DFM in Appendices 1 and 2. These were produced using different exclusion criteria from the previous report (see Section 2.5). The revised mean lengths are similar to the results previously reported. GABAergic medicine prescriptions tended to be issued for longer than the other types of DFM; benzodiazepines, Z-drug and opioid prescriptions averaged a mean length of between 24-25 days in 2014 compared with 31 days for GABAergic medicines. The average length of prescriptions for GABAergic medicines remained stable between 2000 and 2015, but average prescription lengths decreased for all other drugs; decreases were particularly marked for opioids (36 days in 2000 to 24 days in 2015).

Continuous periods of DFM prescribing in 2014 averaged between 103 and 123 days. The average prescribing period for opioids increased from 64 days in 2000, to a peak of 103 days in 2014. The continuous prescribing periods for other DFMs remained more stable over time.


3.3 Prescriptions exceeding thresholds

The length of prescriptions was examined in relation to three thresholds. Rates were calculated for the proportion of prescriptions for benzodiazepines, Z-drugs, opioids and GABAergic medicines (including separately for gabapentin and for pregabalin, presented in the next chapter) to exceed:

- 30 days
- 6 months
- 12 months

Consistent with the trends presented here, the previous report (Cartagena Farias et al., 2017) also showed that the proportion of prescriptions for benzodiazepine and GABAergic medicines to exceed 30 days fluctuated but with general downward trends over time (Figure 1). For opioids, the proportion of prescriptions exceeding 30 days was around 15% from 2000-2007, and between 16-18% from 2007-2015. For Z-drugs, the proportion of prescriptions exceeding 30 days fluctuated between 10-12% between 2000 and 2010 and remained below 10% 2011-2015.

Figure 1: Proportion of prescriptions exceeding 30 days by DFM type



Source: CPRD (see Appendix 3)

The proportion of individual prescriptions to exceed 6 months and 12 months by DFM type was examined, but as expected, the proportion at each year was close to zero for these longer thresholds and no trend in prescribing was detectable.

3.4 Continuous prescribing periods exceeding thresholds


Cartagena Farias and colleagues (2017) described the proportion of continuous prescribing periods to exceed 30 days. The current re-analysis of the same data reproduces these trends using the updated set of exclusion criteria, as well as also presenting trends for the proportion of continuous prescribing periods to exceed 6 and 12 months.

Figures 2-5 below show the proportion of continuous prescribing periods for benzodiazepines, Z-drugs, opioids and GABAergic medicines to exceed 30 days, 6 months and 12 months.

3.4.1 Benzodiazepines


The proportion of continuous benzodiazepine prescribing periods to exceed 30 days fell from about half in 2001 to about a third in 2011-2014 (Figure 2). The proportion to exceed six months was around 12%-13% between 2001 and 2007, and 10%-11% between 2008 and 2014 (Figure 3). Prescribing periods exceeding 12 months followed a similar pattern: the rate was about 6% between 2001 and 2007, and about 5% between 2008 and 2014.

Figure 2: Benzodiazepines: Proportion of continuous prescribing periods exceeding thresholds



(Source: Appendix 4 to Appendix 6)

Figure 3: Benzodiazepines: Proportion of continuous prescribing periods exceeding 6 and 12 months




(Source: Appendix 4 to Appendix 6)

3.4.2 Z-drugs

Less than half of continuous prescribing periods of Z-drugs were in excess of 30 days between 2001 and 2012 (varying between 41% and 44%), and after 2012 the prescribing rate varied between 37%-40% (Figure 4). The proportion to exceed 6 months remained mostly below about 12% between 2001 and 2010, and above 12% since 2011 (Figure 5). Prescribing periods exceeding 12 months followed a similar pattern: about 4% to 5% between 2001 and 2010, since 2011 the rate was 6%.

Figure 4: Z-drugs: Proportion of continuous prescribing periods exceeding thresholds



(Source: Appendix 4 to Appendix 6)

Figure 5: Z-drugs: Proportion of continuous prescribing periods exceeding 6 and 12 months




(Source: Appendix 4 to Appendix 6)

3.4.3 Opioids


The proportion of continuous opioid prescribing periods to exceed 30 days diminished from 2012 onwards, following a consistent rate of around 37%-39% between 2001-2011 (Figure 6). The proportion to exceed 6 months remained around 6%-7% between 2001 and 2008, and 7%-8% between 2009 and 2014 (Figure 8). Prescribing periods exceeding 12 months followed a similar pattern: about 2%-3% between 2001 and 2008, and 3%-4% between 2009 and 2014.

Figure 6: Opioids: Proportion of continuous prescribing periods exceeding thresholds



(Source: Appendix 4 to Appendix 6)

Figure 7: Opioids: Proportion of continuous prescribing periods exceeding 6 and 12 months




(Source: Appendix 4 to Appendix 6)

3.4.4 GABAergic medicines


The proportion of continuous GABAergic medicine prescribing periods to exceed 30 days increased from 58% in 2001 to 71% in 2005 (Figure 8); this covers the period in which pregabalin was first introduced. Prescribing rates diminished from 69% in 2010 to 58% in 2014. The proportion to exceed 6 months remained around 10%-12% between 2001 and 2005, and 13%-14% between 2006 and 2014 (Figure 9). Prescribing periods exceeding 12 months diminished slightly from 5% to 3% between 2001 and 2005, and then increased back up to 5% in 2014.

Figure 8: GABAergic medicines: Proportion of continuous prescribing periods exceeding thresholds



(Source: Appendix 4 to Appendix 6)

Figure 9: GABAergic medicines: Proportion of continuous prescribing periods exceeding 6 and 12 months



(Source: Appendix 4 to Appendix 6)


4 Trends in gabapentin and pregabalin prescribing

As well as producing trends for the combined category of GABAergic medicines, we also examined two of the main individual GABAergic medicines separately: gabapentin and pregabalin.

4.1 Items prescribed in England 2008-2018

Figure 10 draws on recently published NHS Digital data showing the volume of prescriptions dispensed in England between 2008 and 2018 (NHSD 2019). These figures include prescribing for all indications, while our analysis of GABAergic medicines excluded prescribing to those with an epilepsy diagnosis. However, the NHS Digital figures do provide useful context on the increasing volume of overall GABAergic prescribing and demonstrate that most prescribing is for gabapentin or pregabalin.


Figure 10: Number of GABAergic medicine items dispensed in 2008-2018



4.2 Average length of prescriptions and continuous prescribing periods

The average number of days individual gabapentin prescriptions were issued for remained stable over time at around 36 days (Figure 11). Average pregabalin prescriptions increased in length from 2004 (when pregabalin was first approved for use in the European Union) to 2008; from 2008 onwards, the number of days covered by individual pregabalin prescriptions remained stable at a mean of around 35 days.


Figure 11: Average number of days of prescriptions by GABAergic medicine type



Source: CPRD (see Appendix 7)

The average number of days that gabapentin was continuously prescribed for remained relatively stable, but with some fluctuations (Figure 12). The average number of days that pregabalin was prescribed for increased steeply over this time, almost doubling between 2004 (67 days) and 2014 (127 days).

Figure 12: Average number of days of continuous prescribing periods by GABAergic medicine type




Source: CPRD (see Appendix 8)

4.3 Prescriptions exceeding thresholds

Figure 13 shows the proportions of prescriptions exceeding 30 days for people prescribed gabapentin and pregabalin. The proportion of gabapentin prescriptions to exceed 30 days increased over time until around 2011, at which time the proportion declined from 65% to 52% in 2014. The proportion of pregabalin prescriptions to exceed 30 days has also broadly increased over time, from about 13% when the drug was first introduced to about 30% in 2013 and 2014.

Figure 13: Proportion of prescriptions exceeding 30 days by GABAergic medicine type



Source: CPRD (see Appendix 9)


4.4 Continuous prescribing periods exceeding thresholds

The figures below show the proportion of continuous prescribing periods for gabapentin and pregabalin to exceed 30 days, 6 months and 12 months.

4.4.1 Gabapentin

The proportion of continuous prescribing periods exceeding 30 days remained stable up to 2010, when rates fell sharply for the next 4 years. Rates of prescribing for thresholds exceeding 6 months and 12 months remained relatively stable from 2001 to 2014 (Figure 14).

Figure 14: Gabapentin: Proportion of continuous prescribing periods exceeding thresholds




(Source: CPRD Appendix 10 to Appendix 12)

4.4.2 Pregabalin


The proportion of continuous prescribing periods exceeding 30 days fluctuated from 2004 to 2014, but there was no particular upward or downward trend over this time (Figure 15). Conversely, rates of prescribing exceeding 6 months and 12 months steadily increased over time (Figure 16)

Figure 15: Pregabalin: Proportion of continuous prescribing periods exceeding thresholds



Source: CPRD (see Appendix 10 to Appendix 12)

Figure 16: Pregabalin: Proportion of continuous prescribing periods exceeding 6 and 12 months



Source: CPRD (see Appendix 10 to Appendix 12)

5 Characteristics associated with DFM prescribing in excess of 6 months


5.1 Variation in continuous prescribing by age-group

Among patients prescribed DFM, the characteristics of those prescribed to continuously for six months or more could be compared with the characteristics of those prescribed to for less than six months. It is important to bear in mind, however, that these comparisons do not take account of the characteristics associated with being prescribed DFM at all. Too few patients in the sample were prescribed to for more than 12 months for these results to be robust. They are therefore not discussed in the text but are presented in the tables in Appendix A for reference.

5.1.1 Benzodiazepines

Older people prescribed benzodiazepines were more likely to be prescribed to in excess of 6 months than younger people prescribed the drug. This association with age has remained consistent over time.

Figure 17: Benzodiazepines: Proportion to exceed continuous prescribing threshold of 6 months, by age




Base: People prescribed benzodiazepines each year. Source: CPRD (see Appendix 14)

5.1.2 Z-drugs

Similar to benzodiazepine prescribing, older people prescribed Z-drugs were more likely than younger people prescribed the drug to be prescribed for periods exceeding 6 months (and 12 months, see Appendix 18). This pattern has remained consistent over time.

Figure 18: Z-drug: Proportion to exceed continuous prescribing threshold of 6 months, by age




Base: People prescribed Z-drugs each year. Source: CPRD (see Appendix 17)

5.1.3 Opioids

Among people prescribed opioids, the association between age and being prescribed to longer-term (6+ months) was less clear cut. While younger people prescribed the drug were generally less likely to be prescribed it longer term, the rates for other age groups were similar.

Figure 19: Opioid: Proportion to exceed continuous prescribing threshold of 6 months, by age




Base: People prescribed opioids each year. Source: CPRD (see Appendix 20)

5.1.4 GABAergic medicines

Age related differences in prescribing of GABAergic medicines in excess of 6 months have changed over the study period. The pattern of prescribing is variable from 2001 to 2007, but an age association emerged from 2008 with longer-term prescribing becoming more common in older than younger people.

Figure 20: GABAergic medicines: Proportion to exceed continuous prescribing threshold of 6 months, by age



Base: People prescribed GABAergic medicines each year. Source: CPRD (see Appendix 23)

5.2 Variation in continuous prescribing by gender


The previous report found little in terms of an association with gender for any DFM prescribing in excess of 30 days. The results from this report largely replicate these findings for prescribing exceeding 6 months and 12 months. Notable exceptions to this overall pattern include evidence of gender differences in prescribing exceeding 6 months up to 2008/2009 for benzodiazepines and GABAergic medicines, and men were more likely to be prescribed to in 2014 for periods exceeding 12 months across all DFMs (see Appendix 25 to Appendix 27).

5.3 Variation in continuous prescribing by area level deprivation

Variations in continuous prescribing by area level deprivation was examined using measures of IMD at the lower level super output area (LSOA) of the patient's home address⁴. Figure 21 shows that people prescribed DFM who lived in the most deprived areas were more likely to be prescribed benzodiazepines, Z-drugs and opioids for 6 months or more than those in the least deprived areas; the variation in long term prescribing periods exceeding 6 months for GABAergic medicines by deprivation level was more mixed. Similarly, people prescribed DFM who lived in the most deprived areas were more likely to be prescribed benzodiazepines, Z-drugs and opioids for 12 months or more compared to those in the least deprived areas, while the pattern for GABAergic medicines by area deprivation level was again more mixed.


Figure 21: Proportion of continuous prescribing periods to exceed 6 months among people prescribed DFM and living in the least (Q1) and most (Q5) deprived areas

Benzodiazepines




⁴ Practice level IMD was available in CPRD but we chose to use patient level IMD as we are interested in patient characteristics as opposed to those of the GP practice.


Z-drugs



Opioids



GABAergic medicines



Source: CPRD (see Appendix 29, Appendix 32, Appendix 35, Appendix 38) Based on people living in the fifth of areas with the most deprivation (Q5) and the fifth of areas with the least deprivation (Q1) according to the 2007 Index of Multiple Deprivation

5.4 Characteristics associated with long-term prescribing in 2014

CPRD data for 2014 were examined to compare the circumstances of people prescribed DFMs short term (that is, for continuous periods of 30 days or less) and long-term (more than 6 and 12 months). See Table 1 to Table 4. Comparisons by characteristics were made separately for each threshold.

5.4.1 Gender variations in long-term prescribing

Among people prescribed DFM, men were more likely than women to be prescribed to for more than 12 months; this was the case for every type of DFM. For instance, among women prescribed benzodiazepines, 5.1% were prescribed to for periods exceeding 12 months, compared to 7.3% of men; gender differences were not evident for relatively shorter long-term prescribing periods of over 6 months.

5.4.2 Age-group variations in long-term prescribing

A continuous measure of age was used to examine whether there were age-related variations in long-term prescribing in excess of 6 months and 12 months, so no reference category was assigned. Older people were more likely than younger people to be prescribed for longer than 6 months.⁵; this was the case for all types of DFM apart from opioids. Apart from Z-drugs, older people were no more likely than younger people to be prescribed DFMs for longer than 12 months.

5.4.3 Area level deprivation variations in long-term prescribing

Comparisons in the rates of long-term prescribing among people living in the most (V) compared to least (I) deprived areas was examined. People prescribed DFM and living in the most deprived areas were more likely to be prescribed to for periods in excess of 6 months. For example, among people prescribed benzodiazepines and living in the least deprived neighbourhoods, 8.8% were prescribed to for longer than 6 months, while among those living in the most deprived neighbourhoods 19.4% were prescribed to at this level. For GABAergic medicines, this was evident only in prescribing in excess of 12 months.

5.4.4 Regional variations in long-term prescribing

The ten available regions in the CPRD were grouped in to five larger regions, North of England, Midlands and East of England, London, South East and South West, in order to maximise power. North of England was chosen as the reference category as it was the most populated region in this sample.

People prescribed DFM and living in the North of England were the most likely to be prescribed to long-term for periods in excess of 6 and 12 months. For instance, 15.5% of those living in North of England were prescribed to for longer than 6 months

⁵ Mean age (years) for short-term periods lasting under 30 days: 59.3 (benzodiazepines), 58.9 (Z-drugs), 60.6 (opioids) and 58.2 (GABAergic medicines).

compared to 11.7% living in the South East. This was the case for all classes of DFM, although the pattern was less pronounced for GABAergic medicines.

Please refer to Appendix 40 to 44 for related analyses. These present the characteristics associated with being prescribed each type of DFM for up to 3 months, between 3 to 6 months, between 6 to 12 months and for more than 12 months.

Table 1: Characteristics of people prescribed benzodiazepines in excess of 6 months and in excess of 12 months, 2014

Benzodiazepines		
	Long-term	
	Over 6 months	Over 12 months
Mean age (years)	64.0**	62.3
IMD quintile (%)		
I (least deprived) §	8.8	3.3
II	9.6	3.5
III	12.0*	4.9
IV	11.5*	7.5***
V (most deprived)	19.4***	10.6***
Gender (%)		
Male §	12.9	7.3
Female	11.7	5.1***
Region (%)		
North of England §	15.5	9.7
Midlands and East of England	11.3***	4.8***
London	9.9***	7.3
South East	11.7**	3.7***
South West	10.1***	5.0***

* $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, § - reference category
Source: CPRD

Table 2: Characteristics of people prescribed Z-drugs in excess of 6 months and in excess of 12 months, 2014

Z-drugs		
	Long-term	
	Over 6 months	Over 12 months
Mean age (years)	67.9***	67.5***
IMD quintile (%)		
I (least deprived) §	13.0	6.2
II	13.1	6.0
III	9.6*	5.4
IV	11.8	4.8
V (most deprived)	17.6*	8.0
Gender (%)		
Male §	13.9	7.7
Female	12.2	5.1**
Region (%)		
North of England §	16.7	9.5
Midlands and East of England	11.4***	4.7***
London	13.5	5.6*
South East	11.6***	5.4***
South West	11.7*	4.2***

* $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, § - reference category
 Source: CPRD

Table 3: Characteristics of people prescribed opioids in excess of 6 months and in excess of 12 months, 2014

Opioids		
	Long-term	
	Over 6 months	Over 12 months
Mean age (years)	63.3	63.1
IMD quintile (%)		
I (least deprived) §	4.6	0.9
II	7.4***	4.6***
III	7.1***	3.7***
IV	8.1***	4.2***
V (most deprived)	8.3***	3.8***
Gender (%)		
Male §	7.3	4.1
Female	7.3	3.3**
Region (%)		
North of England §	9.2	4.7
Midlands and East of England	6.5***	3.6*
London	5.3***	2.2***
South East	6.9***	3.3***
South West	5.3***	2.0***

* $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, § - reference category
Source: CPRD

Table 4: Characteristics of people prescribed GABAergic medicines in excess of 6 months and in excess of 12 months, 2014

GABAergic medicines		
	Long-term	
	Over 6 months	Over 12 months
Mean age (years)	63.2***	61.1
IMD quintile (%)		
I (least deprived) §	14.3	3.9
II	12.0	5.6*
III	13.0	3.3
IV	16.2	6.0*
V (most deprived)	14.5	6.0**
Gender (%)		
Male §	14.3	6.9
Female	13.8	3.9***
Region (%)		
North of England §	15.2	4.8
Midlands and East of England	15.6	7.4***
London	12.1	2.2*
South East	13.6	4.4
South West	9.0***	4.8

* $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, § - reference category

Source: CPRD

6 Characteristics associated with gabapentin and pregabalin prescribing in excess of 6 months


6.1 Variation in continuous prescribing by age-group

The previous chapter examined the characteristics of people prescribed benzodiazepines, opioids, Z-drugs and GABAergic medicines long-term; the focus in this chapter is on the characteristics of people prescribed gabapentin and pregabalin. One of the reasons why these drugs are looked at separately is because pregabalin only entered the market in 2004. Again, due to the small number of people in the sample prescribed to for more than 12 months, the focus here is on those prescribed to for more than 6 months. Even at this threshold, numbers are relatively low, and results should be treated with caution. The data tables for 30 days, 6 months and 12 months can be found in Appendix A.

6.1.1 Gabapentin

From 2007 older people prescribed gabapentin were more likely than younger people prescribed the drug to receive it long-term (Figure 22, and Appendix 45). Prior to 2007, associations with age were unclear.

Figure 22: Gabapentin: Proportion of continuous prescribing periods to exceed 6 months, by age




Source: CPRD (see Appendix 48)

6.1.2 Pregabalin

The youngest age group of 18-40 had the lowest rate of pregabalin prescribed for longer than 6 months from 2007 onwards (apart from a spike in prescriptions at 2012); there were no age-related differences in long-term prescribing prior to 2007.

Figure 23: Pregabalin: Proportion of continuous prescribing periods to exceed 6 months, by age



Source: CPRD (see Appendix 51)

6.2 Variation in continuous prescribing by gender

The results did not show any clear gender differences over time. However, overall, women prescribed gabapentin and pregabalin for periods exceeding 6 months tended to have a lower prescription rate for some periods of time. For example, rates between 2001-2006 were lower for women prescribed gabapentin, and rates between 2006-2010 were lower for women prescribed pregabalin.

6.3 Variation in continuous prescribing by area level deprivation

Rates of continuous gabapentin prescribing exceeding 6 months varied over time among people living in the most compared to least deprived areas (Figure 24); a similar trend is observed for prescribing periods exceeding 12 months.

Overall, people prescribed pregabalin living in the most compared to least deprived areas had a higher rate for continuous prescribing periods exceeding 6 months (Figure 25); however, rates of prescribing for people living in the least deprived areas spiked in 2008-2009 and were higher than those in the most deprived areas. There was no clear trend for prescribing periods exceeding 12 months, as rates between the most and least deprived areas varies over time.

Figure 24: Proportion of continuous prescribing periods to exceed 6 months among people prescribed gabapentin living in the least (Q1) and most (Q5) deprived areas




Figure 25: Proportion of continuous prescribing periods exceeding 6 months among people prescribed pregabalin living in the least (Q1) and most (Q5) deprived areas



Source: CPRD (see Appendix 57 and Appendix 60)

6.4 Characteristics associated with long-term prescribing in 2014

CPRD data for 2014 were examined to compare the circumstances of people prescribed gabapentin and pregabalin short- and long-term (see Tables 9 to 12 below).

6.4.1 Gender variations in long-term prescribing

There were no gender differences in prescribing rates for long-term prescriptions of gabapentin, but women receiving pregabalin were less likely to be prescribed to for more than both 6 months and 12 months. For instance, 4.9% of women were prescribed to for longer than 12 months compared to 13% of men.

6.4.2 Age-group variations in long-term prescribing

Long-term prescribing was more common in older than younger people prescribed gabapentin (for periods exceeding 6 months only), but there were no age-related differences in long-term pregabalin prescribing⁶.

6.4.3 Area level deprivation variations in long-term prescribing

People living in the most compared to least deprived areas were no more likely to be prescribed gabapentin or pregabalin long-term.

6.4.4 Regional variations in long-term prescribing

Overall, there were no regional differences in long-term prescribing (over 6 and 12 months) of gabapentin and pregabalin relative to the North of England (Tables 9 and 10). The one exception was a lower prescribing rate of pregabalin for continuous prescribing periods exceeding 12 months in the South East (4%) compared to the North of England (11.7%).

Please refer to Appendices 62 and 63 for related analyses. These present the characteristics associated with being prescribed gabapentin and pregabalin for up to 3 months, between 3 to 6 months, between 6 to 12 months and for more than 12 months.

⁶ Mean age (years) for short-term periods lasting under 30 days: 61.0 (gabapentin) and 55.0 (pregabalin).

Table 5: Characteristics of people prescribed gabapentin in excess of 6 months and in excess of 12 months, 2014

Gabapentin		
	Long-term	
	Over 6 months	Over 12 months
Mean age (years)	64.0**	64.1
IMD quintile (%)		
I (least deprived) §	15.2	4.4
II	12.4	4.6
III	9.6	1.5
IV	14.6	7.3
V (most deprived)	10.9	3.4
Gender (%)		
Male §	10.3	4.5
Female	13.5	4.1
Region (%)		
North of England §	12.5	4.1
Midlands and East of England	15.7	5.2
London	8.1	0
South East	12.7	5.1
South West	5.4	3.2

* $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, § - reference category

Source: CPRD

Table 6: Characteristics of people prescribed pregabalin in excess of 6 months and in excess of 12 months, 2014

Pregabalin		
	Long-term	
	Over 6 months	Over 12 months
Mean age (years)	60.7	59.4
IMD quintile (%)		
I (least deprived) §	10.7	3.3
II	15.1	8.2
III	16.1	7.1
IV	22.2*	11.1*
V (most deprived)	14.6	7.9
Gender (%)		
Male §	19.9	13.0
Female	13.9*	4.9***
Region (%)		
North of England §	19.4	11.7
Midlands and East of England	15.6	6.5
London	14.0	10.5
South East	14.3	4.0**
South West	14.8	11.5


* $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, § - reference category

Source: CPRD

7 Time trends in sales of codeine- and dihydrocodeine-containing medications

A data extract of over the counter (OTC) sales of codeine and dihydrocodeine-containing medicines was acquired from IRI Group Ltd, a market research company which provides market intelligence data.⁷ Total counts of individual tablets were derived for three consecutive 12-month periods, ending in the final week of February 2016, 2017 and 2018.

Figure 26: Total counts of sales in individual codeine and dihydrocodeine-containing medicines



See Appendix 64 for precise counts.

There was a small decrease in total OTC sales of medicines containing codeine or dihydrocodeine between 2015/2016 and 2017/2018, broadly consistent across categories. Apart from a small increase over time in sales of ibuprofen and codeine combinations (1% increase), all types of medicine showed small decreases in sales volume between 2015/6 and 2017/18. The largest drop in sales was in aspirin and codeine products (15% reduction).

These trends are broadly consistent with those reported for all analgesics in *The Pharmaceutical Journal* using sales data supplied by IRI Ltd (Connelly, 2017), as well as by Nielson Scantrack (Connelly, 2018). The more recent article described sales of adult oral analgesics as 'stagnated'.

⁷ Data provided by IRI Group Ltd. Data are for sales of OTC products (including own-label and generic) from all multiples and independent pharmacies and most supermarkets and grocery outlets in Great Britain. These included: Asda, Iceland, Morrisons, Sainsburys (inc. local), Tesco (inc. Express, Metro), Co-operative, Waitrose, Boots, Superdrug, Lloyds, Wilkinson, and all independent chemists. Independent grocers were generally not included in the sales data. This means that trends over time are likely to be reliable, but that the total volume is an underestimate.

8 Conclusions

Prevalence

Individual DFM prescriptions almost never exceeded 12 months. However, once repeat prescribing was accounted for a sizeable minority of prescribing periods exceed this level: with about one in twenty lasting more than a year. This ranged from about 4% of prescribing periods for opioids and gabapentin, to 6% for benzodiazepines and gabapentin, and 8% for pregabalin.

Change over time

While the prevalence of continuous prescribing over 30 days tended to show signs of decline, there is little evidence of decline at the longer-term thresholds. Prescribing for periods in excess of 12 months increased particularly sharply for pregabalin since its introduction in 2004.

Pregabalin trends

As pregabalin and gabapentin become controlled as class C drugs (Home Office, 2018), it will be important to monitor the impact of reclassification on prescribing practice (Torjesen, 2019). Awareness of this steep increase in long-term pregabalin prescribing is relevant across sectors, and should inform service provision in primary care, specialist services (such as pain management), and psychiatry. Reclassification has made it illegal to supply pregabalin and gabapentin through repeat dispensing and restricts prescription lengths to 28 days. In an analysis of the impact of tramadol reclassification, which occurred in 2014 due to concerns about potential misuse, overprescribing, and increasing numbers of associated deaths, prescriptions and related deaths fell (Chen et al., 2018).

Variation

Among people prescribed DFM, those most likely to end up being prescribed to for longer were older, living in deprived neighbourhoods, and living in the North of England. In 2014, being male emerged as associated with being prescribing DFM for periods exceeding 12 months. It is possible that changing prescribing practices are not addressing the issue of very long-term prescribing in some groups of men.

Further research

The current analyses drew on a relatively small extract of data from the CPRD. There is a need for further research with larger extracts which explore patterns in long-term prescribing for individual medicines. In relation to the monitoring of opioid prescribing periods, this should include taking account of oral morphine equivalence (OME) (Curtis et al., 2019). The current research should be viewed as an initial and descriptive visualisation of patterns, future work should extend this with more detailed analyses.

9 References

BMA (2015) *Prescribed drugs associated with dependence and withdrawal – building a consensus for action*.

http://bmaopac.hosted.exlibrisgroup.com/exlibris/aleph/a23_1/apache_media/H6IB5G1BL8SX1KJ7VY4MCRCXVG6EV7.pdf

British Pain Society. Opioids for persistent pain: summary of guidance on good practice from the British Pain Society. *Br J Pain* 2012; **6**: 9–10.

Cartagena Farias J, Porter L, McManus S, Strang J, Hickman M, Reed K, Smith N. (2017) *Prescribing Patterns in Dependence Forming Medicines*. London. Available at: http://phrc.lshtm.ac.uk/project_2011-2019_014.html.

Chen TC, Chen LC, Knaggs RDA. *A 15-year overview of increasing tramadol utilisation and associated mortality and the impact of tramadol classification in the United Kingdom*. *Pharmacoepidemiol Drug Saf* 2018; **27**:487-94. doi:10.1002/pds.4320 pmid:28944519

Connelly D. A breakdown of the over-the-counter medicines market in Britain in 2016. *The Pharmaceutical Journal*, April 2017, Vol 298, No 7900, online | DOI: 10.1211/PJ.2017.20202662.

Connelly D. A breakdown of the over-the-counter medicines market in Britain in 2017. *The Pharmaceutical Journal*, May 2018, Vol 300, No 7913,

Curtis H, Croker R, Walker AJ, Richards GC, Quinlan J, Goldacre B. Opioid Prescribing Trends and geographical variation in England, 1998-2018 a retrospective database study. *Lancet Psychiatry*. 2019, 6: 2; 140-150.

Faculty of Pain Medicine (2019) Opioids Aware: A resource for patients and healthcare professionals to support prescribing of opioid medicines for pain. <https://www.rcoa.ac.uk/faculty-of-pain-medicine/opioids-aware>

Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. Data Resource Profile: Clinical Practice Research Datalink (CPRD). *International Journal of Epidemiology*, Volume 44, Issue 3, 1 June 2015, Pages 827–836.

Home Office. Atkins V. Pregabalin and gabapentin to be controlled as class C drugs. 15 Oct 2018. www.gov.uk/government/news/pregabalin-and-gabapentin-to-be-controlled-as-class-c-drugs.

McManus S. Opioids: long-term prescribing trends. *Lancet Psychiatry*. 2019, 6: 2; 140-150doi.or/10.1016/S2215-0366(18)30507-8

Montastruc F, Loo SY, Renoux C. Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017 *JAMA*. 2018; **320**(20):2149-2151. doi:10.1001/jama.2018.12358

NHS Digital (2019). *Prescription cost analysis-England 2018*. <https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/2018>. (Accessed May 9th, 2019)

Reed K, Bond A, Witton J, Cornish R, Hickman M, Strang J. (2011) *The changing use of prescribed benzodiazepines and z-drugs and of over-the-counter codeine-containing products in England*. Kings: London.

Taylor S, Annand F, Burkinshaw P, Greaves F, Kelleher M, Knight J, Perkins C, Tran A, White M, Marsden J. *An evidence review of dependence and withdrawal associated with some prescribed medicines*. 2019. Public Health England, London.

Torjesen I. Pregabalin and gabapentin: what impact will reclassification have on doctors and patients? *BMJ* 2019; 364: l1107.

Appendix A. Data tables

Appendix 1 Average number of days of prescriptions by DFM type

Year	Benzodiazepines	Z-drugs	Opioids	GABAergic medicines
2000 ⁸	31.0	27.9	35.8	30.9
2001	30.9	26.8	30.2	32.3
2002	30.8	26.7	26.2	32.0
2003	30.0	26.4	22.9	31.9
2004	29.0	26.6	23.2	32.6
2005	28.3	26.6	23.0	31.5
2006	27.1	26.6	22.9	31.1
2007	26.5	26.2	22.6	31.5
2008	25.6	26.7	22.8	31.4
2009	26.2	26.3	23.3	31.7
2010	25.4	25.7	23.7	31.2
2011	25.5	25.2	23.8	31.1
2012	24.8	24.3	23.8	30.9
2013	23.9	23.7	24.0	31.3
2014	24.7	24.2	24.2	30.6
2015	25.5	24.6	23.9	30.7

Appendix 2 Average number of days of continuous prescribing periods by DFM type

Year	Benzodiazepines	Z-drugs	Opioids	GABAergic medicines
2000	95.0	78.2	64.1	80.2
2001	106.4	94.9	72.1	112.0
2002	115.9	94.6	73.9	100.5
2003	117.8	91.4	77.5	99.6
2004	113.5	87.3	76.5	98.8
2005	117.2	107.9	81.7	105.2
2006	117.5	100.3	83.0	116.8
2007	113.7	104.1	80.9	111.7
2008	118.3	104.6	84.8	108.8
2009	120.7	103.2	90.3	113.5
2010	121.9	103.4	92.0	121.1
2011	112.0	109.9	99.4	115.3
2012	123.2	113.3	96.0	119.4
2013	110.0	106.6	102.6	122.8
2014	117.0	107.7	103.2	123.1
2015	108.9	112.8	93.8	113.5

⁸ In the tables data for 2000 and 2015 are presented but should be treated with caution due to the impact of truncation near the start and end of the data extract. To emphasize this, these figures are presented in grey.

Appendix 3 Proportion of prescriptions exceeding 30 days by DFM type.

% Long-term prescriptions (over 30 days)				
Year	Benzodiazepines	Z-drugs	Opioids	GABAergic medicines
2000	21.7	12.9	15.7	24.7
2001	21.3	10.0	15.4	29.4
2002	21.0	11.8	16.0	31.2
2003	20.7	11.6	15.0	36.9
2004	19.8	11.0	15.4	38.0
2005	18.5	11.5	15.3	32.9
2006	16.7	11.6	15.7	30.8
2007	14.5	10.5	15.1	32.5
2008	12.0	10.7	15.3	31.8
2009	12.9	12.1	15.8	32.4
2010	12.4	11.8	16.1	31.5
2011	12.2	9.5	16.2	31.9
2012	11.5	8.9	16.7	29.0
2013	11.0	8.6	18.2	26.7
2014	12.1	9.2	17.5	23.6
2015	11.7	9.9	15.7	25.0

Appendix 4 Proportion of continuous prescribing periods exceeding 30 days by DFM type

% Long-term prescribing (over 30 days)				
Year	Benzodiazepines	Z-drugs	Opioids	GABAergic medicines
2000	50.7	43.8	37.1	55.8
2001	49.1	42.7	38.5	58.0
2002	46.0	44.0	37.9	62.2
2003	45.6	42.2	37.3	69.3
2004	44.0	43.7	38.8	67.3
2005	43.5	42.9	37.8	70.7
2006	42.6	42.4	37.3	65.5
2007	39.6	40.6	36.8	66.7
2008	37.9	41.6	37.0	67.4
2009	35.5	42.8	37.3	67.8
2010	34.3	40.7	38.1	69.3
2011	33.0	41.8	36.7	64.8
2012	34.2	43.5	35.9	61.6
2013	32.3	40.2	34.2	58.7
2014	32.7	37.0	33.7	58.0
2015	31.8	37.1	32.3	56.3

Appendix 5 Proportion of continuous prescribing periods exceeding 6 months by DFM type

% Long-term prescribing (over 6 months)				
Year	Benzodiazepines	Z-drugs	Opioids	GABAergic medicines
2000	12.3	7.9	5.7	9.1
2001	12.6	12.3	7.2	10.4
2002	13.2	10.8	5.7	12.3
2003	13.2	9.8	6.8	12.5
2004	11.2	11.2	6.9	11.6
2005	12.8	11.9	7.4	11.3
2006	12.7	11.7	7.2	13.5
2007	11.7	12.6	6.8	13.0
2008	11.0	11.1	7.1	13.4
2009	10.6	11.9	8.2	13.3
2010	11.2	10.7	7.5	14.5
2011	10.8	12.5	7.5	13.7
2012	11.5	13.3	7.5	13.6
2013	10.0	12.1	7.4	14.3
2014	12.1	12.8	7.3	14.0
2015	9.0	12.0	6.6	11.9

Appendix 6 Proportion of continuous prescribing periods exceeding 12 months by DFM type

% Long-term prescribing (over 12 months)				
Year	Benzodiazepines	Z-drugs	Opioids	GABAergic medicines
2000	3.8	2.8	1.8	1.7
2001	5.4	5.1	2.5	5.1
2002	6.4	4.7	2.5	3.4
2003	6.1	4.7	3.0	4.0
2004	5.3	4.0	2.4	3.0
2005	5.8	5.4	2.8	3.1
2006	5.7	5.1	2.9	5.0
2007	5.5	5.1	2.6	3.7
2008	5.2	4.7	2.7	4.3
2009	5.1	5.5	3.3	4.6
2010	5.5	4.3	3.0	5.7
2011	5.0	5.9	3.1	5.0
2012	5.2	6.2	3.4	4.4
2013	4.5	6.0	3.3	5.7
2014	5.9	6.0	3.6	5.0
2015	4.4	5.5	1.8	3.6

Appendix 7 Average number of days of prescriptions by GABAergic medicine type

Year	Gabapentin	Pregabalin
2000	31.8	-
2001	35.4	-
2002	37.0	-
2003	35.1	-
2004	35.3	26.6
2005	36.3	31.1
2006	36.5	31.6
2007	35.6	32.9
2008	35.7	34.9
2009	36.7	34.3
2010	37.0	34.9
2011	36.4	34.5
2012	36.5	34.7
2013	36.3	35.1
2014	36.5	35.3
2015	35.1	36.3

Appendix 8 Average number of days of continuous prescribing periods by GABAergic medicine type

Year	Gabapentin	Pregabalin
2000	75.3	-
2001	91.4	-
2002	93.1	-
2003	95.3	-
2004	84.7	64.2
2005	103.4	66.8
2006	98.2	90.2
2007	95.2	91.4
2008	100.8	110.3
2009	99.4	110.5
2010	104.5	104.4
2011	95.2	108.6
2012	96.9	107.6
2013	100.2	114.2
2014	102.4	126.6
2015	94.0	116.3

Appendix 9 Proportion of prescriptions exceeding 30 days by GABAergic medicine type

Year	Gabapentin	Pregabalin
2000	29.2	-
2001	49.2	-
2002	51.4	-
2003	56.6	-
2004	55.9	13.3
2005	57.7	15.6
2006	57.1	15.6
2007	58.4	21.6
2008	59.8	28.8
2009	64.4	25.4
2010	64.0	25.4
2011	65.1	25.6
2012	58.6	27.5
2013	54.8	29.6
2014	52.2	29.6
2015	49.7	30.1

Appendix 10 Proportion of continuous prescribing periods exceeding 30 days by GABAergic medicine type

Year	Gabapentin	Pregabalin
2000	55.5	-
2001	68.5	-
2002	68.2	-
2003	72.6	-
2004	71.5	60.0
2005	75.5	56.7
2006	73.4	54.6
2007	72.7	59.5
2008	74.0	62.6
2009	74.8	63.9
2010	75.7	60.8
2011	71.3	58.5
2012	68.7	57.3
2013	62.2	57.6
2014	59.8	62.7
2015	58.3	61.8

Appendix 11 Proportion of continuous prescribing periods exceeding 6 months by GABAergic medicine type

Year	Gabapentin	Pregabalin
2000	9.2	-
2001	9.6	-
2002	8.0	-
2003	12.3	-
2004	8.7	6.7
2005	11.9	3.0
2006	11.5	11.4
2007	10.5	11.3
2008	11.3	12.2
2009	12.7	13.2
2010	11.7	12.0
2011	9.1	14.1
2012	11.3	13.7
2013	11.5	15.9
2014	12.3	16.0
2015	9.2	13.8

Appendix 12 Proportion of continuous prescribing periods exceeding 12 months by GABAergic medicine type

Year	Gabapentin	Pregabalin
2000	0.0	-
2001	4.1	-
2002	2.6	-
2003	4.0	-
2004	2.6	0.0
2005	4.3	0.8
2006	3.1	4.0
2007	3.1	2.8
2008	4.0	3.8
2009	3.8	4.5
2010	3.9	4.7
2011	3.1	5.7
2012	3.4	4.5
2013	4.0	6.1
2014	4.2	7.7
2015	1.7	5.2

Appendix 13 Benzodiazepines: Proportion of continuous prescribing periods exceeding 30 days, by age

Year	18-40	41-60	61-80	81+
2000	35.9	43.8	52.3	62.1
2001	34.1	42.5	50.7	60.7
2002	26.5	37.9	49.5	58.1
2003	27.5	38.7	46.8	59.9
2004	28.5	35.9	45.8	56.6
2005	30.4	35.9	45.2	56.9
2006	26.6	36.5	44.9	55.5
2007	26.6	34.7	41.7	51.2
2008	28.8	31.9	39.5	48.7
2009	23.4	30.2	36.9	47.0
2010	23.3	31.1	35.8	41.7
2011	16.0	28.5	35.7	43.1
2012	20.8	29.8	37.4	44.0
2013	16.4	26.9	37.8	42.0
2014	22.7	31.4	35.6	37.0
2015	19.2	31.0	33.1	40.9

Appendix 14 Benzodiazepines: Proportion of continuous prescribing periods exceeding 6 months, by age

Year	18-40	41-60	61-80	81+
2000	6.5	8.7	13.3	17.4
2001	8.9	11.1	12.4	16.4
2002	7.2	10.2	12.5	21.1
2003	6.5	9.6	13.4	20.2
2004	5.5	9.5	11.5	15.0
2005	9.1	11.4	13.1	16.2
2006	5.9	11.3	13.3	17.1
2007	8.9	10.1	11.6	16.0
2008	5.7	8.1	11.7	16.9
2009	5.4	8.9	10.5	15.9
2010	9.5	10.3	11.0	13.5
2011	4.9	9.9	10.4	15.6
2012	7.7	8.4	12.0	17.5
2013	2.3	10.0	10.0	16.0
2014	10.8	10.7	12.5	14.7
2015	4.7	8.6	8.7	13.6

Appendix 15 Benzodiazepines: Proportion of continuous prescribing periods exceeding 12 months, by age

Year	18-40	41-60	61-80	81+
2000	2.2	3.2	4.4	4.1
2001	3.4	4.7	5.6	6.7
2002	4.0	4.2	6.7	9.7
2003	3.9	4.0	5.5	10.7
2004	3.2	5.1	5.5	6.1
2005	4.0	4.8	6.0	7.8
2006	2.6	6.3	5.9	6.6
2007	2.5	4.7	5.5	8.4
2008	3.6	4.1	5.3	7.6
2009	3.2	4.0	4.6	8.4
2010	4.8	5.6	6.1	4.5
2011	2.2	5.2	4.4	7.2
2012	3.3	3.7	5.9	7.1
2013	0.3	3.9	5.4	7.0
2014	6.3	6.4	5.9	4.6
2015	0.8	4.8	5.4	4.7

Appendix 16 Z-drugs: Proportion of continuous prescribing periods exceeding 30 days, by age

Year	18-40	41-60	61-80	81+
2000	30.8	43.7	44.4	61.7
2001	34.0	37.1	45.0	60.8
2002	30.5	40.2	47.9	58.5
2003	35.2	35.9	49.2	50.6
2004	33.4	36.9	51.8	52.5
2005	28.4	36.4	49.3	54.5
2006	31.5	35.8	46.0	61.1
2007	30.5	37.1	45.6	47.8
2008	30.5	36.3	45.7	57.7
2009	29.6	36.9	46.9	59.6
2010	31.0	34.3	43.1	61.7
2011	27.9	37.2	50.2	47.4
2012	30.0	37.6	48.5	56.0
2013	27.8	32.7	46.2	53.5
2014	21.8	32.7	41.8	46.0
2015	21.2	33.7	41.4	45.8

Appendix 17 Z-drugs: Proportion of continuous prescribing periods exceeding 6 months, by age

Year	18-40	41-60	61-80	81+
2000	5.3	6.3	7.9	14.7
2001	5.2	10.8	13.6	21.4
2002	6.6	10.9	10.7	15.4
2003	8.4	8.5	9.5	15.7
2004	5.8	9.8	13.4	15.3
2005	8.7	9.8	12.8	16.9
2006	5.2	8.7	12.9	22.6
2007	9.5	11.6	13.2	16.9
2008	6.7	9.2	11.6	19.0
2009	5.5	7.9	14.6	21.3
2010	6.0	8.7	10.7	21.0
2011	4.5	11.2	13.8	20.4
2012	8.1	10.8	13.7	22.2
2013	7.0	11.6	11.4	19.8
2014	5.1	10.5	14.7	18.7
2015	6.5	11.1	11.4	18.7

Appendix 18 Z-drugs: Proportion of continuous prescribing periods exceeding 12 months, by age

Year	18-40	41-60	61-80	81+
2000	2.2	2.1	3.2	4.3
2001	1.8	4.2	6.0	8.8
2002	3.5	5.3	4.0	6.6
2003	4.4	4.0	4.8	6.1
2004	3.3	3.8	3.9	5.5
2005	4.6	4.7	5.4	7.9
2006	3.5	3.2	6.2	8.9
2007	3.6	5.9	4.9	5.3
2008	2.3	4.1	5.1	8.0
2009	2.4	3.9	6.3	10.4
2010	2.6	4.9	3.6	6.7
2011	1.7	5.9	6.3	9.1
2012	5.1	3.9	6.1	12.2
2013	6.1	5.7	4.5	9.6
2014	3.0	5.0	6.8	8.2
2015	3.7	4.6	5.2	9.1

Appendix 19 Opioids: Proportion of continuous prescribing periods exceeding 30 days, by age

Year	18-40	41-60	61-80	81+
2000	28.5	36.1	39.6	45.3
2001	28.4	36.3	43.3	42.8
2002	29.4	37.8	42.6	35.8
2003	25.6	36.3	40.7	44.7
2004	27.8	36.2	44.0	41.8
2005	26.9	36.7	41.1	42.9
2006	30.6	35.9	38.3	44.6
2007	28.2	36.0	39.4	39.2
2008	26.8	38.1	39.9	36.0
2009	24.6	37.0	40.4	39.7
2010	26.8	37.1	40.6	41.9
2011	28.6	36.7	38.2	39.1
2012	28.9	34.9	37.0	41.3
2013	28.1	34.6	36.8	31.7
2014	25.1	35.1	36.0	31.5
2015	23.4	35.2	33.1	29.7

Appendix 20 Opioids: Proportion of continuous prescribing periods exceeding 6 months, by age

Year	18-40	41-60	61-80	81+
2000	5.4	5.4	5.8	6.7
2001	5.9	6.9	7.5	8.6
2002	4.5	7.1	5.6	4.8
2003	6.2	7.2	6.7	7.5
2004	4.8	6.4	8.2	6.5
2005	6.9	7.3	7.7	7.4
2006	6.4	7.5	6.6	9.2
2007	5.1	6.8	7.0	8.3
2008	5.0	7.0	7.2	8.7
2009	5.9	7.4	9.5	8.4
2010	6.0	7.3	7.7	8.5
2011	5.6	8.3	7.8	6.5
2012	5.0	6.4	8.4	9.6
2013	6.7	8.0	7.8	6.1
2014	6.4	7.5	7.9	6.2
2015	4.7	6.5	7.3	6.1

Appendix 21 Opioids: Proportion of continuous prescribing periods exceeding 12 months, by age

Year	18-40	41-60	61-80	81+
2000	1.9	1.6	1.9	1.8
2001	2.1	2.5	2.8	2.4
2002	2.5	3.1	2.5	1.2
2003	2.8	3.6	2.5	3.1
2004	1.8	2.4	2.6	2.5
2005	2.9	2.7	3.0	2.6
2006	2.7	3.0	2.7	3.9
2007	2.8	3.2	2.1	2.8
2008	3.0	2.2	2.9	3.2
2009	2.4	3.5	3.6	2.6
2010	3.1	3.0	2.8	3.3
2011	2.4	3.6	3.2	2.6
2012	2.8	2.9	3.8	3.9
2013	3.3	4.2	2.9	2.3
2014	3.8	3.6	4.0	2.7
2015	2.1	1.9	1.7	2.0

Appendix 22 GABAergic medicines: Proportion of continuous prescribing periods exceeding 30 days, by age

Year	18-40	41-60	61-80	81+
2000	38.1	62.1	60.1	76.9
2001	57.5	66.8	57.8	53.6
2002	52.0	69.2	74.8	44.2
2003	63.8	77.9	73.2	65.7
2004	61.8	68.8	70.3	71.0
2005	69.8	70.5	75.6	62.5
2006	62.6	67.5	64.7	64.6
2007	68.5	68.6	68.2	60.5
2008	66.0	64.0	74.3	63.2
2009	64.8	65.3	74.7	61.1
2010	59.1	68.2	74.9	69.2
2011	56.1	66.8	66.9	64.8
2012	50.8	62.6	65.0	61.2
2013	50.3	58.7	60.7	63.9
2014	44.2	58.2	61.6	63.9
2015	56.9	51.8	61.1	58.1

Appendix 23 GABAergic medicines: Proportion of continuous prescribing periods exceeding 6 months, by age

Year	18-40	41-60	61-80	81+
2000	5.8	13.0	6.2	0.0
2001	9.7	10.8	10.4	8.9
2002	9.7	16.1	9.5	7.2
2003	9.4	11.3	14.9	14.3
2004	18.2	8.1	12.0	11.2
2005	19.0	9.4	10.9	7.1
2006	20.0	11.7	12.2	14.1
2007	13.7	16.1	10.6	11.3
2008	12.0	13.9	12.7	15.0
2009	7.7	14.0	13.1	21.3
2010	10.8	15.6	14.3	18.6
2011	8.5	12.6	16.4	15.9
2012	12.0	11.3	15.8	15.8
2013	10.6	11.4	16.5	19.5
2014	9.5	12.9	14.4	21.0
2015	15.4	11.0	11.7	12.3

Appendix 24 GABAergic medicines: Proportion of continuous prescribing periods exceeding 12 months, by age

Year	18-40	41-60	61-80	81+
2000	0.0	1.9	0.0	0.0
2001	5.8	5.3	5.8	0.0
2002	1.6	6.0	1.0	3.6
2003	0.0	4.9	4.0	5.7
2004	7.1	0.2	4.5	2.2
2005	8.5	2.5	2.3	0.4
2006	5.4	4.0	4.9	7.2
2007	5.5	3.6	3.3	3.9
2008	1.8	5.2	4.0	6.7
2009	3.3	4.5	4.1	9.9
2010	3.3	6.9	5.0	7.8
2011	1.8	5.1	5.9	7.1
2012	3.9	4.0	4.6	5.7
2013	5.2	4.4	5.9	9.3
2014	5.0	4.3	5.5	5.9
2015	2.6	3.6	4.3	2.4

Appendix 25 Proportion of continuous prescribing periods exceeding 30 days, by DFM type and gender

Years	Benzodiazepines		Z-drugs		Opioids		GABAergic medicines	
	Male	Female	Male	Female	Male	Female	Male	Female
2000	48.9	51.5	42.7	44.4	36.2	37.7	54.6	56.8
2001	47.3	50.0	41.0	43.5	38.5	38.6	60.7	55.7
2002	44.1	47.0	45.9	43.0	38.0	37.8	65.2	60.3
2003	44.9	45.9	44.5	41.0	36.7	37.7	73.5	66.9
2004	41.5	45.2	46.4	42.2	36.0	40.4	73.5	63.2
2005	41.8	44.3	45.5	41.5	36.2	38.8	75.6	67.5
2006	41.6	43.1	43.9	41.5	35.3	38.5	72.5	61.2
2007	39.4	39.7	42.1	39.8	37.3	36.5	68.4	65.7
2008	38.3	37.7	40.1	42.4	35.1	38.1	72.5	64.6
2009	34.5	35.9	43.1	42.5	36.4	37.8	68.7	67.3
2010	35.8	33.5	40.6	40.8	38.5	37.8	69.4	69.2
2011	33.5	32.7	41.8	41.8	36.1	37.1	67.0	63.2
2012	33.6	34.6	42.3	44.1	35.3	36.2	63.4	60.3
2013	34.1	31.3	40.2	40.2	34.2	34.2	59.1	58.5
2014	36.0	31.0	36.9	37.0	31.9	34.7	56.8	58.7
2015	32.9	31.2	36.4	37.4	31.5	32.7	55.9	56.5

Appendix 26 Proportion of continuous prescribing periods exceeding 6 months, by DFM type and gender

Years	Benzodiazepines		Z-drugs		Opioids		GABAergic medicines	
	Male	Female	Male	Female	Male	Female	Male	Female
2000	10.5	13.1	7.5	8.0	6.6	5.2	8.5	9.6
2001	10.4	13.7	12.8	12.1	6.5	7.6	12.5	8.5
2002	11.9	13.8	11.5	10.4	5.4	5.9	15.8	10.0
2003	10.6	14.4	10.3	9.5	7.2	6.6	17.1	9.9
2004	9.6	12.0	11.3	11.2	6.2	7.2	16.8	8.2
2005	11.7	13.3	11.7	12.0	7.5	7.3	14.5	9.2
2006	11.6	13.3	10.7	12.3	6.6	7.5	15.8	12.0
2007	11.3	12.0	13.5	12.1	6.6	7.0	13.6	12.7
2008	11.0	11.0	10.1	11.5	6.4	7.4	16.2	11.9
2009	10.5	10.7	10.8	12.5	7.6	8.6	12.5	13.8
2010	11.6	11.0	10.4	10.8	6.9	7.8	12.7	15.7
2011	10.0	11.2	11.2	13.1	7.9	7.1	13.5	13.9
2012	10.8	11.9	13.3	13.3	6.6	8.1	13.3	13.7
2013	11.1	9.4	11.5	12.5	7.4	7.4	13.9	14.6
2014	12.9	11.7	13.9	12.2	7.3	7.3	14.3	13.8
2015	8.2	9.4	9.0	13.6	6.3	6.7	13.0	11.3

Appendix 27 Proportion of continuous prescribing periods exceeding 12 months, by DFM type and gender

Years	Benzodiazepines		Z-drugs		Opioids		GABAergic medicines	
	Male	Female	Male	Female	Male	Female	Male	Female
2000	4.0	3.7	3.3	2.6	1.8	1.8	2.4	1.0
2001	4.6	5.8	5.0	5.1	2.5	2.6	5.6	4.7
2002	5.0	7.1	5.6	4.3	2.1	2.7	5.4	2.1
2003	4.8	6.7	4.7	4.6	3.3	2.8	3.9	4.1
2004	4.4	5.7	4.5	3.7	2.2	2.5	4.4	2.1
2005	5.8	5.8	5.3	5.5	2.8	2.8	4.1	2.4
2006	5.7	5.7	4.7	5.4	2.5	3.2	5.8	4.6
2007	5.3	5.6	6.2	4.5	2.6	2.7	5.0	3.0
2008	4.1	5.8	3.4	5.4	2.2	3.0	4.9	4.0
2009	5.3	5.0	5.6	5.4	3.3	3.2	4.2	4.8
2010	6.6	4.9	3.9	4.5	2.8	3.1	5.6	5.7
2011	4.2	5.4	5.1	6.3	3.3	2.9	4.6	5.3
2012	5.5	5.1	6.3	6.2	3.3	3.4	4.0	4.6
2013	4.2	4.7	6.2	5.8	3.5	3.2	5.6	5.7
2014	7.3	5.1	7.7	5.1	4.2	3.3	6.9	3.9
2015	3.8	4.7	4.9	5.8	1.3	2.1	4.2	3.2

Appendix 28 Proportion of continuous benzodiazepine prescribing periods exceeding 30 days, by IMD quintile

Proportion of benzodiazepine prescribing					
Index of multiple deprivation (IMD) quintiles					
Year	Q1 (least deprived)	Q2	Q3	Q4	Q5 (most deprived)
2000	47.4	49.2	52.4	51.0	53.7
2001	44.9	47.1	50.0	52.2	51.6
2002	43.0	39.6	51.4	47.9	49.7
2003	44.4	41.3	48.6	46.8	47.8
2004	38.3	40.8	44.8	47.0	50.6
2005	35.8	42.8	44.0	47.0	48.0
2006	43.9	40.8	43.5	41.8	43.9
2007	35.9	36.0	44.8	35.9	47.7
2008	33.2	36.4	40.0	37.7	43.4
2009	32.3	36.0	36.3	35.1	38.3
2010	33.0	31.8	35.1	34.3	38.9
2011	29.4	31.4	36.9	35.0	31.9
2012	31.7	30.2	40.2	37.7	31.2
2013	29.4	31.3	34.9	33.9	31.3
2014	28.1	27.3	36.0	33.4	39.5
2015	29.8	31.1	31.9	32.4	34.4

Appendix 29 Proportion of continuous benzodiazepine prescribing periods exceeding 6 months, by IMD quintile

Proportion of benzodiazepine prescribing					
Index of multiple deprivation (IMD) quintiles					
Year	Q1 (least deprived)	Q2	Q3	Q4	Q5 (most deprived)
2000	9.3	11.2	12.1	14.9	14.2
2001	9.5	11.3	11.8	13.9	16.9
2002	9.6	12.5	16.4	12.0	16.3
2003	11.9	11	12.9	13.7	17.2
2004	9.5	8.5	12.3	12.3	14.8
2005	8.9	10.7	14.5	13.7	17.3
2006	12.9	10.8	12.0	12.7	16.4
2007	8.3	9.7	13.6	10.8	17.4
2008	7.1	10.7	11.8	11.6	14.2
2009	9.5	11.0	11.1	11.2	10.3
2010	8.7	10.3	11.3	9.9	17.5
2011	10.5	10.7	8.7	13.3	10.1
2012	9.7	11.3	13.9	10.4	12.7
2013	7.3	9.7	10.0	10.8	12.5
2014	8.8	9.6	12.0	11.5	19.4
2015	7.9	6.6	7.2	12.9	11.5

Appendix 30 Proportion of continuous benzodiazepine prescribing periods exceeding 12 months, by IMD quintile

Proportion of benzodiazepine prescribing					
Index of multiple deprivation (IMD) quintiles					
Year	Q1 (least deprived)	Q2	Q3	Q4	Q5 (most deprived)
2000	3.0	3.5	4.1	3.5	5.2
2001	3.0	5.5	6.0	6.1	6.5
2002	4.1	5.8	8.0	6.9	7.4
2003	5.8	4.8	5.9	6.5	7.8
2004	4.1	3.4	5.6	5.9	8.6
2005	3.1	3.6	7.7	6.1	9.7
2006	4.9	4.0	6.4	6.3	7.9
2007	3.4	4.2	6.7	5.2	8.8
2008	2.9	5.2	5.8	4.5	8.2
2009	4.2	5.3	6.0	5.1	5.0
2010	3.3	4.0	6.4	5.7	9.0
2011	4.3	4.9	3.1	5.8	7.3
2012	2.7	6.5	5.4	4.5	6.9
2013	4.1	3.4	4.5	5.3	5.6
2014	3.3	3.5	4.9	7.5	10.6
2015	3.7	3.4	2.9	6.2	6.3

Appendix 31 Proportion of continuous Z-drugs prescribing periods exceeding 30 days, by IMD quintile

Proportion of Z-drug prescribing					
Index of multiple deprivation (IMD) quintiles					
Year	Q1 (least deprived)	Q2	Q3	Q4	Q5 (most deprived)
2000	50.1	42.1	41.9	40.5	45
2001	39.3	49.3	44.5	40.9	39.9
2002	41.7	48.6	43.4	44.6	40.9
2003	38.8	48.1	44.6	34.8	43.3
2004	42.4	43.8	43.8	42.6	47.5
2005	42.2	41.2	47.1	48.6	34.1
2006	41.7	43.9	43.8	41.0	40.7
2007	34.8	44.1	34.6	45.1	44.3
2008	44.7	41.9	42.8	37.5	41.1
2009	43.1	40.3	44.8	40.9	46.3
2010	37.7	41.0	39.4	45.0	41.7
2011	42.0	42.1	36.9	43.8	44.6
2012	43.7	42.8	40.0	47.7	43.6
2013	37.5	48.1	39.3	35.9	37.2
2014	42.2	37.5	36.8	29.5	38.2
2015	40.3	39	37.5	33.9	32.7

Appendix 32 Proportion of continuous Z-drugs prescribing periods exceeding 6 months, by IMD quintile

Proportion of Z-drug prescribing					
Index of multiple deprivation (IMD) quintiles					
Year	Q1 (least deprived)	Q2	Q3	Q4	Q5 (most deprived)
2000	6.3	8.8	9.1	7.1	7.8
2001	9.3	17.9	15.3	8.5	10.8
2002	11.3	11.2	12.8	9.3	9.4
2003	8.5	7.7	10.6	8.5	14.4
2004	9.4	9.6	10.3	10.8	17.3
2005	8.6	12.5	11.7	14.1	12.7
2006	9.3	11.7	15.8	9.9	11.7
2007	12.3	12.2	12.3	12.2	14.7
2008	10.4	9.7	11.8	10.9	13.3
2009	11.9	11.8	11.4	11.1	13.8
2010	9.4	10.7	9.4	12.7	11.8
2011	12.3	9.2	10.2	15.5	18.0
2012	14.1	10.9	13.3	14.2	15.1
2013	9.0	12.4	10.8	12.4	17.3
2014	13.0	13.1	9.6	11.8	17.5
2015	11.4	11.5	14.2	14.0	8.4

Appendix 33 Proportion of continuous Z-drugs prescribing periods exceeding 12 months, by IMD quintile

Proportion of Z-drug prescribing					
Index of multiple deprivation (IMD) quintiles					
Year	Q1 (least deprived)	Q2	Q3	Q4	Q5 (most deprived)
2000	2.4	4.0	1.6	3.2	2.8
2001	4.8	7.5	5.2	3.0	4.7
2002	3.9	5.1	5.0	5.6	3.9
2003	3.3	3.2	6.2	4.2	6.6
2004	4.0	3.6	2.9	4.0	6.0
2005	4.2	6.6	5.1	5.8	5.3
2006	4.0	3.6	8.9	4.7	4.4
2007	3.7	5.3	3.9	5.1	8.1
2008	4.7	3.5	6.2	3.2	6.7
2009	5.7	5.3	6.3	3.8	6.5
2010	3.4	3.2	3.4	6.6	5.7
2011	5.0	3.6	5.8	7.2	10.1
2012	5.9	5.0	7.1	6.4	7.2
2013	4.0	5.8	4.5	5.1	11.6
2014	6.2	6.0	5.4	4.7	7.9
2015	3.3	4.3	8.4	8.1	3.8

Appendix 34 Proportion of continuous opioids prescribing periods exceeding 30 days, by IMD quintile

Proportion of opioid prescribing					
Index of multiple deprivation (IMD) quintiles					
Year	Q1 (least deprived)	Q2	Q3	Q4	Q5 (most deprived)
2000	41.9	37.0	41.92	32.4	34.6
2001	38.7	41.1	42.8	34.6	36.3
2002	35.6	40.4	41.1	34.5	37.6
2003	34.7	37.4	41.5	34.0	38.5
2004	35.4	39.3	40.3	41.6	35.6
2005	34.5	37.9	38.8	39.9	36.5
2006	35.3	37.7	42.1	35.5	35.9
2007	37.8	35.4	38.8	36.6	35.9
2008	37.1	39.1	40.2	35.3	34.0
2009	37.5	39.4	39.4	36.0	34.2
2010	37.8	38.8	39.5	35.9	38.2
2011	37.0	38.4	34.8	36.4	36.7
2012	33.3	36.9	35.2	36.7	36.4
2013	30.6	35.6	33.5	34.5	35.4
2014	33.6	34.1	31.1	36.3	32.7
2015	33.8	35.0	28.6	33.3	31.0

Appendix 35 Proportion of continuous opioids prescribing periods exceeding 6 months, by IMD quintile

Proportion of Opioid prescribing					
Index of multiple deprivation (IMD) quintiles					
Year	Q1 (least deprived)	Q2	Q3	Q4	Q5 (most deprived)
2000	6.6	5.2	7.7	4.8	4.7
2001	5.9	8.4	8.1	5.7	7.5
2002	4.3	6.6	4.2	5.9	6.8
2003	6.6	5.8	7.4	6.5	7.8
2004	5.4	7.6	6.2	5.9	8.6
2005	5.5	7.4	7.6	6.5	9.4
2006	6.6	6.6	8.3	7.0	7.3
2007	6.8	6.5	7.3	6.3	7.3
2008	5.0	7.6	7.1	6.6	8.3
2009	6.5	10.2	9.5	6.9	7.7
2010	6.2	7.7	7.9	7.4	7.9
2011	6.4	8.0	6.2	7.7	8.7
2012	6.2	7.7	7.4	7.5	8.3
2013	5.0	7.6	6.7	8.2	8.5
2014	4.6	7.4	7.1	8.1	8.3
2015	6.5	8.4	5.8	5.6	6.8

Appendix 36 Proportion of continuous opioids prescribing periods exceeding 12 months, by IMD quintile

Proportion of opioid prescribing					
Index of multiple deprivation (IMD) quintiles					
Year	Q1 (least deprived)	Q2	Q3	Q4	Q5 (most deprived)
2000	2.9	2.0	2.2	1.4	1.1
2001	1.5	3.4	3.1	2.5	1.8
2002	1.4	3.2	2.0	2.5	2.7
2003	3.4	1.3	2.7	3.1	4.6
2004	1.4	2.5	3.0	1.5	3.5
2005	2.3	1.8	3.4	3.0	3.3
2006	3.2	3.1	2.9	2.8	2.9
2007	2.5	2.6	2.4	2.7	2.9
2008	1.5	2.8	2.9	2.4	3.8
2009	1.9	3.4	4.4	2.9	3.6
2010	1.4	2.8	3.3	3.4	3.6
2011	1.7	3.5	2.0	3.0	4.8
2012	2.5	3.1	3.1	3.9	3.9
2013	2.1	4.2	2.2	3.8	3.5
2014	0.8	4.6	3.6	4.2	3.9
2015	1.4	2.6	1.5	1.5	2.1

Appendix 37 Proportion of continuous GABAergic medicines prescribing periods exceeding 30 days, by IMD quintile

Proportion of GABAergic medicines prescribing					
Index of multiple deprivation (IMD) quintiles					
Year	Q1 (least deprived)	Q2	Q3	Q4	Q5 (most deprived)
2000	39.2	31.2	72.2	64.1	65.6
2001	56.2	47.7	63.3	65.7	57.0
2002	58.4	66.0	63.0	58.0	66.5
2003	66.8	74.1	70.7	66.7	68.3
2004	71.3	69.8	68.8	67.0	60.6
2005	71.6	66.5	80.3	68.1	68.4
2006	65.5	62.4	67.3	65.8	66.8
2007	68.5	63.8	62.5	63.0	77.5
2008	65.1	68.5	68.8	64.9	69.8
2009	72.9	66.1	70.5	68.2	62.8
2010	70.5	71.3	69.7	72.0	63.1
2011	62.9	67.3	64.6	69.3	59.1
2012	61.9	62.6	59.5	64.8	58.8
2013	58.2	58.1	63.4	59.9	53.3
2014	56.5	54.6	62.8	59.6	56.3
2015	54.1	56.9	56.0	57.4	56.7

Appendix 38 Proportion of continuous GABAergic medicines prescribing periods exceeding 6 months, by IMD quintile

Proportion of GABAergic medicines prescribing Index of multiple deprivation (IMD) quintiles					
Year	Q1 (least deprived)	Q2	Q3	Q4	Q5 (most deprived)
2000	16.7	7.9	8.2	7.8	7.8
2001	15.4	8.8	8.4	12.5	7.9
2002	12.2	19.6	6.8	10.4	12.9
2003	13.9	16.1	16.5	10.3	5.5
2004	12.5	11.3	13.2	15.0	6.1
2005	14.1	7.0	10.2	15.4	10.0
2006	12.2	10.9	11.9	12.6	19.7
2007	17.0	8.4	11.1	14.6	13.7
2008	14.8	10.6	16.5	13.7	12.3
2009	15.4	14.4	15.3	13.1	9.4
2010	15.4	18.3	14.2	15.5	9.7
2011	11.6	15.0	14.3	14.5	13.1
2012	13.3	11.9	13.6	15.3	13.6
2013	11.9	16.7	12	17.5	12.3
2014	14.5	11.9	12.8	16.1	14.9
2015	8.5	13.8	12.6	10.3	14.5

Appendix 39 Proportion of continuous GABAergic medicines prescribing periods exceeding 12 months, by IMD quintile

Proportion of GABAergic medicines prescribing					
Index of multiple deprivation (IMD) quintiles					
Year	Q1 (least deprived)	Q2	Q3	Q4	Q5 (most deprived)
2000	0.0	2.0	3.0	4.0	7.8
2001	6.2	3.5	4.2	8.9	2.3
2002	1.7	6.4	3.2	1.3	4.7
2003	5.4	3.6	5.3	1.9	4.9
2004	0.5	2.4	4.4	3.7	3.5
2005	2.2	0.7	4.4	5.6	2.6
2006	6.3	4.3	4.3	4.3	5.8
2007	5.5	2.2	3.1	4.2	2.9
2008	4.9	3.2	5.4	4.1	4.3
2009	3.5	5.5	4.5	5.8	3.5
2010	6.7	7.0	4.2	5.7	5.0
2011	2.9	7.0	5.7	4.8	4.7
2012	4.6	3.6	2.2	4.9	6.4
2013	5.7	7.0	4.4	7.1	3.8
2014	3.8	5.7	3.2	5.9	6.2
2015	1.7	4.7	3.1	2.7	5.8

Appendix 40 Characteristics of people prescribed benzodiazepines in 2014, by continuous prescribing period length

Benzodiazepines				
	Up to 3 months	3 to 6 months	6 to 12 months	Over 12 months
Mean age (years)	61.0***	63.8*	65.6***	62.3
IMD quintile (%)				
I (least deprived) §	57.5	6.0	6.0	3.3
II	56.3	6.0	6.8	3.5
III	43.6***	9.3**	8.3*	4.9
IV	49.7***	11.7***	4.5	7.5***
V (most deprived)	43.0***	12.0***	9.4**	10.6***
Gender (%)				
Male §	51.6	10.0	6.1	7.3
Female	49.1	8.4*	7.5	5.1***
Region (%)				
North of England §	46.6	10.1	6.7	9.7
Midlands and East of England	54.5***	10.2	6.9	4.8***
London	51.9*	3.7***	3.4**	7.3
South East	53.3***	9.6	9.2**	3.7***
South West	35.6***	6.9*	5.1	5.0***

* $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, § - reference category

Appendix 41 Characteristics of people prescribed Z-drugs in 2014, by continuous prescribing period length

Z-drugs				
	Up to 3 months	3 to 6 months	6 to 12 months	Over 12 months
Mean age (years)	60.4***	65.0***	68.1***	67.5***
IMD quintile (%)				
I (least deprived) §	61.7	11.8	7.2	6.2
II	67.1*	9.1	7.6	6.0
III	64.1	9.1	5.0*	5.4
IV	67.8**	6.3***	7.8	4.8
V (most deprived)	52.7***	3.6***	11.3**	8.0
Gender (%)				
Male §	27.5	16.5	14.8	7.7
Female	26.9**	17.4*	15.3	5.1**
Region (%)				
North of England §	61.6	7.0	9.1	9.5
Midlands and East of England	68.8***	7.3	7.2	4.7***
London	71.6***	6.6	7.9	5.6*
South East	62.7	11.2***	7.0	5.4***
South West	51.8***	5.2	7.5	4.2***

* $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, § - reference category

Appendix 42 Characteristics of people prescribed opioids in 2014, by continuous prescribing period length

Opioids				
	Up to 3 months	3 to 6 months	6 to 12 months	Over 12 months
Mean age (years)	61.6***	63.3	63.8	63.1
IMD quintile (%)				
I (least deprived) §	52.1	10.4	4.2	0.9
II	45.4***	10.6	3.5	4.6***
III	51.8	8.1**	3.8	3.6***
IV	55.0*	9.6	4.4	4.***
V (most deprived)	50.5	7.3***	5.1	3.9***
Gender (%)				
Male §	52.3	8.7	3.6	4.2
Female	49.7***	9.4	4.6**	3.3**
Region (%)				
North of England §	53.6	8.8	5.3	4.7
Midlands and East of England	52.9	9.9	3.1***	3.6*
London	52.4	10.1	3.8*	2.2***
South East	46.0***	8.9	4.0**	3.3***
South West	49.9**	8.3	3.8*	2.0***

* $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, § - reference category

Appendix 43 Characteristics of people prescribed GABAergic medicines in 2014, by continuous prescribing period length

GABAergic medicines				
	Up to 3 months	3 to 6 months	6 to 12 months	Over 12 months
Mean age (years)	59.7	60.1	63.7***	61.1
IMD quintile (%)				
I (least deprived) §	41.0	10.7	13.2	3.8
II	38.1	17.7***	7.3***	5.6*
III	44.0	21.1***	12.5	3.2
IV	41.5	19.1***	11.6	5.9*
V (most deprived)	47.5***	12.0	10.0**	6.2**
Gender (%)				
Male §	43.5	15.1	8.4	6.9
Female	42.2	16.8	12.2***	3.9***
Region (%)				
North of England §	44.9	14.2	12.2	4.8
Midlands and East of England	43.1	16.0	9.6*	7.4***
London	43.2	13.7	11.7	2.2*
South East	41.3*	16.8*	11.0	4.4
South West	37.4***	23.9***	7.3***	4.8

* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, § - reference category

Appendix 44 Proportion of continuous prescribing periods exceeding 30 days by GABAergic medicine type

Year	Gabapentin	Pregabalin
2000	55.5	-
2001	68.5	-
2002	68.2	-
2003	72.6	-
2004	71.5	60.0
2005	75.5	56.7
2006	73.4	54.6
2007	72.7	59.5
2008	74.0	62.6
2009	74.8	63.9
2010	75.7	60.8
2011	71.3	58.5
2012	68.7	57.3
2013	62.2	57.6
2014	59.8	62.7
2015	58.3	61.8

Appendix 45 Proportion of continuous prescribing periods exceeding 6 months by GABAergic medicine type

Year	Gabapentin	Pregabalin
2000	9.2	-
2001	9.6	-
2002	8.0	-
2003	12.3	-
2004	8.7	6.7
2005	11.9	3.0
2006	11.5	11.4
2007	10.5	11.3
2008	11.3	12.2
2009	12.7	13.2
2010	11.7	12.0
2011	9.1	14.1
2012	11.3	13.7
2013	11.5	15.9
2014	12.3	16.0
2015	9.2	13.8

Appendix 46 Proportion of continuous prescribing periods exceeding 12 months by GABAergic medicine type

Year	Gabapentin	Pregabalin
2000	0.0	-
2001	4.1	-
2002	2.6	-
2003	4.0	-
2004	2.6	0.0
2005	4.3	0.8
2006	3.1	4.0
2007	3.1	2.8
2008	4.0	3.8
2009	3.8	4.5
2010	3.9	4.7
2011	3.1	5.7
2012	3.4	4.5
2013	4.0	6.1
2014	4.2	7.7
2015	1.7	5.2

Appendix 47 Gabapentin: Proportion of continuous prescribing periods exceeding 30 days, by age

Year	18-40	41-60	61-80	81+
2000	32.0	67.5	54.3	75.0
2001	61.8	78.3	61.3	70.6
2002	57.4	74.7	76.1	41.9
2003	54.1	78.0	75.8	68.4
2004	62.2	73.9	72.4	75.5
2005	66.2	76.4	78.5	73.2
2006	64.0	77.8	73.5	74.6
2007	67.5	75.8	71.0	73.5
2008	76.4	71.9	78.1	63.0
2009	70.0	71.7	80.1	69.5
2010	66.9	76.6	79.2	71.6
2011	66.7	71.6	73.5	67.3
2012	60.1	70.2	71.3	63.1
2013	58.5	64.6	61.0	62.6
2014	48.9	63.5	62.9	53.2
2015	53.2	55.4	63.0	58.4

Appendix 48 Gabapentin: Proportion of continuous prescribing periods exceeding 6 months, by age

Year	18-40	41-60	61-80	81+
2000	4.0	17.5	6.5	0.0
2001	2.9	10.1	10.7	11.8
2002	5.9	8.4	9.4	6.5
2003	9.8	10.1	15.8	10.5
2004	8.5	4.9	11.4	13.2
2005	11.7	9.3	14.6	10.7
2006	17.4	8.0	11.5	15.3
2007	9.1	11.0	8.8	15.7
2008	5.5	11.4	10.8	18.0
2009	9.0	12.2	11.8	23.2
2010	5.2	11.9	12.4	17.4
2011	7.4	6.0	11.1	14.5
2012	9.1	8.1	14.1	14.9
2013	9.4	10.8	11.0	17.4
2014	6.8	11.7	13.5	16.9
2015	12.1	8.0	8.5	12.9

Appendix 49 Gabapentin: Proportion of continuous prescribing periods exceeding 12 months, by age

Year	18-40	41-60	61-80	81+
2000	0.0	0.0	0.0	0.0
2001	2.9	4.3	4.0	0.0
2002	2.9	4.2	0.9	3.2
2003	3.3	3.1	4.2	7.9
2004	1.2	0.5	5.4	1.9
2005	7.8	2.7	5.3	1.8
2006	3.5	2.2	2.3	8.5
2007	2.6	2.9	2.8	4.8
2008	1.8	4.7	3.6	6.0
2009	2.0	3.3	3.9	7.3
2010	2.6	5.6	2.6	5.5
2011	0.0	3.3	2.5	9.1
2012	3.5	2.9	3.4	5.0
2013	1.9	3.3	4.7	6.1
2014	1.5	4.2	4.3	7.3
2015	0.8	1.9	2.0	1.0

Appendix 50 Pregabalin: Proportion of continuous prescribing periods exceeding 30 days, by age

Year	18-40	41-60	61-80	81+
2004	100.0	33.3	83.3	50.0
2005	47.1	71.4	52.6	27.3
2006	62.2	61.0	46.0	44.4
2007	55.0	57.4	68.5	37.0
2008	60.0	54.2	72.7	74.3
2009	67.9	58.1	70.4	57.1
2010	58.6	59.2	63.8	62.2
2011	56.4	58.2	60.2	59.0
2012	47.1	56.1	62.4	64.7
2013	47.1	55.6	63.6	60.9
2014	48.1	62.2	66.7	75.0
2015	61.6	61.7	63.0	65.5

Appendix 51 Pregabalin: Proportion of continuous prescribing periods exceeding 6 months, by age

Year	18-40	41-60	61-80	81+
2004	0.0	0.0	16.7	0.0
2005	5.9	4.1	1.8	0.0
2006	13.5	10.2	13.0	5.6
2007	13.3	9.2	12.9	11.1
2008	10.0	10.7	16.5	8.6
2009	4.9	14.7	14.8	14.3
2010	5.4	14.3	12.1	16.2
2011	9.8	13.0	17.2	16.4
2012	15.9	9.8	16.4	16.2
2013	8.6	17.3	17.8	16.1
2014	13.7	14.0	18.2	19.7
2015	13.4	14.4	14.0	13.8

Appendix 52 Pregabalin: Proportion of continuous prescribing periods exceeding 12 months, by age

Year	18-40	41-60	61-80	81+
2004	0.0	0.0	0.0	0.0
2005	0.0	0.0	1.8	0.0
2006	8.1	2.5	5.0	0.0
2007	5.0	1.4	4.0	0.0
2008	0.0	3.4	5.8	5.7
2009	1.2	4.1	5.6	7.1
2010	0.0	7.2	4.3	5.4
2011	3.8	4.5	7.3	9.8
2012	5.8	1.8	5.2	11.8
2013	5.0	7.8	4.4	8.0
2014	8.4	6.5	8.3	9.2
2015	2.7	6.6	4.3	8.6

Appendix 53 Proportion of continuous prescribing periods exceeding 30 days, by GABAergic medicine type and gender

Years	Gabapentin		Pregabalin	
	Male	Female	Male	Female
2000	52.6	58.1	-	-
2001	68.2	68.8	-	-
2002	70.1	67.0	-	-
2003	78.6	69.7	-	-
2004	74.3	69.8	75.0	54.5
2005	79.7	72.9	46.9	62.4
2006	79.8	69.2	55.8	54.1
2007	77.8	69.6	65.5	56.7
2008	77.0	72.3	65.7	61.0
2009	73.7	75.4	66.5	62.7
2010	79.1	73.3	59.0	61.8
2011	75.3	68.3	57.4	59.1
2012	70.6	67.4	55.5	58.5
2013	65.5	60.1	50.3	61.6
2014	59.9	59.8	60.2	64.0
2015	59.9	57.4	62.2	61.5

Appendix 54 Proportion of continuous prescribing periods exceeding 6 months, by GABAergic medicine type and gender

Years	Gabapentin		Pregabalin	
	Male	Female	Male	Female
2000	3.5	14.5	-	-
2001	12.9	7.1	-	-
2002	11.1	6.2	-	-
2003	17.1	9.9	-	-
2004	10.7	7.5	0.0	9.1
2005	13.0	11.2	2.0	3.5
2006	11.9	11.2	14.3	10.2
2007	10.4	10.6	13.3	10.4
2008	12.6	10.5	16.4	10.0
2009	11.9	13.2	16.5	11.6
2010	11.3	11.9	12.1	11.8
2011	9.6	8.7	13.1	14.6
2012	11.0	11.5	12.0	14.8
2013	10.1	12.4	15.0	16.4
2014	10.3	13.5	19.9	13.9
2015	9.9	8.7	14.2	13.6

Appendix 55 Proportion of continuous prescribing periods exceeding 12 months, by GABAergic medicine type and gender

Years	Gabapentin		Pregabalin	
	Male	Female	Male	Female
2000	0.0	0.0	-	-
2001	5.9	2.7	-	-
2002	5.1	1.0	-	-
2003	5.7	3.2	-	-
2004	2.1	2.8	0.0	0.0
2005	5.2	3.7	0.0	1.2
2006	5.1	1.8	2.6	4.6
2007	3.1	3.0	3.5	2.5
2008	4.4	3.8	6.0	2.7
2009	3.1	4.2	6.6	3.4
2010	4.4	3.5	5.1	4.5
2011	2.8	3.4	3.9	6.8
2012	2.9	3.7	3.5	5.1
2013	3.6	4.3	5.8	6.3
2014	4.5	4.1	13.0	4.9
2015	2.4	1.3	6.9	4.2

Appendix 56 Proportion of continuous gabapentin prescribing periods exceeding 30 days, by IMD quintile

Proportion of gabapentin prescribing					
	Index of multiple deprivation (IMD) quintiles				
Year	Q1	Q2	Q3	Q4	Q5
2000	47.4	42.9	61.3	61.5	59.1
2001	72.0	61.4	71.4	77.1	60.5
2002	64.9	71.4	70.8	63.4	70.9
2003	68.8	80.2	73.5	67.3	73.7
2004	76.3	72.1	76.1	70.7	64.6
2005	67.7	80.6	81.2	72.9	73.9
2006	75.7	66.0	78.3	78.7	70.2
2007	69.6	71.0	69.9	75.5	76.4
2008	70.0	73.3	78.8	73.0	75.1
2009	78.4	74.5	74.9	77.2	69.6
2010	81.6	78.7	76.7	80.8	64.5
2011	74.8	71.8	72.9	77.3	60.3
2012	71.1	67.5	69.5	70.6	66.1
2013	70.9	60.8	68.3	61.4	52.6
2014	63.3	54.6	59.3	66.1	57.5
2015	61.0	58.2	57.0	58.4	57.5

Appendix 57 Proportion of continuous gabapentin prescribing periods exceeding 6 months, by IMD quintile

Proportion of gabapentin prescribing					
	Index of multiple deprivation (IMD) quintiles				
Year	Q1	Q2	Q3	Q4	Q5
2000	15.8	9.5	9.7	11.5	0.0
2001	4.0	9.1	11.9	12.5	7.9
2002	5.3	14.3	4.6	8.5	7.3
2003	8.8	15.6	16.2	12.5	7.9
2004	12.5	7.7	8.7	12.9	2.7
2005	11.1	10.5	13.7	12.8	11.2
2006	11.2	8.8	7.8	14.0	15.3
2007	15.2	7.1	6.5	13.8	10.4
2008	10.8	6.8	14.4	13.3	10.4
2009	16.3	13.7	13.8	12.5	8.8
2010	11.8	15.3	11.9	13.5	7.0
2011	7.7	11.1	8.6	12.4	5.0
2012	10.0	11.7	11.9	12.1	10.9
2013	9.7	11.7	9.8	12.3	13.3
2014	15.2	12.4	9.5	14.6	10.9
2015	7.6	10.3	7.3	9.0	11.3

Appendix 58 Proportion of continuous gabapentin prescribing periods exceeding 12 months, by IMD quintile

Proportion of gabapentin prescribing					
	Index of multiple deprivation (IMD) quintiles				
Year	Q1	Q2	Q3	Q4	Q5
2000	0.0	0.0	0.0	0.0	0.0
2001	0.0	2.3	7.1	6.3	2.6
2002	0.0	4.8	3.1	1.4	3.6
2003	2.5	4.2	5.9	2.9	5.3
2004	5.0	1.0	3.3	4.3	0.0
2005	2.0	3.2	4.3	6.0	5.2
2006	3.7	2.7	1.7	5.1	2.3
2007	6.3	0.6	1.3	5.3	2.1
2008	5.0	3.1	4.4	3.5	4.5
2009	3.9	3.1	4.2	4.0	3.7
2010	4.6	5.0	2.5	3.9	3.9
2011	2.6	3.7	2.7	4.4	1.7
2012	3.3	3.3	2.5	3.8	3.9
2013	2.9	4.6	3.1	4.7	4.4
2014	4.4	4.6	1.5	7.3	3.6
2015	0.6	0.0	0.0	2.7	4.2

Appendix 59 Proportion of continuous pregabalin prescribing periods exceeding 30 days, by IMD quintile

Proportion of pregabalin prescribing					
	Index of multiple deprivation (IMD) quintiles				
Year	Q1	Q2	Q3	Q4	Q5
2004	33.3	100.0	100.0	100.0	33.3
2005	57.7	50.0	66.7	66.7	41.7
2006	54.3	61.7	56.6	47.3	51.7
2007	57.4	65.8	58.5	48.9	69.0
2008	75.5	60.4	59.4	62.5	59.8
2009	72.9	66.9	57.0	61.0	62.2
2010	61.8	62.0	60.2	58.2	61.6
2011	55.2	65.1	57.4	59.5	55.8
2012	59.0	66.5	53.2	55.5	53.7
2013	59.5	55.5	57.2	59.1	56.4
2014	59.8	61.6	67.1	66.7	57.6
2015	60.9	66.4	65.4	57.7	59.8

Appendix 60 Proportion of continuous pregabalin prescribing periods exceeding 6 months, by IMD quintile

Proportion of pregabalin prescribing					
	Index of multiple deprivation (IMD) quintiles				
Year	Q1	Q2	Q3	Q4	Q5
2004	0.0	0.0	100.0	0.0	0.0
2005	3.8	0.0	0.0	4.8	8.3
2006	8.7	8.3	20.8	7.3	10.3
2007	11.1	6.8	16.9	8.0	14.1
2008	18.9	12.1	5.8	12.5	13.0
2009	18.8	15.3	9.7	12.7	10.4
2010	8.8	13.4	15.0	12.1	11.0
2011	12.7	11.6	16.2	12.0	18.2
2012	11.5	14.6	10.9	15.9	14.7
2013	13.5	16.8	13.9	18.2	16.8
2014	10.7	15.1	16.1	22.2	14.5
2015	12.2	19.8	14.2	8.0	16.4

Appendix 61 Proportion of continuous pregabalin prescribing periods exceeding 12 months, by IMD quintile

Proportion of pregabalin prescribing					
	Index of multiple deprivation (IMD) quintiles				
Year	Q1	Q2	Q3	Q4	Q5
2004	0.0	0.0	0.0	0.0	0.0
2005	0.0	0.0	0.0	4.8	0.0
2006	4.3	3.3	5.7	1.8	3.4
2007	0.0	1.4	4.6	0.0	7.0
2008	1.9	5.5	2.9	3.4	4.3
2009	4.2	5.1	4.3	6.8	2.2
2010	4.4	4.2	4.4	6.4	4.1
2011	6.0	6.2	5.9	4.0	7.1
2012	3.6	5.7	3.8	3.8	5.3
2013	4.1	6.5	5.6	6.6	8.1
2014	3.3	8.2	7.1	11.1	7.9
2015	5.2	7.6	4.7	1.8	7.4

Appendix 62 Characteristics of people prescribed gabapentin in 2014, by continuous prescribing period length

Gabapentin				
	Up to 3 months	3 to 6 months	6 to 12 months	Over 12 months
Mean age (years)	59.9	59.5	62.7	64.1
IMD quintile (%)				
I (least deprived) §	44.9	8.2	12.0	4.4
II	39.5	15.6*	8.7	4.6
III	48.7	17.6*	8.5	1.5
IV	51.0	15.6*	8.3	7.3
V (most deprived)	50.6	10.9	9.3	3.6
Gender (%)				
Male §	48.8	15.6	6.3	4.5
Female	46.0	12.7	11.0*	4.1
Region (%)				
North of England §	48.1	12.8	10.2	4.1
Midlands and East of England	45.2	17.0	10.9	5.2
London	46.0	10.8	9.5	-
South East	46.7	10.5	8.3	5.1
South West	49.5	21.5*	4.3	3.2

* $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, § - reference category

Appendix 63 Characteristics of people prescribed pregabalin in 2014, by continuous prescribing period length

Pregabalin				
	Up to 3 months	3 to 6 months	6 to 12 months	Over 12 months
Mean age (years)	56.6*	59.8	62.4*	59.4
IMD quintile (%)				
I (least deprived) §	59.0	18.0	9.8	3.3
II	48.6	21.9	8.2	8.2
III	51.0	25.8	11.0	7.1
IV	43.2**	20.4	13.0	11.1*
V (most deprived)	57.0	18.2	7.3	7.9
Gender (%)				
Male §	52.6	17.2	7.7	13.0
Female	50.9	22.9	11.0	4.9***
Region (%)				
North of England §	48.5	19.4	8.7	11.7
Midlands and East of England	54.6	20.8	10.4	6.5
London	52.6	19.3	3.5	10.5
South East	54.4	21.3	12.5	4.0**
South West	39.3	26.2	6.6	11.5

* $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, § - reference category

Source: CPRD

Appendix 64 Total counts of sales of individual codeine and dihydrocodeine-containing medicines

	3/2015 to 2/2016	3/2016 to 2/2017	3/2017 to 2/2018
Paracetamol & codeine	7,713,634	7,133,170	7,269,506
Paracetamol & codeine & caffeine	3,848,998	3,753,986	3,322,000
Ibuprofen & codeine	2,223,748	2,160,476	2,254,624
Paracetamol & dihydrocodeine	1,129,152	1,119,408	986,080
Buclizine & paracetamol & codeine	291,948	278,772	271,008
Aspirin & codeine	115,872	109,184	98,368
Total	15,323,352	14,554,996	14,201,586

Appendix B. Evaluation of published estimates of dependence on prescribed medicine

What proportion of adults in England are dependent on medicines they are being prescribed?

Information needed

There is concern about the extent of dependence on medicines that people are prescribed. To understand the scale of the problem, an estimate is needed of the proportion of adults in England who are dependent on (in terms of showing signs of addiction to) the medicines they are prescribed. With a reliable estimate of the proportion, an estimate of the number of people can also be extrapolated.

To produce such an estimate, a large sample representative of (and therefore generalisable to) the wider national population is needed. Information about what potentially DFMs each individual in the sample was taking would need to be combined at the patient level with information about whether they have any indicators of dependence.

The focus here is on four classes of medicine that have been identified as potentially dependence forming: opioids, benzodiazepines, Z-drugs, and GABAergic medicines. Ideally, prescribing that was clinically appropriate despite dependence risk would be excluded. For example, the risk of dependence may be secondary when managing pain in palliative care, or implicit when treating a person for established dependence with maintenance therapy. The focus here is also on medicines prescribed through NHS primary care, and not on those obtained either illicitly or through private practice. Other research has addressed the abuse and misuse of prescription medicines, for example through diversion. Those findings are only relevant here where they relate to individuals taking the medicines that have been prescribed to them. Given enormous international variation in health care systems, prescribing practices, and the epidemiology of prescription drug dependence, understanding of the context in England needs to be based on data from England.

Information available

From a research (and clinical) perspective, identifying dependence is complex. The subjective experience of signs and symptoms of dependence could be captured using a screening tool (where people are able and willing to report those signs openly). However, many of the available screening tools focus on a specific class of medicine, on drug misuse rather than dependence on a medication that is being taken as prescribed, or they take a long time, and so are costly, to administer.⁹

⁹ See this paper for discussion of some available tools: Wickersham JA, Azar MM, Cannon CM et al. Validation of a Brief Measure of Opioid Dependence: ⁶The Rapid Opioid Dependence Screen (RODS) *J Correct Health Care*. 2015 21(1): 12-26.

Length of prescribing (at various thresholds, e.g. four, six, and 12 months) has been used in research as an indicator of dependence. However, not everyone prescribed to long-term is dependent, and some prescribed to shorter-term will be dependent. The Royal College of Anaesthetists produced a list of eighteen 'indicators that suggest the possibility of dependence should be explored in those on a long term opioid prescription'.¹⁰ Indications that someone being prescribed opioids long-term might be dependent include: presence of psychiatric illness; concern expressed by family members, carers, or pharmacists; and resistance to attending appointments to review opioid prescribing or addiction assessment. What the list demonstrates is that length of prescribing alone may not be enough, and identification is not straightforward.

The validity of using length of prescribing as a single proxy for dependence on prescribed medicines is not considered here. Instead, we briefly consider the statistical robustness of the following three studies as sources for estimating the prevalence of long-term prescribing in the adult population in England. These are reviewed because they are commonly quoted sources for estimates of there being 1-1.5m people dependent, cited by the media and others to demonstrate the scale of the need for action. The first two papers focus on long-term prescribing (exceeding four and six months) of benzodiazepines around 18 years ago, the third on long-term term prescribing (exceeding 12 months) of benzodiazepines and Z-drugs in 2014/5.

Heather et al.: Benzodiazepine prescribing in 1997-1999 exceeding six months

A research study carried out in seven GP practices in Newcastle and North Tyneside in 1997-1999 identified 1,297 patients who had been prescribed benzodiazepines for longer than six months.^{11,12} These figures were subsequently scaled up (not by the study authors) to a projected 1.5 million people in England being prescribed benzodiazepines for periods exceeding six months.

Representativeness of the sample: The papers present findings from a well-run evaluation. The sample was designed to evaluate an intervention and the selection criteria were not intended to produce a sample representative of the wider population. In personal communication one of the authors said: 'There is no way our 2004 paper could be used to estimate prevalence [of long-term benzodiazepine prescribing]. Apart from geographical restrictions, there were several kinds of restrictions on entry to the study.'

Exclusions: Most of the 1,297 patients identified in the trial were not considered suitable for an intervention aimed at reducing their long-term benzodiazepine prescribing. This was for a range of reasons, including because they were taking benzodiazepines for a serious acute illness (such as cancer) or for a medical

<https://www.rcoa.ac.uk/system/files/FPM-OA-identification-treatment.pdf>

¹¹ Heather N, Bowie A, Ashton H, et al. Randomised controlled trial of two brief interventions against long-term benzodiazepine use: outcome of intervention. *Addiction Research and Theory* 2004; 12(2): 141–154.

<http://www.benzo.org.uk/amisc/rndoi.pdf>

¹² Godfrey C, Heather N, Bowie A, et al. Randomised controlled trial of two brief interventions against long-term benzodiazepine use: Cost-effectiveness. *Addiction Research and Theory*. 2008; 16(4): 309–317.

<https://www.benzo.org.uk/amisc/rndce.pdf>

condition (such as epilepsy). These conditions have been applied as exclusion criteria in subsequent research on long-term prescribing of potentially DFMs, and further reinforce the conclusion that the rates generated in this paper are not comparable with rates generated in the latter studies.

Recency: While the papers were published in 2004 and 2008, it is important to note that they are based on data collected in 1997 to 1999, and so relate to benzodiazepine prescribing practice in those GP surgeries two decades ago. The proportion of people to be prescribed benzodiazepines has fallen in recent years and estimates based on data collected at that time are unlikely to reflect current prescribing levels.¹³

BBC Panorama poll: Benzodiazepine prescribing in 2000-2001 exceeding four months

In 2001, Panorama commissioned a poll of about two thousand adults which found that 3% of the sample had been prescribed a benzodiazepine for longer than four months.¹⁴ Based on the 2001 adult population, this was extrapolated to a projected 1.5 million people in England being prescribed benzodiazepines long-term (for four months or more).

Assessing methods: Attempts have been made to obtain information about the sampling or survey methods, both with the polling agency (NOP) and with Panorama. However, no details could be located. We are therefore unable to confirm whether this poll was robust.

Outcome definition: It is also not clear what questions survey participants were asked, and therefore precisely what was being measured. For example, whether the 3% of participants were being prescribed a benzodiazepine for a period exceeding four months at the time of the interview, or whether these patients had been prescribed at that level in the previous 12 months, or at some point in their life. Analysis of CPRD data¹⁵ has found that about 3.5% of adults had been prescribed benzodiazepines at some point in 2000, but that most prescribing periods were around 30 days or less. Irrespective of the measure used on the Panorama poll, this suggests that the rate generated by the poll may have been an overestimate. The poll also likely relied on people being aware of what medicines they were being prescribed, other research has found that self-reports may be inaccurate in relation to prescribing.¹⁶

Recency: As mentioned above, other work has since found that the proportion of the population to be prescribed this class of medicine to have fallen since 2000/2001. This indicates that results from 2000-2001 are unlikely to reflect recent prescribing patterns.

¹³ Cartagena Farias J, Porter L, McManus S, Strang J, Hickman M, Reed K, Smith N. (2017) *Prescribing patterns in dependence forming medicines*. London: NatCen.

¹⁴ <http://news.bbc.co.uk/1/hi/programmes/panorama/tranquillisers/1325909.stm>

¹⁵ Cartagena Farias J, Porter L, McManus S, Strang J, Hickman M, Reed K, Smith N. (2017) *Prescribing patterns in dependence forming medicines*. London: NatCen.

¹⁶ <https://www.sciencedaily.com/releases/2009/12/091210000845.htm>

Davies et al.: Benzodiazepine and Z-drugs prescribing exceeding 12 months

Analysis of data on patients registered at a number of GP surgeries in Bradford in 2014-2015 found that the proportion of 16 to 80 year olds taking benzodiazepines and/or Z-drugs very long-term (for more than one year) was 0.69%.¹⁷ This figure was then applied by the authors to the registered NHS patient population that age in England. The projection was that there were between 265,000 and 295,000 patients age 16-80 taking benzodiazepines and/or Z-drugs long-term in England. The study found that 35% of all patients prescribed benzodiazepines or Z-drugs had been prescribed them very long term (for more than 12 months).

Assessing methods: While the results of this survey are published as a paper in the *British Journal of General Practice*, relatively limited methodological detail was provided. For example, it is not stated how many GP surgeries were visited, and whether any surgeries were selected but did not take part.

Exclusions are well defined, appropriate, and lean towards the rate of long-term prescribing generated being a conservative estimate. The results were filtered to exclude children and those aged 80 years and over, those in receipt of palliative care, those with a diagnosis of epilepsy, those with severe and enduring mental health issues, and those 'with illness at the time of the survey' (although how this latter exclusion was applied is not defined).

Representativeness of the sample: The key issue is with the appropriateness of extrapolating to a national prevalence based on an unadjusted sample of patients living in and around one city. Considerable variation in prescribing is evident between clinical commissioning groups within a region, as well as between regions.¹⁸ In order to justify scaling estimates from one area to a national prevalence, the characteristics of that sample would need to be profiled so that they could be compared with the national profile. This is particularly relevant for those characteristics known to be associated with prescribing propensity, such as age, sex, ethnicity and area level deprivation. Weighting factors could then be applied to adjust the profile of the patient sample to better approximate that of the national population. Without knowing how representative the patient sample is of the national population, and how representative the GP practice sample is of GP practices nationally, it is not possible to establish how robust an estimate this is of long-term benzodiazepine and Z-drug prescribing nationally.

¹⁷ Davies J, Rae TC, Montagu L (2017) Long-term benzodiazepine and Z-drugs use in England: a survey of general research. *British Journal of General Practice* 67(662): e:609-e613.

<http://bjgp.org/content/67/662/e609>

¹⁸ OpenPrescribing.net allows for variation in volume of items prescribed per 1,000 registered patients to be charted and finds significant variation between practices, CCGs, and regions (Curtis et al. 2019).

Appendix C. Estimating the minimum proportion of the population prescribed DFM long-term in 2014

Estimates of the proportion of people in primary care to have been prescribed dependence forming medicines long-term can be extrapolated from the prescribing data. It should be noted that the estimates that we could derive from the available data were crude, based on several assumptions, and likely to significantly underestimate rates. The figures presented should therefore be considered the minimum. The methods used to generate these estimates, and their limitations, are set out in Chapter 2.

The proportion of people in primary care in 2014 who had been prescribed DFM long-term varied by type of drug. Opioids had the highest prevalence of the population being prescribed in excess of 30 days: at least 1.8%. 1.1% of adults were prescribed GABAergic medicines in excess of 30 days, 0.9% were prescribed benzodiazepines and 0.7% were prescribed Z-drugs at this level.

Very broadly, at least one person in 500 in 2014 had been continuously prescribed an opioid for over a year; with a similar minimum proportion prescribed benzodiazepines for over a year. The rates for Z-drugs and GABAergic medicines appeared to be lower, at a minimum of at least one person in a 1000.

It should be noted that there is a lot of uncertainty in these estimates and they should be regarded as minimum estimates.

Table 7: Minimum proportion of the population exceeding DFM continuous prescribing periods in 2014, by length (%)

	>30 days	>6 months	>12 months
Benzodiazepines	0.9	0.3	0.2
Z-drugs	0.7	0.2	0.1
Opioids	1.8	0.4	0.2
GABAergic medicines	1.1	0.3	0.1

Appendix D. Clinical Practice Research Datalink

A full consideration of the CPRD data extract analysed can be found in the previous report. Some of that information is provided below for reference.

CPRD data collection and structure

The Clinical Practice Research Datalink (CPRD) GOLD¹⁹ is an ongoing primary care database of anonymised medical records. There are 701 contributing GP practices in the UK which includes 15.8 million patients that meet the quality criteria. From those, 4.4 million patients are active (currently registered and/or alive)(CPRD, July 2016), representing approximately 6.9% of the UK population. Data collection begins when a patient is registered with a contributing practice. Thereafter the information recorded for each patient consultation or contact with the practice is uploaded to the CPRD on a monthly basis.

The CPRD primary care database is a rich source of health data for research. It includes data on:

- Demographics (gender and age)
- Strategic Health Authority
- Medical symptoms and diagnoses
- Tests and vaccinations
- Therapies
- Health-related behaviours
- Referrals to secondary care.
- Drug prescriptions.


Prescriptions are recorded by the GP using the GEMscript product code system (which includes the generic name of the product) with a therapy record containing the British National Formulary (BNF) code, daily dose, quantity prescribed, numbers of packs, and issue sequence (if it is a repeat prescription). Additionally, the CPRD also allows for the study of geographical differences using the ten former Strategic Health Authorities in England (SHA).

In terms of the data structure, the CPRD is a longitudinal dataset that combines location information for each GP practice with the consultation record for each registered patient. Each consultation in the CPRD is associated with a unique patient identifier and a date. A patient can have several consultations over time, with each consultation containing all the clinical and associated therapies and referrals information connected to it. However, it was not possible to directly associate diagnoses with treatments. For example, in a single consultation, a patient may be diagnosed with anxiety and flu and be prescribed paracetamol, ibuprofen, gabapentin

¹⁹ The main primary care database held by CPRD is known as GOLD (formerly GPRD). GOLD contains the anonymised, longitudinal medical records of patients registered with contributing primary care practices across the UK.

and diazepam with no systematic way to link each drug to each diagnosis. This represents a significant challenge to the management of the data within the CPRD.

Data structure of the CPRD



Arrows indicate that several diagnoses and several treatments may be present for each clinical encounter, but a definitive link between a specific diagnosis and a specific treatment is not available in the dataset.

CPRD representativeness

For the analysis, it was important to establish how representative the CPRD information was in order to know with what confidence results could be generalised to the wider patient population. In terms of representativeness of patients within the CPRD, a study concluded that patients are broadly representative of the UK general population in terms of age, sex and ethnicity when compared with the 2011 UK Census and are comparable to the Health Survey for England (HSE) for body mass index (BMI) distribution (Herrett et al., 2015).

In terms of representation of practices, historically the CPRD has gathered data from practices using the Vision IT system.²⁰ Over the last two years there has been a significant fall in the number of practices using Vision, and even a complete drop off in practices in certain geographical areas. This is attributable to some Clinical Commissioning Groups (CCGs) requiring different software to be used. Therefore, the

²⁰ Vision is an IT package designed to provide NHS patients with joined up services. It makes relevant information available to the whole healthcare team, intended to facilitate collaboration and reduce duplication of effort.

CPRD may not be representative of all practices in the UK based on geography and size.

Profile of the CPRD extract

The CPRD extract contains 49,999 patients who have been prescribed at least one of the four types of DFMs of interest at some point between 2000 and 2015. The extract is a geographically representative random sample of patients in England on the CPRD, with the proportion of patients in each area determined by the proportion of the overall population living there at the 2011 Census. For example, from the total number of patients requested in the extract, 10% are located in the South West, 10% are in Yorkshire and 15% are in London. See Table A.8.

Table A.8: Geographical distribution of patients

Region	%	N
North East	5	2,449
North West	13	6,651
Yorkshire	10	4,983
East Midlands	9	4,276
West Midlands	11	5,284
East of England	11	5,515
London	15	7,709
South East	16	8,144
South West	10	4,988
Total	100	49,999

As well as providing a geographically representative sample for national analysis, the number of patients across each of the nine regions listed above is also sufficient for regional analysis. It should be noted that the nature of data collection from a self-selecting sample of GP practices does not allow for the production of probability weights which could account for non-response bias.

The 49,999 patients have an associated 13,868,419 consultations distributed between 2000 and 2015. This is an average of 23 consultations per patient per year. Of those patients, 59.5% are women. The patients span a wide age range, including some children and some adults in their nineties and over. Median age in 2000 was 50 years old, increasing to 52 in 2007, and 56 years in 2015.²¹ It is important to note that this increase in patients' age over time. Some patients are included in the extract from 2000 and continue to be prescribed over time until 2015, thereby contributing their own ageing effect to the age distribution of the sample. Conversely, patients who were first prescribed in later years contribute fewer years to the age distribution.

²¹ Mean age in 2015 was 56.19 and the standard deviation was 18.71.

The CPRD does not contain individual level information on socioeconomic characteristics. However, it does contain area level deprivation based on the location of the GP practice which acts as a proxy measure of socioeconomic circumstances of the patient. Overall, the extract contained roughly similar proportions of patients at each decile of deprivation.

Appendix E. Medicines included in the analysis

Drug name	Product name	BNF code	BNF header
Benzodiazepines			
Temazepam	Temazepam 10mg tablets	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Nitrazepam	Nitrazepam 5mg tablets	4010100	Hypnotics
Diazepam	Diazepam 2mg tablets	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Diazepam	Diazepam 5mg tablets	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Lorazepam	Lorazepam 4mg/1ml solution for injection ampoules	04010201/04080200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Benzodiazepines (peri-operative)
Temazepam	Temazepam 10mg/5ml oral solution sugar free	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Clonazepam	Clonazepam 1mg/1ml solution for injection ampoules and diluent	4080200	Drugs Used In Status Epilepticus
Temazepam	Temazepam 10mg capsules	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Lorazepam	Lorazepam 1mg tablets	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Diazepam	Diazepam 10mg tablets	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Chlordiazepoxide hydrochloride	Chlordiazepoxide 10mg capsules	04010201/04105000/10020200	Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants
Clonazepam	Clonazepam 500microgram tablets	4080100	Control Of Epilepsy
Temazepam	Temazepam 20mg tablets	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Clonazepam	Clonazepam 2mg tablets	4080100	Control Of Epilepsy
Diazepam	Diazepam 5mg RecTubes (Wockhardt UK)	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Diazepam	Diazepam 10mg RecTubes (Wockhardt UK)	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Lorazepam	Lorazepam 2.5mg tablets	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Chlordiazepoxide hydrochloride	Chlordiazepoxide 5mg capsules	04010201/04105000/10020200	Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants
Diazepam	Diazepam 2mg/5ml oral solution	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Diazepam	Valium 2mg Tablet (Roche Products)	04010100/04010200	Hypnotics/Anxiolytics
Temazepam	Temazepam 20mg capsules	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Triazolam	Triazolam 250microgram Tablet	4010100	Hypnotics
Nitrazepam	Nitrazepam 5mg Capsule	4010100	Hypnotics
Flurazepam hydrochloride	Dalmane 30mg capsules (Meda Pharmaceuticals)	4010201	Benzodiazepines
Clobazam	Clobazam 10mg capsules	04010200/04080100	Anxiolytics/Control Of Epilepsy
Clobazam	Clobazam 10mg tablets	4080100	Control Of Epilepsy
Chlordiazepoxide Hydrochloride	Chlordiazepoxide 10mg tablets	4010200	Anxiolytics
Diazepam	Diazepam 5mg	04010100/04010200	Hypnotics/Anxiolytics

Lormetazepam	Lormetazepam 1mg tablets	4010100	Hypnotics
Lormetazepam	Lormetazepam 1mg Capsule	4010100	Hypnotics
Nitrazepam	Mogadon 5mg Capsule (Roche Products)	4010100	Hypnotics
Nitrazepam	Nitrazepam 10mg Tablet	4010100	Hypnotics
Lormetazepam	Lormetazepam 500microgram tablets	4010100	Hypnotics
Diazepam	Diazepam 2mg capsules	04010100/04010200	Hypnotics/Anxiolytics
Flurazepam hydrochloride	Flurazepam 15mg capsules	4010201	Benzodiazepines
Flurazepam hydrochloride	Dalmane 15mg capsules (Meda Pharmaceuticals)	4010201	Benzodiazepines
Diazepam	Tensium 10mg tablets (DDSA Pharmaceuticals)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Oxazepam	Oxazepam 30mg Capsule	4010200	Anxiolytics
Oxazepam	Oxazepam 15mg tablets	4010201	Benzodiazepines
Diazepam	Diazepam 10mg/2.5ml rectal solution tube	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Diazepam	Valium 5mg Tablet (Roche Products)	04010100/04010200	Hypnotics/Anxiolytics
Diazepam	Stesolid 5mg rectal tube (Actavis UK)	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Clonazepam	Clonazepam 2.5mg/ml drops sugar free	4080100	Control Of Epilepsy
Chlordiazepoxide Hydrochloride	Chlordiazepoxide 5mg tablets	4010200	Anxiolytics
Oxazepam	Oxazepam 10mg tablets	4010201	Benzodiazepines
Loprazolam mesilate	Loprazolam 1mg tablets	4010100	Hypnotics
Chlordiazepoxide hydrochloride	Chlordiazepoxide 10mg tablets	04010201/04105000/10020200	Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants
Diazepam	Stesolid 10mg Rectal tubes (Dumex)	04010200/04080200	Anxiolytics/Drugs Used In Status Epilepticus
Diazepam	Diazepam 2.5mg/1.25ml rectal solution tube	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Chlordiazepoxide hydrochloride	Chlordiazepoxide 5mg tablets	04010201/04105000/10020200	Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants
Chlordiazepoxide Hydrochloride	Chlordiazepoxide 25mg tablets	4010200	Anxiolytics
Diazepam	Diazepam 5mg/2.5ml rectal solution tube	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Lorazepam	Ativan 4mg/1ml solution for injection ampoules (Pfizer)	04010201/04080200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Benzodiazepines (peri-operative)
Flurazepam hydrochloride	Flurazepam 30mg capsules	4010201	Benzodiazepines
Temazepam	Temazepam planpak Capsule (Manufacturer unknown)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Temazepam	Temazepam 15mg capsules	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Triazolam	Triazolam 125microgram Tablet	4010100	Hypnotics
Nitrazepam	Mogadon 5mg Tablet (ICN Pharmaceuticals France S.A.)	4010100	Hypnotics
Nitrazepam	Nitrazepam 2.5mg/5ml oral suspension	4010100	Hypnotics
Clonazepam	Rivotril 2mg tablets (Roche Products)	4080100	Control Of Epilepsy
Diazepam	Diazepam 10mg suppositories	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Diazepam	Diazepam 5mg suppository	04010200/04080200	Anxiolytics/Drugs Used In Status Epilepticus
Diazepam	Stesolid 10mg rectal tube (Actavis UK)	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Clobazam	Frisium 10mg Capsule (Aventis Pharma)	04010200/04080100	Anxiolytics/Control Of Epilepsy

Chlordiazepoxide Hydrochloride	Chlordiazepoxide 25mg tablets	4010200	Anxiolytics
Oxazepam	Oxazepam 30mg Tablet	4010200	Anxiolytics
Temazepam	Temazepam gelthix 10mg Capsule (Pharmacia)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Chlordiazepoxide hydrochloride	Librium 10mg Capsule (ICN Pharmaceuticals France S.A.)	4010200	Anxiolytics
Diazepam	Diazepam 1mg/5ml suspension	04010100/04010200	Hypnotics/Anxiolytics
Chlordiazepoxide hydrochloride	Librium 5mg Tablet (ICN Pharmaceuticals France S.A.)	4010200	Anxiolytics
Diazepam	Diazepam 5mg/5ml oral solution	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Diazepam	Diazepam 10mg capsules	04010100/04010200	Hypnotics/Anxiolytics
Diazepam	Diazepam 2.5mg/5ml oral suspension	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Alprazolam	Alprazolam 250microgram tablets	4010201	Benzodiazepines
Bromazepam	Lexotan 3mg Tablet (Roche Products)	4010200	Anxiolytics
Nitrazepam	Nitrazepam 5mg/5ml oral suspension	4010100	Hypnotics
Diazepam	Diazepam 2mg/5ml oral solution sugar free	4010201	Benzodiazepines
Diazepam	Valium 10mg Tablet (Roche Products)	04010100/04010200	Hypnotics/Anxiolytics
Temazepam	Temazepam 30mg capsules	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Clonazepam	Rivotril 500microgram tablets (Roche Products)	4080100	Control Of Epilepsy
Medazepam	Nobrium 10mg Capsule (Roche Products)	4010200	Anxiolytics
Medazepam	Medazepam 10mg Capsule	4010200	Anxiolytics
Medazepam	Nobrium 5mg Capsule (Roche Products)	4010200	Anxiolytics
Alprazolam	Xanax 250microgram tablets (Pfizer)	4010201	Benzodiazepines
Lorazepam	Ativan 1mg Tablet (Wyeth Pharmaceuticals)	04010200/15010401	Anxiolytics/Benzodiazepines (peri-operative)
Alprazolam	Alprazolam 500microgram tablets	4010201	Benzodiazepines
Bromazepam	Lexotan 1.5mg Tablet (Roche Products)	4010200	Anxiolytics
Diazepam	Diazepam 10mg/2ml solution for injection ampoules	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Ketazolam	Anxon 30mg Capsule (Beecham Research Laboratories)	4010200	Anxiolytics
Diazepam	Diazepam 10mg/2ml emulsion for injection ampoules	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Temazepam	Normison 10mg Capsule (Wyeth Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Ketazolam	Anxon 15mg Capsule (Beecham Research Laboratories)	4010200	Anxiolytics
Temazepam	Temazepam gelthix 20mg Capsule (Pharmacia)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Chlordiazepoxide hydrochloride	Librium 5mg Capsule (ICN Pharmaceuticals France S.A.)	4010200	Anxiolytics
Alprazolam	Xanax 500microgram tablets (Pfizer)	4010201	Benzodiazepines
Diazepam	Diazepam 10mg/5ml oral suspension	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Clonazepam	Clonazepam 2mg/5ml oral solution sugar free	4080100	Control Of Epilepsy
Lorazepam	Lorazepam 500micrograms/5ml oral suspension	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Diazepam	Diazemuls 10mg/2ml emulsion for injection ampoules (Actavis UK)	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Clobazam	Frisium 10mg tablets (Sanofi)	4080100	Control Of Epilepsy

Clonazepam	Clonazepam 500micrograms/5ml oral suspension	4080100	Control Of Epilepsy
Temazepam	Temazepam 10mg/5ml Oral solution (Generics (UK))	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Nitrazepam	Nitrados 5mg Tablet (Rorer Pharmaceuticals)	4010100	Hypnotics
Chlordiazepoxide Hydrochloride	Librium 100mg Injection (Roche Products)	4010200	Anxiolytics
Diazepam	Valium 5mg/ml Injection (Roche Products)	04010200/04080200	Anxiolytics/Drugs Used In Status Epilepticus
Diazepam	Diazepam rectubes 20mg Rectal tubes (C P Pharmaceuticals)	04010200/04080200	Anxiolytics/Drugs Used In Status Epilepticus
Clonazepam	Rivotril 2.5mg/1ml drops (Imported (Switzerland))	4080100	Control Of Epilepsy
Clobazam	Clobazam 5mg/5ml oral suspension	4080100	Control Of Epilepsy
Chlordiazepoxide hydrochloride	Librium 10mg Tablet (ICN Pharmaceuticals France S.A.)	4010200	Anxiolytics
Clonazepam	Clonazepam 500micrograms/5ml solution sugar free	4080100	Control Of Epilepsy
Lorazepam	Ativan 2.5mg Tablet (Wyeth Pharmaceuticals)	04010200/15010401	Anxiolytics/Benzodiazepines (peri-operative)
Chlordiazepoxide hydrochloride	Librium 5mg capsules (Meda Pharmaceuticals)	04010201/04105000/10020200	Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants
Lormetazepam	Noctamid 1mg Tablet (Schering Health Care)	4010100	Hypnotics
Diazepam	Diazepam 2.5mg RecTubes (Wockhardt UK)	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Diazepam	Valium 5mg Capsule (Roche Products)	04010100/04010200	Hypnotics/Anxiolytics
Nitrazepam	Mogadon 5mg tablets (Meda Pharmaceuticals)	4010100	Hypnotics
Bromazepam	Bromazepam 3mg tablets	4010200	Anxiolytics
Diazepam	Valium 2mg Capsule (Roche Products)	04010100/04010200	Hypnotics/Anxiolytics
Temazepam	Temazepam 10mg gel-fill capsules	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Diazepam	Valium 10mg Suppository (Roche Products)	04010200/04080200	Anxiolytics/Drugs Used In Status Epilepticus
	CHLORDIAZEPOXIDE	0	Unknown
Temazepam	Temazepam gelthix 30mg Capsule (Pharmacia)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Clobazam	Clobazam 10mg/5ml oral suspension	4080100	Control Of Epilepsy
Diazepam	Diazepam 2mg/5ml oral solution sugar free (Actavis UK)	4010201	Benzodiazepines
Amitriptyline	Amitriptyline 12.5mg / Chlordiazepoxide 5mg capsules	4030100	Tricyclic And Related Antidepressant Drugs
Hydrochloride/Chlordiazepoxide Lormetazepam	Loramet 1mg Capsule (Wyeth Pharmaceuticals)	4010100	Hypnotics
Temazepam	Normison 20mg Capsule (Wyeth Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Medazepam	Medazepam 5mg Capsule	4010200	Anxiolytics
	CHLORDIAZEPOXIDE	0	Unknown
Bromazepam	Bromazepam 1.5mg tablets	4010200	Anxiolytics
Temazepam	Temazepam gelthix 15mg Capsule (Pharmacia)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Loprazolam mesilate	Dormonox 1mg Tablet (Hoechst Marion Roussel)	4010100	Hypnotics
Ketazolam	Ketazolam 15mg Capsule	4010200	Anxiolytics
Diazepam	Diazepam 20mg rectal tubes	04010200/04080200	Anxiolytics/Drugs Used In Status Epilepticus
Nitrazepam	Somnite 2.5mg/5ml oral suspension (Norgine Pharmaceuticals)	4010100	Hypnotics
Flurazepam hydrochloride	Paxane 30mg Capsule (M A Steinhart)	4010100	Hypnotics

Chlordiazepoxide hydrochloride	Librium 10mg capsules (Meda Pharmaceuticals)	04010201/04105000/10020200	Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants
Chlordiazepoxide Hydrochloride	Chlordiazepoxide 100mg injection	4010200	Anxiolytics
Oxazepam	Oxanid 10mg Tablet (M A Steinhart)	4010200	Anxiolytics
Prazepam	Centrax 10mg Tablet (Parke-davis Research Laboratories)	4010200	Anxiolytics
Clonazepam	Rivotril 1mg/1ml concentrate for solution for injection ampoules (Roche Products)	4080200	Drugs Used In Status Epilepticus
Temazepam	Temazepam 10mg/5ml oral solution sugar free (Rosemont Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Nitrazepam	Surem 5mg Capsule (Galen)	4010100	Hypnotics
Chlordiazepoxide hydrochloride	Tropium 5mg capsules (Dr Reddy's Laboratories (UK))	04010201/10020200	Benzodiazepines/Skeletal Muscle Relaxants
	CHLORDIAZEPOXIDE	0	Unknown
Diazepam	Diazepam 2mg Tablet (Crosspharma)	04010100/04010200	Hypnotics/Anxiolytics
Ketazolam	Ketazolam 30mg Capsule	4010200	Anxiolytics
Diazepam	Valium 5mg Suppository (Roche Products)	04010200/04080200	Anxiolytics/Drugs Used In Status Epilepticus
Diazepam	Evacalm 5mg Tablet (Unimed Pharmaceuticals)	04010100/04010200	Hypnotics/Anxiolytics
Chlordiazepoxide hydrochloride	Chlordiazepoxide 5mg Tablet (DDSA Pharmaceuticals)	4010200	Anxiolytics
Temazepam	Euhypnos forte 20mg Capsule (Pharmacia)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Diazepam	Diazepam 2mg tablets (Ranbaxy (UK))	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Chlordiazepoxide hydrochloride	Tropium 5mg tablets (Dr Reddy's Laboratories (UK))	04010201/10020200	Benzodiazepines/Skeletal Muscle Relaxants
Diazepam	Valium 2mg/5ml Oral solution (Roche Products)	04010100/04010200	Hypnotics/Anxiolytics
Temazepam	Temazepam 20mg Tablet (Wyeth Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Temazepam	Temazepam 20mg tablets (IVAX Pharmaceuticals UK)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Diazepam	Valclair 10mg suppositories (Durbin Plc)	0	Unknown
Chlordiazepoxide Hydrochloride	Librium 25mg Tablet (ICN Pharmaceuticals France S.A.)	4010200	Anxiolytics
Diazepam	Diazepam 5mg tablets (Actavis UK)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Temazepam	Temazepam 20mg gel-fill capsules	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Diazepam	Diazepam 10mg/2ml solution for injection ampoules (Wockhardt UK)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Clonazepam	Clonazepam 250micrograms/5ml oral solution	4080100	Control Of Epilepsy
Temazepam	Temazepam 10mg/5ml oral solution sugar free (A A H Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Diazepam	Diazepam 2mg/5ml oral solution (Sandoz)	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Diazepam	Solis 5mg Capsule (Galen)	04010100/04010200	Hypnotics/Anxiolytics
Lorazepam	Lorazepam 1mg tablets (Teva UK)	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Temazepam	Temazepam 10mg Tablet (Wyeth Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Diazepam	Diazepam 2mg tablets (A A H Pharmaceuticals)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Diazepam	Diazepam 10mg/2ml solution for injection ampoules (Hameln Pharmaceuticals)	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Temazepam	Temazepam 10mg tablets (IVAX Pharmaceuticals UK)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Diazepam	Diazepam 5mg/2.5ml rectal solution tube (Sandoz)	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Diazepam	Diazepam 5mg/5ml oral solution (Sandoz)	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning

Lormetazepam	Lormetazepam 500microgram tablets (A A H Pharmaceuticals)	4010100	Hypnotics
Diazepam	Diazepam 10mg tablets (Mylan)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Temazepam	Temazepam 10mg tablets (A A H Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Diazepam	Diazepam 2mg tablets (Teva UK)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Diazepam	Diazepam 2mg tablets (Mylan)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Diazepam	Diazepam 10mg tablets (Ranbaxy (UK))	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Lormetazepam	Lormetazepam 500microgram tablets (Genus Pharmaceuticals)	4010100	Hypnotics
Temazepam	Temazepam 10mg tablets (Teva UK)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Nitrazepam	Nitrazepam 5mg tablets (A A H Pharmaceuticals)	4010100	Hypnotics
Diazepam	Diazepam 5mg tablets (Teva UK)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Clonazepam	Clonazepam 2mg/5ml oral solution sugar free (Rosemont Pharmaceuticals)	4080100	Control Of Epilepsy
Temazepam	Temazepam 10mg tablets (Mylan)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Lormetazepam	Lormetazepam 1mg tablets (Mylan)	4010100	Hypnotics
Diazepam	Diazepam 2mg tablets (Actavis UK)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Lormetazepam	Lormetazepam 1mg Tablet (Wyeth Pharmaceuticals)	4010100	Hypnotics
Nitrazepam	Nitrazepam 5mg tablets (Wockhardt UK)	4010100	Hypnotics
Diazepam	Diazepam 2mg Tablet (Regent Laboratories)	04010100/04010200	Hypnotics/Anxiolytics
Temazepam	Temazepam 20mg tablets (Mylan)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Diazepam	Diazepam 10mg/2.5ml rectal solution tube (Sandoz)	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Diazepam	Diazepam 5mg tablets (Mylan)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Diazepam	Diazepam 5mg tablets (A A H Pharmaceuticals)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Lormetazepam	Lormetazepam 500microgram tablets (Mylan)	4010100	Hypnotics
Diazepam	Diazepam 2mg tablets (IVAX Pharmaceuticals UK)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Diazepam	Diazepam 5mg Tablet (Crosspharma)	04010100/04010200	Hypnotics/Anxiolytics
Nitrazepam	Nitrazepam 5mg tablets (Teva UK)	4010100	Hypnotics
Lormetazepam	Lormetazepam 1mg tablets (Genus Pharmaceuticals)	4010100	Hypnotics
Nitrazepam	Nitrazepam 5mg Tablet (DDSA Pharmaceuticals)	4010100	Hypnotics
Nitrazepam	Nitrazepam 5mg tablets (Mylan)	4010100	Hypnotics
Diazepam	Diazepam 10mg tablets (Actavis UK)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Diazepam	Diazepam 2mg Tablet (Berk Pharmaceuticals)	04010100/04010200	Hypnotics/Anxiolytics
Diazepam	Diazepam 5mg Tablet (Berk Pharmaceuticals)	04010100/04010200	Hypnotics/Anxiolytics
Chlordiazepoxide hydrochloride	Chlordiazepoxide 5mg Capsule (DDSA Pharmaceuticals)	4010200	Anxiolytics
Nitrazepam	Nitrazepam 5mg Tablet (Berk Pharmaceuticals)	4010100	Hypnotics
Lorazepam	Lorazepam 2.5mg tablets (Teva UK)	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Chlordiazepoxide hydrochloride	Chlordiazepoxide 5mg capsules (A A H Pharmaceuticals)	04010201/04105000/10020200	Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants
Lorazepam	Lorazepam 1mg tablets (Mylan)	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)

Diazepam	Atensine 10mg Tablet (Rorer Pharmaceuticals)	04010100/04010200	Hypnotics/Anxiolytics
Temazepam	Temazepam 20mg Tablet (Pharmacia)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Oxazepam	Oxazepam 10mg tablets (A A H Pharmaceuticals)	4010201	Benzodiazepines
Temazepam	Euhypnos 10mg/5ml Oral solution (Pharmacia)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Nitrazepam	Remnos 10mg Tablet (DDSA Pharmaceuticals)	4010100	Hypnotics
Lorazepam	Lorazepam 1mg/5ml oral suspension	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Clobazam	Clobazam 2.5mg capsules	4080100	Control Of Epilepsy
Lorazepam	Lorazepam 1mg/5ml oral solution	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Diazepam	Diazepam 5mg Rectal tubes (Hillcross Pharmaceuticals)	04010200/04080200	Anxiolytics/Drugs Used In Status Epilepticus
Temazepam	Temazepam 10mg Capsule (Berk Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Temazepam	Temazepam 20mg Capsule (Berk Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Lorazepam	Lorazepam 1mg tablets (Genus Pharmaceuticals)	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Chlordiazepoxide Hydrochloride	Chlordiazepoxide 25mg Tablet (DDSA Pharmaceuticals)	4010200	Anxiolytics
Clobazam	Clobazam 25mg/5ml oral solution	4080100	Control Of Epilepsy
Nitrazepam	Nitrazepam 5mg tablets (Actavis UK)	4010100	Hypnotics
Lorazepam	Lorazepam 1mg tablets (Arrow Generics)	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Oxazepam	Oxazepam 15mg tablets (A A H Pharmaceuticals)	4010201	Benzodiazepines
Temazepam	Temazepam 10mg Tablet (IVAX Pharmaceuticals UK)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Oxazepam	Oxazepam 10mg tablets (Actavis UK)	4010201	Benzodiazepines
Oxazepam	Oxazepam 10mg Tablet (IVAX Pharmaceuticals UK)	4010200	Anxiolytics
Oxazepam	Oxazepam 10mg tablets (Genus Pharmaceuticals)	4010201	Benzodiazepines
Temazepam	Temazepam 10mg Tablet (Pharmacia)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Chlordiazepoxide hydrochloride	Chlordiazepoxide 10mg Capsule (Approved Prescription Services)	4010200	Anxiolytics
Chlordiazepoxide hydrochloride	Chlordiazepoxide 10mg Capsule (IVAX Pharmaceuticals UK)	4010200	Anxiolytics
Chlordiazepoxide hydrochloride	Chlordiazepoxide 5mg capsules (Actavis UK)	04010201/10020200	Benzodiazepines/Skeletal Muscle Relaxants
Chlordiazepoxide hydrochloride	Chlordiazepoxide 10mg capsules (Actavis UK)	04010201/10020200	Benzodiazepines/Skeletal Muscle Relaxants
Loprazolam mesilate	Loprazolam 1mg tablets (Zentiva)	4010100	Hypnotics
Oxazepam	Oxazepam 15mg Tablet (IVAX Pharmaceuticals UK)	4010200	Anxiolytics
Oxazepam	Oxazepam 15mg tablets (Actavis UK)	4010201	Benzodiazepines
Chlordiazepoxide hydrochloride	Chlordiazepoxide 5mg Capsule (Approved Prescription Services)	4010200	Anxiolytics
Diazepam	Diazepam 10mg tablets (Teva UK)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Chlordiazepoxide hydrochloride	Chlordiazepoxide 10mg Capsule (DDSA Pharmaceuticals)	4010200	Anxiolytics
Diazepam	Diazepam 10mg tablets (A A H Pharmaceuticals)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Temazepam	Temazepam 20mg Capsule (Hillcross Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Diazepam	Diazepam 10mg Suppository (Sinclair IS Pharma Plc)	04010200/04080200	Anxiolytics/Drugs Used In Status Epilepticus
Temazepam	Temazepam 20mg tablets (A A H Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)

Temazepam	Temazepam 20mg tablets (A A H Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Temazepam	Temazepam 10mg Capsule (Hillcross Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Temazepam	Temazepam 10mg Capsule (Hillcross Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Triazolam	Triazolam 0.25mg Tablet (Berk Pharmaceuticals)	4010100	Hypnotics
Triazolam	Triazolam 0.25mg Tablet (Berk Pharmaceuticals)	4010100	Hypnotics
Chlordiazepoxide hydrochloride	Chlordiazepoxide 10mg Tablet (DDSA Pharmaceuticals)	4010200	Anxiolytics
Diazepam	Diazepam 5mg/5ml oral solution (A A H Pharmaceuticals)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Lorazepam	Lorazepam 2.5mg tablets (Genus Pharmaceuticals)	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Chlordiazepoxide hydrochloride	Chlordiazepoxide 5mg tablets (A A H Pharmaceuticals)	04010201/10020200	Benzodiazepines/Skeletal Muscle Relaxants
Midazolam	Midazolam Oral solution	04080200/15010401	Drugs Used In Status Epilepticus/Benzodiazepines (peri-operative)
Chlordiazepoxide hydrochloride	Tropium 10mg tablets (Dr Reddy's Laboratories (UK))	04010201/10020200	Benzodiazepines/Skeletal Muscle Relaxants
Clonazepam	Clonazepam 500microgram/5ml Oral solution (Rosemont Pharmaceuticals)	4080100	Control Of Epilepsy
Diazepam	Diazepam 2mg Tablet (M & A Pharmachem)	04010100/04010200	Hypnotics/Anxiolytics
Diazepam	Diazepam 5mg tablets (Ranbaxy (UK))	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Chlordiazepoxide hydrochloride	Chlordiazepoxide 10mg capsules (A A H Pharmaceuticals)	04010201/04105000/10020200	Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants
Diazepam	Diazepam 5mg tablets (Sandoz)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Temazepam	Temazepam 10mg tablets (Actavis UK)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Temazepam	Temazepam 10mg tablets (Genus Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Diazepam	Diazepam 2mg tablets (Almus Pharmaceuticals)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Midazolam	Midazolam 2.5mg/ml oral solution	15010401	Benzodiazepines (peri-operative)
Lorazepam	Lorazepam 1mg tablets (Sandoz)	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Temazepam	Temazepam 20mg tablets (Genus Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Clobazam	Clobazam 10mg/5ml oral solution	4080100	Control Of Epilepsy
Clobazam	Clobazam 5mg/5ml oral solution	4080100	Control Of Epilepsy
Lorazepam	Lorazepam 500micrograms/5ml oral solution	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Triazolam	Triazolam (roi) 125microgram Tablet	4010100	Hypnotics
Diazepam	Diazepam 10mg tablets (IVAX Pharmaceuticals UK)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Temazepam	Temazepam 20mg tablets (Teva UK)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Oxazepam	Oxazepam 15mg tablets (Genus Pharmaceuticals)	4010201	Benzodiazepines
Nitrazepam	Nitrazepam 5mg tablets (Ranbaxy (UK))	4010100	Hypnotics
Temazepam	Temazepam 20mg tablets (Actavis UK)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Diazepam	Diazepam 5mg tablets (IVAX Pharmaceuticals UK)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Clonazepam	Clonazepam 500micrograms/5ml oral solution	4080100	Control Of Epilepsy
Clobazam	Clobazam 25mg/5ml oral suspension	4080100	Control Of Epilepsy
Lormetazepam	Lormetazepam 1mg/5ml oral suspension	4010100	Hypnotics
Clonazepam	Clonazepam 500micrograms/5ml oral solution sugar free	4080100	Control Of Epilepsy

Midazolam	Midazolam 10mg/1ml oromucosal solution pre-filled oral syringes	0	Unknown
Midazolam	Midazolam 5mg/0.5ml oromucosal solution pre-filled syringes	4080200	Drugs Used In Status Epilepticus
Temazepam	Temazepam 10mg tablets (Sandoz)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Clonazepam	Clonazepam 2mg/5ml oral solution sugar free	4080100	Control Of Epilepsy
Clobazam	Clobazam 4mg/5ml oral solution	4080100	Control Of Epilepsy
Diazepam	Diazepam 10mg/5ml oral solution	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Clobazam	Clobazam 2.5mg/5ml oral solution	4080100	Control Of Epilepsy
Midazolam	Epistatus 10mg/1ml oromucosal solution (Special Products)	4080200	Drugs Used In Status Epilepticus
Diazepam	Diazepam 10mg/2ml solution for injection ampoules (A A H Pharmaceuticals)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Midazolam	Epistatus 7.5mg/0.75ml oromucosal solution pre-filled oral syringes (Special Products)	4080200	Drugs Used In Status Epilepticus
	Diazepam 2mg/5ml oral suspension	4010201	Benzodiazepines
Clobazam	Clobazam 4mg/5ml oral suspension	4080100	Control Of Epilepsy
Clobazam	Clobazam 2.5mg/5ml oral suspension	4080100	Control Of Epilepsy
Clobazam	Clobazam 100mg/5ml oral suspension	4080100	Control Of Epilepsy
Midazolam	Epistatus 10mg/1ml oromucosal solution pre-filled oral syringes (Special Products)	4080200	Drugs Used In Status Epilepticus
Clonazepam	Clonazepam 500microgram tablets (Phoenix Healthcare Distribution)	4080100	Control Of Epilepsy
Diazepam	Diazepam 2mg/5ml oral solution sugar free (A A H Pharmaceuticals)	4010201	Benzodiazepines
Diazepam	Diazepam 2.5mg/5ml oral solution	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Clonazepam	Clonazepam 2mg tablets (Sigma Pharmaceuticals Plc)	4080100	Control Of Epilepsy
Midazolam	Midazolam 7.5mg/0.75ml oromucosal solution pre-filled syringes	4080200	Drugs Used In Status Epilepticus
Diazepam	Diazepam 10mg Tablet (M & A Pharmachem)	04010100/04010200	Hypnotics/Anxiolytics
Midazolam	Epistatus 5mg/0.5ml oromucosal solution pre-filled oral syringes (Special Products)	4080200	Drugs Used In Status Epilepticus
Clobazam	Taplob 5mg/5ml oral suspension (Martindale Pharmaceuticals)	04010201/04080100	Benzodiazepines/Control Of Epilepsy
Triazolam	Triazolam 0.125mg Tablet (Berk Pharmaceuticals)	4010100	Hypnotics
Clobazam	Clobazam 10mg/5ml oral suspension sugar free	04010201/04080100	Benzodiazepines/Control Of Epilepsy
Bromazepam	Bromazepam 3mg tablets	4010000	Hypnotics And Anxiolytics
Temazepam	Temazepam 10mg/5ml oral solution sugar free (Focus Pharmaceuticals)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Midazolam	Midazolam 10mg/1ml oromucosal solution pre-filled oral syringes	15010401	Benzodiazepines (peri-operative)
Diazepam	Diazepam 2mg tablets (Wockhardt UK)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Lorazepam	Lorazepam 5mg/5ml oral solution	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Clobazam	Taplob 10mg/5ml oral suspension (Martindale Pharmaceuticals)	04010201/04080100	Benzodiazepines/Control Of Epilepsy
Temazepam	Temazepam 10mg tablets (F.Maltby & Sons)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Temazepam	Temazepam 10mg tablets (Ethigen)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Lorazepam	Lorazepam 2.5mg tablets (Sandoz)	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Clobazam	Frisium 10mg tablets (Waymade Healthcare Plc)	4080100	Control Of Epilepsy
Clonazepam	Clonazepam 250micrograms/5ml oral suspension	4080100	Control Of Epilepsy

Diazepam	Diazepam 5mg tablets (Waymade Healthcare Plc)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Diazepam	Diazepam 5mg tablets (Sovereign Medical)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Clonazepam	Clonazepam 312.5micrograms/5ml oral suspension	4080100	Control Of Epilepsy
Clonazepam	Clonazepam 500microgram tablets (A A H Pharmaceuticals)	4080100	Control Of Epilepsy
Diazepam	Diazepam 10mg/5ml oral solution (AM Distributions (Yorkshire))	04010201/04080200/10020200/15010401/54140000	Benzodiazepines/Drugs Used In Status Epilepticus/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)/Therapy Of Convulsions Due To Poisoning
Diazepam	Diazepam 5mg/5ml oral solution (AM Distributions (Yorkshire))	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Clonazepam	Clonazepam 500microgram tablets (Almus Pharmaceuticals)	4080100	Control Of Epilepsy
Diazepam	Diazepam 5mg tablets (DE Pharmaceuticals)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Clobazam	Clobazam 5mg/5ml oral suspension (Special Order)	4080100	Control Of Epilepsy
Temazepam	Temazepam 20mg tablets (Sandoz)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Diazepam	Diazepam 5mg tablets (Arrow Generics)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Lorazepam	Lorazepam 1mg tablets (A A H Pharmaceuticals)	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Clonazepam	Clonazepam 500microgram tablets (Actavis UK)	4080100	Control Of Epilepsy
	Nitrazepam 2mg/5ml oral suspension	4010100	Hypnotics
Lorazepam	Lorazepam 5mg/5ml oral suspension	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Diazepam	Diazepam 10mg tablets (Almus Pharmaceuticals)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Chlordiazepoxide hydrochloride	Chlordiazepoxide 10mg tablets (A A H Pharmaceuticals)	04010201/04105000/10020200	Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants
Diazepam	Diazepam 2mg tablets (Sovereign Medical)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Temazepam	Temazepam 20mg Tablet (Lagap)	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Clobazam	Clobazam 7.5mg/5ml oral suspension	4080100	Control Of Epilepsy
Diazepam	Diazepam 2mg tablets (Waymade Healthcare Plc)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Lormetazepam	Noctamid 0.5mg Tablet (Schering Health Care)	4010100	Hypnotics
Temazepam	Temazepam 30mg gel-fill capsules	04010100/15010401	Hypnotics/Benzodiazepines (peri-operative)
Diazepam	Diazepam 2mg tablets (Phoenix Healthcare Distribution)	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Diazepam	Diazepam 2mg tablets (Alliance Healthcare (Distribution))	04010201/04080200/04080300/10020200/15010401	Benzodiazepines/Drugs Used In Status Epilepticus/Febrile Convulsions/Skeletal Muscle Relaxants/Benzodiazepines (peri-operative)
Chlordiazepoxide hydrochloride	Chlordiazepoxide 10mg tablets (Phoenix Healthcare Distribution)	04010201/04105000/10020200	Benzodiazepines/Drugs Used In Substance Dependence - Alcohol Dependence/Skeletal Muscle Relaxants
Clonazepam	Clonazepam 5mg/5ml oral suspension	4080100	Control Of Epilepsy
Lorazepam	Lorazepam 1mg tablets (Genesis Pharmaceuticals)	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Nitrazepam	Nitrazepam 10mg/5ml oral suspension	4010100	Hypnotics
Lorazepam	Lorazepam 2mg/5ml oral suspension	04010201/15010401	Benzodiazepines/Benzodiazepines (peri-operative)
Clobazam	Clobazam 5mg/5ml oral suspension sugar free (A A H Pharmaceuticals)	04010201/04080100	Benzodiazepines/Control Of Epilepsy
Clonazepam	Clonazepam 10mg/5ml oral solution	4080100	Control Of Epilepsy
GABAergics			
Gabapentin	Gabapentin 100mg capsules	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Pregabalin	Pregabalin 25mg capsules	04030000/04070300/04080100	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy
Pregabalin	Pregabalin 75mg capsules	04030000/04070300/04080100	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy

Gabapentin	Gabapentin 300mg capsules	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 25mg tablets	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 50mg tablets	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 5mg dispersible tablets sugar free	4080100	Control Of Epilepsy
Vigabatrin	Vigabatrin 500mg tablets	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 200mg tablets	4080100	Control Of Epilepsy
Vigabatrin	Vigabatrin 500mg oral powder sachets sugar free	4080100	Control Of Epilepsy
Lamotrigine	Lamictal 25mg tablets (GlaxoSmithKline UK)	4080100	Control Of Epilepsy
Gabapentin	Gabapentin 400mg capsules	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 100mg tablets	4080100	Control Of Epilepsy
Gabapentin	Gabapentin 600mg tablets	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 25mg dispersible tablets sugar free	4080100	Control Of Epilepsy
Lamotrigine	Lamictal 100mg dispersible tablets (GlaxoSmithKline UK)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 100mg dispersible tablets sugar free	4080100	Control Of Epilepsy
Gabapentin	Neurontin 300mg capsules (Pfizer)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 2mg dispersible tablets sugar free	4080100	Control Of Epilepsy
Pregabalin	Lyrica 75mg capsules (Pfizer)	04030000/04070300/04080100/06010500	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy
Pregabalin	Pregabalin 150mg capsules	04030000/04070300/04080100	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy
Pregabalin	Pregabalin 50mg capsules	04030000/04070300/04080100	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy
Pregabalin	Pregabalin 200mg capsules	04030000/04070300/04080100	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy
Pregabalin	Pregabalin 100mg capsules	04030000/04070300/04080100	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy
Pregabalin	Pregabalin 300mg capsules	04030000/04070300/04080100	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamictal 50mg tablets (GlaxoSmithKline UK)	4080100	Control Of Epilepsy
Lamotrigine	Lamictal 100mg tablets (GlaxoSmithKline UK)	4080100	Control Of Epilepsy
Pregabalin	Lyrica 100mg capsules (Pfizer)	04030000/04070300/04080100/06010500	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy
Pregabalin	Lyrica 50mg capsules (Pfizer)	04030000/04070300/04080100/06010500	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy
Pregabalin	Lyrica 200mg capsules (Pfizer)	04030000/04070300/04080100/06010500	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy
Gabapentin	Gabapentin 800mg tablets	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Neurontin 100mg capsules (Pfizer)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamictal 200mg tablets (GlaxoSmithKline UK)	4080100	Control Of Epilepsy
Pregabalin	Lyrica 300mg capsules (Pfizer)	04030000/04070300/04080100/06010500	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy
Vigabatrin	Sabril 500mg tablets (Sanofi)	4080100	Control Of Epilepsy
Lamotrigine	Lamictal 25mg dispersible tablets (GlaxoSmithKline UK)	4080100	Control Of Epilepsy
Lamotrigine	Lamictal 5mg dispersible tablets (GlaxoSmithKline UK)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 50mg dispersible tablets sugar free	4080100	Control Of Epilepsy
Gabapentin	Neurontin 400mg capsules (Pfizer)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy

Pregabalin	Lyrica 150mg capsules (Pfizer)	04030000/04070300/04080100/06010500	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy
Pregabalin	Lyrica 25mg capsules (Pfizer)	04030000/04070300/04080100/06010500	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy
Vigabatrin	Vigabatrin 125mg capsules	4080100	Control Of Epilepsy
Gabapentin	Neurontin 600mg tablets (Pfizer)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Vigabatrin	Sabril 500mg oral powder sachets (Sanofi)	4080100	Control Of Epilepsy
Gabapentin	Gabapentin 250mg/5ml oral solution	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
	TIAGABINE	0	Unknown
Lamotrigine	Lamictal 2mg dispersible tablets (GlaxoSmithKline UK)	4080100	Control Of Epilepsy
Gabapentin	Gabapentin 400mg/5ml oral suspension	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Gabapentin 300mg capsules (Teva UK)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Neurontin 800mg tablets (Pfizer)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 25mg tablets (Actavis UK)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 100mg tablets (Actavis UK)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 25mg tablets (Mylan)	4080100	Control Of Epilepsy
Gabapentin	Gabapentin 100mg capsules (Teva UK)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Gabapentin 100mg capsules (A A H Pharmaceuticals)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Gabapentin 300mg capsules (A A H Pharmaceuticals)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Gabapentin 600mg tablets (Teva UK)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 25mg dispersible tablets sugar free (Arrow Generics)	4080100	Control Of Epilepsy
Pregabalin	Pregabalin 225mg capsules	04030000/04070300/04080100	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy
Pregabalin	Lyrica 225mg capsules (Pfizer)	04030000/04070300/04080100/06010500	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy
Lamotrigine	Lamotrigine 50mg tablets (Actavis UK)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 25mg tablets (Teva UK)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 100mg tablets (Teva UK)	4080100	Control Of Epilepsy
Gabapentin	Gabapentin 250mg/5ml oral suspension	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Gabapentin 600mg tablets (A A H Pharmaceuticals)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Gabapentin 250mg/5ml Oral solution (Boots Pharmaceuticals)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 50mg Suppository	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 50mg tablets (Teva UK)	4080100	Control Of Epilepsy
Gabapentin	Gabapentin 100mg capsules (Sandoz)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 50mg tablets (IVAX Pharmaceuticals UK)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 25mg tablets (Fannin UK)	4080100	Control Of Epilepsy
Gabapentin	Gabapentin 300mg capsules (Mylan)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Gabapentin 300mg capsules (Sandoz)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 25mg dispersible tablets sugar free (A A H Pharmaceuticals)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 25mg tablets (Arrow Generics)	4080100	Control Of Epilepsy

Pregabalin	Lyrica 150mg capsules (Lexon (UK))	04030000/04070300/04080100/06010500	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy
Lamotrigine	Lamotrigine 25mg tablets (Accord Healthcare)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 25mg tablets (A A H Pharmaceuticals)	4080100	Control Of Epilepsy
Gabapentin	Gabapentin 300mg capsules (Ranbaxy (UK))	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
	Pregabalin 20mg/ml oral solution sugar free	04030000/04070300/04080100/06010500	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy
Lamotrigine	Lamictal 25mg tablets (DE Pharmaceuticals)	4080100	Control Of Epilepsy
Lamotrigine	Lamictal 25mg tablets (Lexon (UK))	4080100	Control Of Epilepsy
	Lyrica 20mg/ml oral solution (Pfizer)	04030000/04070300/04080100/06010500	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy
Pregabalin	Lyrica 50mg capsules (Waymade Healthcare Plc)	04030000/04070300/04080100/06010500	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy
Gabapentin	Gabapentin 300mg capsules (Actavis UK)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Gabapentin 300mg/5ml oral solution	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 5mg dispersible tablets sugar free (Actavis UK)	4080100	Control Of Epilepsy
	Gabapentin 50mg/ml oral solution sugar free	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Gabapentin 300mg capsules (Almus Pharmaceuticals)	0	Unknown
Gabapentin	Gabapentin 300mg capsules (Bristol Laboratories)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 25mg tablets (Bristol Laboratories)	4080100	Control Of Epilepsy
	Pregabalin 150mg/5ml oral solution	04030000/04070300/04080100	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 25mg dispersible tablets sugar free (Tillomed Laboratories)	4080100	Control Of Epilepsy
Gabapentin	Gabapentin 100mg capsules (Mylan)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Neurontin 300mg capsules (Dowelhurst)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Gabapentin 300mg capsules (Arrow Generics)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 50mg tablets (Alliance Healthcare (Distribution))	4080100	Control Of Epilepsy
	Gabapentin 600mg/5ml oral solution	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Gabapentin 100mg capsules (Actavis UK)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Gabapentin 400mg capsules (Almus Pharmaceuticals)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Gabapentin 300mg/5ml oral suspension	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Gabapentin 100mg capsules (Zentiva)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 100mg tablets (A A H Pharmaceuticals)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 100mg tablets (Alliance Healthcare (Distribution))	4080100	Control Of Epilepsy
Vigabatrin	Vigabatrin 500mg/5ml oral solution	4080100	Control Of Epilepsy
Gabapentin	Gabapentin 600mg tablets (Zentiva)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
	Gabapentin 400mg/5ml oral solution	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 100mg dispersible tablets sugar free (Teva UK)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 25mg dispersible tablets sugar free (Teva UK)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 50mg tablets (A A H Pharmaceuticals)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 25mg tablets (Alliance Healthcare (Distribution))	4080100	Control Of Epilepsy

Lamotrigine	Lamotrigine 100mg dispersible tablets sugar free (A A H Pharmaceuticals)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 200mg tablets (A A H Pharmaceuticals)	4080100	Control Of Epilepsy
Gabapentin	Gabapentin 300mg capsules (Creo Pharma)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamictal 25mg dispersible tablets (Lexon (UK))	4080100	Control Of Epilepsy
	Pregabalin 75mg/5ml oral solution	04030000/04070300/04080100	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 200mg tablets (Waymade Healthcare Plc)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 50mg/5ml oral suspension	4080100	Control Of Epilepsy
Gabapentin	Gabapentin 300mg capsules (Waymade Healthcare Plc)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Lamotrigine	Lamotrigine 50mg tablets (Accord Healthcare)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 100mg tablets (Accord Healthcare)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 200mg tablets (Accord Healthcare)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 50mg tablets (Sigma Pharmaceuticals Plc)	4080100	Control Of Epilepsy
Pregabalin	Rewisca 75mg capsules (Consilient Health)	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Rewisca 50mg capsules (Consilient Health)	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Rewisca 300mg capsules (Consilient Health)	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Rewisca 150mg capsules (Consilient Health)	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Rewisca 100mg capsules (Consilient Health)	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Rewisca 200mg capsules (Consilient Health)	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Rewisca 25mg capsules (Consilient Health)	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Rewisca 225mg capsules (Consilient Health)	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Gabapentin	Gabapentin 300mg capsules (Zentiva)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Pregabalin	Pregabalin 50mg capsules (A A H Pharmaceuticals)	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Alzain 25mg capsules (Dr Reddy's Laboratories (UK))	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Alzain 100mg capsules (Dr Reddy's Laboratories (UK))	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Lamotrigine	Lamotrigine 25mg dispersible tablets sugar free (Actavis UK)	4080100	Control Of Epilepsy
Pregabalin	Pregabalin 100mg capsules (A A H Pharmaceuticals)	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Alzain 300mg capsules (Dr Reddy's Laboratories (UK))	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Alzain 225mg capsules (Dr Reddy's Laboratories (UK))	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Alzain 150mg capsules (Dr Reddy's Laboratories (UK))	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Alzain 75mg capsules (Dr Reddy's Laboratories (UK))	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Alzain 50mg capsules (Dr Reddy's Laboratories (UK))	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Alzain 200mg capsules (Dr Reddy's Laboratories (UK))	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Gabapentin	Gabapentin 600mg tablets (DE Pharmaceuticals)	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Pregabalin	Pregabalin 150mg/5ml oral suspension	04030000/04070300/04080100	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy
Gabapentin	Gabapentin 300mg capsules (Alliance Healthcare (Distribution))	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Gabapentin	Gabapentin 50mg/ml oral solution sugar free (Alliance Healthcare (Distribution))	04070300/04080100	Neuropathic Pain/Control Of Epilepsy

Pregabalin	Lyrica 75mg capsules (Waymade Healthcare Plc)	04030000/04070300/04080100/06010500	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy
Pregabalin	Lyrica 150mg capsules (Sigma Pharmaceuticals Plc)	04030000/04070300/04080100/06010500	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy
Lamotrigine	Lamotrigine 100mg tablets (Kent Pharmaceuticals)	4080100	Control Of Epilepsy
Gabapentin	Gabapentin 100mg/5ml oral solution	04070300/04080100	Neuropathic Pain/Control Of Epilepsy
Pregabalin	Pregabalin 75mg capsules (Teva UK)	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Pregabalin 25mg capsules (Teva UK)	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Lecaent 50mg capsules (Actavis UK)	04030000/04080100	Antidepressant Drugs/Control Of Epilepsy
Pregabalin	Pregabalin 50mg capsules (Accord Healthcare)	04030000/04070300/04080100	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy
Pregabalin	Pregabalin 50mg capsules (Sandoz)	04030000/04070300/04080100	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy
Pregabalin	Lyrica 75mg capsules (Stephar (U.K.))	04030000/04070300/04080100/06010500	Antidepressant Drugs/Neuropathic Pain/Control Of Epilepsy/Treatment Of Diabetic Nephropathy And Neuropathy
Lamotrigine	Lamictal 50mg tablets (DE Pharmaceuticals)	4080100	Control Of Epilepsy
Lamotrigine	Lamotrigine 5mg/5ml oral solution	4080100	Control Of Epilepsy

Opioids			
Dihydrocodeine tartrate	Dihydrocodeine 30mg tablets	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg capsules	4070200	Opioid Analgesics
Pentazocine Lactate	Fortral 30mg/ml Injection (Sterwin Medicines)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg/5ml linctus	3090100	Cough Suppressants
Codeine phosphate	Codeine 30mg tablets	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Tramadol hydrochloride	Zydol 50mg capsules (Grunenthal)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 10mg/5ml oral solution	4070200	Opioid Analgesics
Codeine phosphate	Codeine 25mg/5ml oral solution	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Pethidine Hydrochloride	Pethidine 25mg tablet	4070200	Opioid Analgesics
Pethidine Hydrochloride	Pethidine 10mg/ml injection	4070200	Opioid Analgesics
Buprenorphine Hydrochloride	Buprenorphine HCl 300micrograms injection	4070200	Opioid Analgesics
Pentazocine hydrochloride	Pentazocine 50mg capsules	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulfate 100mg/50ml solution for infusion vials	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg tablets	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Buprenorphine hydrochloride	Buprenorphine 200microgram sublingual tablets sugar free	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Pethidine Hydrochloride	Pethidine 50mg/ml injection	4070200	Opioid Analgesics
Morphine Sulphate	Morphine 15mg Suppository	4070200	Opioid Analgesics
Codeine phosphate	Codeine 60mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Morphine sulfate	MST Continus 10mg tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 60mg tablets	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Morphine sulfate	MST Continus Suspension 20mg granules sachets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Fentanyl Citrate	Fentanyl 50microgram/ml Injection	04070200/15010403	Opioid Analgesics/Opioid Analgesics (in Anaesthesia)
Fentanyl	Fentanyl 25micrograms/hour transdermal patches	4070200	Opioid Analgesics

Codeine Phosphate	Codeine 30mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg/5ml oral solution unit dose vials sugar free	4070200	Opioid Analgesics
Morphine Sulphate	Morphine 30mg Suppository	4070200	Opioid Analgesics
Tramadol hydrochloride/ Paracetamol	Tramacet 37.5mg/325mg tablets (Grünenthal)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg modified-release capsules	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate 1mg/ml Injection	4070200	Opioid Analgesics
Fentanyl	Durogesic 25micrograms transdermal patches (Janssen-Cilag)	4070200	Opioid Analgesics
Fentanyl	Fentanyl 50micrograms/hour transdermal patches	4070200	Opioid Analgesics
Pethidine hydrochloride	Pethidine 50mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Morphine sulfate	Oramorph 10mg/5ml oral solution (Boehringer Ingelheim)	4070200	Opioid Analgesics
	Migravele tablets (McNeil Products)	04070200/04070401	Opioid Analgesics/Treatment Of Acute Migraine
Bucizine hydrochloride/ Paracetamol/Codeine	Migravele Pink tablets (McNeil Products)	04070200/04070401	Opioid Analgesics/Treatment Of Acute Migraine
Codeine phosphate	Codeine 15mg/5ml linctus sugar free	3090100	Cough Suppressants
Dihydrocodeine tartrate	Dihydrocodeine 60mg modified-release tablets	4070200	Opioid Analgesics
Pentazocine hydrochloride	Pentazocine 25mg tablets	4070200	Opioid Analgesics
Pethidine hydrochloride	Pethidine 50mg tablets	4070200	Opioid Analgesics
Codeine phosphate	Codeine 3mg/5ml linctus paediatric sugar free	3090100	Cough Suppressants
Methadone hydrochloride	Methadone 1mg/ml oral solution	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Morphine sulfate	MST Continus 30mg tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Pethidine Hydrochloride	Pethidine 50mg/ml injection	4070200	Opioid Analgesics
Morphine sulfate	Oramorph sr 10mg Tablet (Boehringer Ingelheim)	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Buprenorphine 400microgram sublingual tablets sugar free	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Diamorphine Hydrochloride	Diamorphine 10mg Injection (Manufacturer unknown)	4070200	Opioid Analgesics
Meptazinol hydrochloride	Meptazinol 200mg tablets	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg soluble tablets sugar free	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Temgesic 200microgram sublingual tablets (RB Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Tramadol hydrochloride	Zydol SR 100mg tablets (Grünenthal)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 50mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Df118 40mg Tablet (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	Sevredol 10mg tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Dextromoramide tartrate	Dextromoramide 5mg tablets	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 100mg modified-release capsules	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 100mg modified-release tablets	4070200	Opioid Analgesics
Dextromoramide tartrate	Palfium 5mg tablets (Roche Products)	4070200	Opioid Analgesics
Morphine sulfate	Morphine 10mg tablets	4070200	Opioid Analgesics
Morphine sulfate	MST Continus 5mg tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics

Codeine phosphate	Galcodine 3mg/5ml Oral solution (Thornton & Ross)	03090100/04070200	Cough Suppressants/Opioid Analgesics
Morphine sulfate	MST Continus Suspension 60mg granules sachets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	MST Continus 60mg tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Fentanyl	Fentanyl 100micrograms/hour transdermal patches	4070200	Opioid Analgesics
Morphine sulfate	Oramorph 10mg/5ml oral solution unit dose vials (Boehringer Ingelheim)	4070200	Opioid Analgesics
Codeine Phosphate	Codeine phosphate 15mg/5ml diabetic oral solution	03090100/04070200	Cough Suppressants/Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 40mg tablets	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 150mg modified-release capsules	4070200	Opioid Analgesics
Tramadol Hydrochloride	Tramadol 24 Modified-release tablet	4070200	Opioid Analgesics
Tramadol Hydrochloride	Tramadol 24 Modified-release tablet	4070200	Opioid Analgesics
Fentanyl	Durogesic 50micrograms transdermal patches (Janssen-Cilag)	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diamorphine hydrochloride 5mg powder for injection solution	4070200	Opioid Analgesics
Hydromorphone hydrochloride	Hydromorphone 2.6mg capsules	4070200	Opioid Analgesics
Hydromorphone hydrochloride	Hydromorphone 1.3mg capsules	4070200	Opioid Analgesics
Tramadol hydrochloride	Zydol SR 200mg tablets (Grünenthal)	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone 2mg/5ml linctus	3090100	Cough Suppressants
Tramadol Hydrochloride	Tramadol 12 Modified-release tablet	4070200	Opioid Analgesics
Methadone hydrochloride	Physeptone 5mg tablets (Martindale Pharmaceuticals)	03090100/04070200/04105200	Cough Suppressants/Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Morphine sulfate	Sevredol 10mg/5ml oral solution (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate 12 20mg Modified-release capsule	4070200	Opioid Analgesics
Codeine phosphate	Galcodine 15mg/5ml linctus (Thornton & Ross)	3090100	Cough Suppressants
Oxycodone hydrochloride	Oxycodone 10mg capsules	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyContin 10mg modified-release tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Fentanyl citrate	Fentanyl 400microgram lozenges	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate 12 50mg Modified-release capsule	4070200	Opioid Analgesics
Fentanyl	Durogesic 75micrograms transdermal patches (Janssen-Cilag)	4070200	Opioid Analgesics
Morphine hydrochloride	Morphine hydrochloride 15mg suppositories	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diamorphine hydrochloride 30mg powder for injection solution	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diamorphine hydrochloride 10mg powder for injection solution	4070200	Opioid Analgesics
Morphine sulfate	Morphine 10mg modified-release tablets	4070200	Opioid Analgesics
Fentanyl citrate	Fentanyl 600microgram lozenges	4070200	Opioid Analgesics
Fentanyl citrate	Fentanyl 800microgram lozenges	4070200	Opioid Analgesics
Morphine sulfate	MST Continus 15mg tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Morphine tartrate/Cyclizine tartrate	Cyclimorph 10 solution for injection 1ml ampoules (AMCo)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg/5ml oral solution	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxycodone 10mg modified-release tablets	4070200	Opioid Analgesics

Buprenorphine	Transtec 35micrograms/hour transdermal patches (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	MST Continus 100mg tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	Morphine 10mg modified-release capsules	4070200	Opioid Analgesics
Buprenorphine	Transtec 52.5micrograms/hour transdermal patches (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Buprenorphine 8mg sublingual tablets sugar free	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Tramadol hydrochloride	Zydol SR 150mg tablets (Grünenthal)	4070200	Opioid Analgesics
Buprenorphine	Transtec 70micrograms/hour transdermal patches (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Subutex 8mg sublingual tablets (RB Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Tramadol hydrochloride	Tramadol 200mg modified-release capsules	4070200	Opioid Analgesics
Morphine sulfate	Sevredol 20mg tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 120mg modified-release tablets	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 20mg/ml oral solution sugar free	4070200	Opioid Analgesics
Fentanyl	Fentanyl 75micrograms/hour transdermal patches	4070200	Opioid Analgesics
Morphine sulfate	Sevredol 50mg tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone Hydrochloride	Oxycodone hydrochloride 10mg/ml injection	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone 5mg tablets	03090100/04070200/04105200	Cough Suppressants/Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Diamorphine Hydrochloride	Diamorphine hydrochloride 500mg powder for injection solution	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diamorphine hydrochloride 100mg powder for injection solution	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Buprenorphine 2mg sublingual tablets sugar free	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Oxycodone hydrochloride	OxyNorm 5mg capsules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol hydrochloride/Paracetamol	Tramadol 37.5mg / Paracetamol 325mg tablets	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxycodone 20mg modified-release tablets	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxycodone 5mg/5ml oral solution sugar free	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxycodone 40mg modified-release tablets	4070200	Opioid Analgesics
Morphine sulfate	Morphine 20mg modified-release granules sachets sugar free	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxycodone 5mg modified-release tablets	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxycodone 5mg capsules	4070200	Opioid Analgesics
Buprenorphine	Buprenorphine 35micrograms/hour transdermal patches	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate 10mg/ml Injection	4070200	Opioid Analgesics
Buprenorphine	Buprenorphine 52.5micrograms/hour transdermal patches	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxycodone 80mg modified-release tablets	4070200	Opioid Analgesics
Fentanyl	Durogesic DTrans 25micrograms transdermal patches (Janssen-Cilag)	4070200	Opioid Analgesics
Fentanyl	Durogesic DTrans 50micrograms transdermal patches (Janssen-Cilag)	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diamorphine 3mg/5ml oral solution	4070200	Opioid Analgesics
Fentanyl	Fentanyl 12micrograms/hour transdermal patches	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyContin 5mg modified-release tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics

Morphine Sulphate	Morphine sulphate 12 30mg Modified-release capsule	4070200	Opioid Analgesics
Buprenorphine	Buprenorphine 10micrograms/hour transdermal patches	4070200	Opioid Analgesics
Buprenorphine	Buprenorphine 20micrograms/hour transdermal patches	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxycodone 20mg capsules	4070200	Opioid Analgesics
Buprenorphine	Buprenorphine 5micrograms/hour transdermal patches	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyNorm 20mg capsules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyContin 20mg modified-release tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Fentanyl	Durogesic DTrans 75micrograms transdermal patches (Janssen-Cilag)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyNorm 10mg/ml concentrate oral solution (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Buprenorphine Hydrochloride	Temgesic 0.3mg/ml Injection (Reckitt Benckiser Healthcare (UK))	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Df118 10mg/5ml Oral solution (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 15mg suppositories	4070200	Opioid Analgesics
Buprenorphine	BuTrans 5micrograms/hour transdermal patches (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Morphine Hydrochloride	Morphine hcl Oral solution (Thornton and Ross)	4070200	Opioid Analgesics
Dextromoramide Tartrate	Palfium 5mg/ml Injection (Roche Products)	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diamorphine 100mg Injection (Manufacturer unknown)	4070200	Opioid Analgesics
Morphine sulfate	Morphine 30mg modified-release tablets	4070200	Opioid Analgesics
Dextromoramide tartrate	Dextromoramide 10mg tablets	0	Unknown
Diamorphine Hydrochloride	Diamorphine 5mg Injection (Manufacturer unknown)	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Temgesic 400microgram sublingual tablets (RB Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Morphine sulfate	MST Continus 200mg tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diamorphine 30mg Injection (Manufacturer unknown)	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate 30mg/ml Injection	4070200	Opioid Analgesics
Pentazocine hydrochloride	Fortral 25mg tablets (Zentiva)	4070200	Opioid Analgesics
Tramadol Hydrochloride	Tramadol 12 Modified-release tablet	4070200	Opioid Analgesics
Meptazinol hydrochloride	Meptid 200mg Tablet (Shire Pharmaceuticals)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	DHC Continus 60mg tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 5mg/5ml Oral solution (Manufacturer unknown)	4070200	Opioid Analgesics
Morphine hydrochloride	Morphine hydrochloride 30mg suppositories	4070200	Opioid Analgesics
Morphine sulfate	Morphine 60mg modified-release tablets	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 10mg Tablet (Manufacturer unknown)	4070200	Opioid Analgesics
Morphine sulfate	Oramorph 20mg/ml concentrated oral solution (Boehringer Ingelheim)	4070200	Opioid Analgesics
Cyclizine hydrochloride/ Diamorphine hydrochloride	Diconal tablets (Amdipharm Plc)	4070200	Opioid Analgesics
Morphine tartrate/Cyclizine tartrate	Cyclimorph 15 solution for injection 1ml ampoules (AMCo)	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diamorphine 500mg Injection (Manufacturer unknown)	4070200	Opioid Analgesics
Morphine sulfate	Morphine 20mg tablets	4070200	Opioid Analgesics

Morphine sulfate	Morphine 100mg modified-release tablets	4070200	Opioid Analgesics
Dihydrocodeine tartrate	DHC Continus 90mg tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	DHC Continus 120mg tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 90mg modified-release tablets	4070200	Opioid Analgesics
Hydromorphone hydrochloride	Hydromorphone 4mg modified-release capsules	4070200	Opioid Analgesics
Hydromorphone hydrochloride	Palladone 2.6mg capsules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Hydromorphone hydrochloride	Palladone SR 4mg capsules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Hydromorphone hydrochloride	Palladone SR 2mg capsules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	MXL 30mg capsules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	MXL 60mg capsules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	MXL 120mg capsules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	MXL 90mg capsules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol hydrochloride	Zamadol SR 50mg capsules (Meda Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol hydrochloride	Zamadol SR 100mg capsules (Meda Pharmaceuticals)	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate 24 60mg Modified-release capsule	4070200	Opioid Analgesics
Morphine sulfate	Morphine 15mg modified-release tablets	4070200	Opioid Analgesics
Morphine sulfate	Morphine 5mg modified-release tablets	4070200	Opioid Analgesics
Hydromorphone hydrochloride	Palladone 1.3mg capsules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	Morphine 100mg modified-release granules sachets sugar free	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone 1mg/ml oral solution sugar free	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Tramadol hydrochloride	Tramadol 100mg effervescent powder sachets sugar free	0	Unknown
Oxycodone hydrochloride	OxyNorm liquid 5mg/5ml oral solution (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyContin 40mg modified-release tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone Hydrochloride	Oxynorm 10mg/ml Solution for injection (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 10mg Tablet (Aurum Pharmaceuticals)	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate 12 60mg Modified-release capsule	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyNorm 10mg capsules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyContin 80mg modified-release tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Subutex 2mg sublingual tablets (RB Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Buprenorphine	BuTrans 10micrograms/hour transdermal patches (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	MXL 150mg capsules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Df118 50mg/ml Injection (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Dextromoramide tartrate	Palfium 10mg tablets (Roche Products)	0	Unknown
Pentazocine Lactate	Pentazocine 30mg/ml injection	4070200	Opioid Analgesics
Morphine Anhydrous	Morphine 10mg/ml Tincture	4070200	Opioid Analgesics
Morphine sulfate	Sevredol 10mg Suppository (Napp Pharmaceuticals)	4070200	Opioid Analgesics

Pentazocine hydrochloride	Fortral 50mg Capsule (Sanofi-Synthelabo)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxycodone hydrochloride 30mg suppositories	0	Unknown
Fentanyl	Durogesic 100micrograms transdermal patches (Janssen-Cilag)	4070200	Opioid Analgesics
Meptazinol hydrochloride	Meptid 100mg/1ml solution for injection ampoules (Almirall)	4070200	Opioid Analgesics
Tramadol hydrochloride	Zydol 50mg soluble tablets (Grünenthal)	4070200	Opioid Analgesics
Papaveretum	Papaveretum 15.4mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Tramadol hydrochloride	Zydol 100mg/2ml solution for injection ampoules (Grünenthal)	4070200	Opioid Analgesics
Morphine sulfate	Oramorph 30mg/5ml oral solution unit dose vials (Boehringer Ingelheim)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxycodone 10mg/ml oral solution sugar free	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 100mg/2ml solution for injection ampoules	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 75mg modified-release tablets	0	Unknown
Tramadol hydrochloride	Tramadol 50mg effervescent powder sachets sugar free	0	Unknown
Buprenorphine	Buprenorphine 70micrograms/hour transdermal patches	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate 24 30mg Modified-release capsule	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone 10mg/ml oral solution sugar free	4105200	Drugs Used In Substance Dependence - Opioid Dependence
Tramadol hydrochloride	Tramadol 50mg orodispersible tablets sugar free	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 300mg modified-release tablets	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 400mg modified-release tablets	4070200	Opioid Analgesics
Morphine sulfate	Morcap SR 20mg capsules (Hospira UK)	0	Unknown
Meptazinol hydrochloride	Meptazinol 100mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Morphine sulfate	Morphine 200mg modified-release tablets	4070200	Opioid Analgesics
Fentanyl citrate	Fentanyl 200microgram lozenges	4070200	Opioid Analgesics
Fentanyl	Durogesic DTrans 12micrograms transdermal patches (Janssen-Cilag)	4070200	Opioid Analgesics
Cyclizine hydrochloride/ Dipipanone hydrochloride	Dipipanone 10mg / Cyclizine 30mg tablets	4070200	Opioid Analgesics
Dextropropoxyphene Napsylate	Dextropropoxyphene 60mg capsules	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 15mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Morphine sulfate	Morphine 60mg modified-release granules sachets sugar free	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg suppositories	4070200	Opioid Analgesics
Morphine sulfate	MST Continus Suspension 100mg granules sachets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Codeine Phosphate/Ibuprofen	Ibuprofen and codeine 200mg + 12.5mg Tablet	04070200/10010100	Opioid Analgesics/Non-steroidal Anti-inflammatory Drugs
Morphine sulfate	Oramorph 100mg/5ml oral solution unit dose vials (Boehringer Ingelheim)	4070200	Opioid Analgesics
Morphine sulfate	MST Continus Suspension 30mg granules sachets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Subutex 0.4mg sublingual tablets (RB Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Fentanyl citrate	Actiq 200microgram lozenges with integral oromucosal applicator (Teva UK)	4070200	Opioid Analgesics
Morphine sulfate	Zomorph 10mg modified-release capsules (ProStrakan)	4070200	Opioid Analgesics
Morphine sulfate	Zomorph 30mg modified-release capsules (ProStrakan)	4070200	Opioid Analgesics

Morphine sulfate	Morphine sulfate 20mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 30mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 60mg/2ml solution for injection ampoules	4070200	Opioid Analgesics
Buprenorphine	BuTrans 20micrograms/hour transdermal patches (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 15mg/5ml Oral solution (Manufacturer unknown)	4070200	Opioid Analgesics
Morphine Sulphate	Morcap sr 20mg Modified-release capsule (Faulding Pharmaceuticals (Dbl))	4070200	Opioid Analgesics
Tramadol hydrochloride	Zamadol 50mg capsules (Meda Pharmaceuticals)	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate 24 200mg Modified-release capsule	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate 100mg Modified-release capsule	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate 12 100mg Modified-release capsule	4070200	Opioid Analgesics
Morphine sulfate	Zomorph 100mg modified-release capsules (ProStrakan)	4070200	Opioid Analgesics
Methadone Hydrochloride	Methadone 10mg/ml Injection	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Morphine sulfate	Morphine sulfate 30mg/5ml oral solution unit dose vials sugar free	4070200	Opioid Analgesics
Morphine sulfate	Morphine 30mg modified-release granules sachets sugar free	4070200	Opioid Analgesics
Phenazocine Hydrobromide	Phenazocine hydrobromide 5mg tablet	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramake 50mg capsules (Galen)	4070200	Opioid Analgesics
Fentanyl	Durogesic DTrans 100micrograms transdermal patches (Janssen-Cilag)	4070200	Opioid Analgesics
Fentanyl citrate	Fentanyl 1.2mg lozenges	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diamorphine 10mg/5ml oral solution	4070200	Opioid Analgesics
Papaveretum	Papaveretum 7.7mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Codeine phosphate	Codeine phosphate powder	50030000	Extemporaneous Item
Morphine Sulphate	Morphine sulphate 24 90mg Modified-release capsule	4070200	Opioid Analgesics
Hydromorphone hydrochloride	Hydromorphone 2mg modified-release capsules	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine hydrochloride powder	4070200	Opioid Analgesics
Hydromorphone hydrochloride	Hydromorphone 8mg modified-release capsules	4070200	Opioid Analgesics
Morphine sulfate	Morphine 50mg tablets	4070200	Opioid Analgesics
Morphine sulfate	Zomorph 200mg modified-release capsules (ProStrakan)	4070200	Opioid Analgesics
Morphine sulfate	Zomorph 60mg modified-release capsules (ProStrakan)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 6.75mg/5ml oral solution	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Morphine Sulphate	Morphine sulphate 10mg/ml Injection	4070200	Opioid Analgesics
Tramadol hydrochloride	Zydol XL 300mg tablets (Grünenthal)	4070200	Opioid Analgesics
Morphine sulfate	Oramorph sr 30mg Tablet (Boehringer Ingelheim)	4070200	Opioid Analgesics
Morphine tartrate/Cyclizine tartrate	Morphine tartrate 10mg/1ml / Cyclizine tartrate 50mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Tramadol hydrochloride	Zydol XL 200mg tablets (Grünenthal)	4070200	Opioid Analgesics
Fentanyl	Tilofyl 75micrograms/hour transdermal patches (Tillomed Laboratories)	4070200	Opioid Analgesics
Nalbuphine Hydrochloride	Nubain 10mg/ml Injection (Bristol-Myers Squibb Pharmaceuticals)	4070200	Opioid Analgesics

Pethidine hydrochloride	Pethidine 100mg/2ml solution for injection ampoules	4070200	Opioid Analgesics
Phenazocine Hydrobromide	Narphen 5mg Tablet (Smith & Nephew Healthcare)	4070200	Opioid Analgesics
Pethidine hydrochloride	Pethidine 50mg Tablet (Roche Products)	4070200	Opioid Analgesics
Morphine tartrate/ Cyclizine tartrate	Morphine tartrate 15mg/1ml / Cyclizine tartrate 50mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone 50mg/1ml solution for injection ampoules	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Dextromoramide Tartrate	Dextromoramide 5mg/ml injection	4070200	Opioid Analgesics
Pentazocine lactate	Pentazocine 50mg suppositories	0	Unknown
Morphine sulfate	Oramorph sr 60mg Tablet (Boehringer Ingelheim)	4070200	Opioid Analgesics
Methadone Hydrochloride	Physeptone 10mg/ml Injection (Martindale Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Morphine sulfate	MXL 200mg capsules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	Sevredol 20mg/ml concentrated oral solution (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate 12 200mg Modified-release capsule	4070200	Opioid Analgesics
Fentanyl citrate	Actiq 400microgram lozenges with integral oromucosal applicator (Teva UK)	4070200	Opioid Analgesics
Morphine anhydrous/ Panormin oil	J Collis Browne's mixture (Thornton & Ross)	01020200/04070200	Other Antispasmodics/Opioid Analgesics
Pethidine hydrochloride/ Promethazine hydrochloride	Pamergan P100 solution for injection 2ml ampoules (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	SRM-RHOTARD 10mg Modified-release tablet (Pharmacia)	4070200	Opioid Analgesics
Morphine sulfate	SRM-RHOTARD 30mg Modified-release tablet (Pharmacia)	4070200	Opioid Analgesics
Morphine sulfate	Oramorph sr 100mg Tablet (Boehringer Ingelheim)	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 10mg tablets	4070200	Opioid Analgesics
Morphine sulfate	Morcap SR 100mg capsules (Hospira UK)	4070200	Opioid Analgesics
Morphine sulfate	Morphgesic SR 10mg tablets (AMCo)	4070200	Opioid Analgesics
Dextropropoxyphene napsylate	Dextropropoxyphene 60mg capsules	0	Unknown
Morphine Sulphate	Morcap sr 50mg Modified-release capsule (Faulding Pharmaceuticals (DbI))	4070200	Opioid Analgesics
Pethidine hydrochloride/ Promethazine hydrochloride	Pethidine 100mg/2ml / Promethazine 50mg/2ml solution for injection ampoules	4070200	Opioid Analgesics
Nalbuphine Hydrochloride	Nalbuphine hc 10mg/ml Injection	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 100mg/5ml oral solution unit dose vials sugar free	4070200	Opioid Analgesics
Codeine Phosphate/Papaverine Hydrochloride/Morphine	Omnopon 10mg Tablet (Roche Products)	4070200	Opioid Analgesics
Morphine sulfate	Morphgesic SR 30mg tablets (AMCo)	4070200	Opioid Analgesics
Morphine sulfate	Morphgesic SR 60mg tablets (AMCo)	4070200	Opioid Analgesics
Morphine sulfate	Morphgesic SR 100mg tablets (AMCo)	4070200	Opioid Analgesics
Codeine Phosphate/ Papaverine Hydrochloride/Morphine	Papaveretum 10mg tablet	4070200	Opioid Analgesics
Hydromorphone hydrochloride	Palladone SR 16mg capsules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Hydromorphone hydrochloride	Hydromorphone 16mg modified-release capsules	4070200	Opioid Analgesics
Tramadol hydrochloride	Dromadol SR 100mg tablets (Teva UK)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg/10ml solution for injection pre-filled syringes	4070200	Opioid Analgesics
Levorphanol Tartrate	Dromoran roche 1.5mg Tablet (Roche Products)	4070200	Opioid Analgesics

Tramadol hydrochloride	Zamadol Melt 50mg tablets (Meda Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 30mg suppositories	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 20mg suppositories	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramake Insts 50mg sachets (Galen)	0	Unknown
Hydromorphone hydrochloride	Palladone SR 8mg capsules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Hydromorphone hydrochloride	Palladone SR 24mg capsules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol hydrochloride	Zydol XL 400mg tablets (Grunenthal)	4070200	Opioid Analgesics
Methadone hydrochloride	Physeptone 1mg/ml mixture sugar free (Martindale Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Tramadol hydrochloride	Dromadol SR 200mg tablets (Teva UK)	4070200	Opioid Analgesics
Tramadol hydrochloride	Zamadol SR 200mg capsules (Meda Pharmaceuticals)	4070200	Opioid Analgesics
Cocaine/Diamorphine Hydrochloride	Diamorphine hydrochloride and cocaine oral solution	4070200	Opioid Analgesics
Tramadol hydrochloride	Zydol XL 150mg tablets (Grunenthal)	4070200	Opioid Analgesics
Morphine sulfate	Rhotard Morphine SR 10mg tablets (Sovereign Medical)	4070200	Opioid Analgesics
Morphine sulfate	Rhotard Morphine SR 30mg tablets (Sovereign Medical)	4070200	Opioid Analgesics
Fentanyl	Tilofyl 50micrograms/hour transdermal patches (Tillomed Laboratories)	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate 24 120mg Modified-release capsule	4070200	Opioid Analgesics
Morphine sulfate	Filnarine SR 30mg tablets (Teva UK)	4070200	Opioid Analgesics
Morphine sulfate	MST Continus Suspension 200mg granules sachets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone 20mg/ml oral solution sugar free	4105200	Drugs Used In Substance Dependence - Opioid Dependence
Dextromoramide Tartrate	Palfium 10mg Suppository (Roche Products)	4070200	Opioid Analgesics
Pethidine hydrochloride	Pethidine 50mg/5ml solution for injection ampoules	4070200	Opioid Analgesics
Tramadol hydrochloride	Dromadol SR 150mg tablets (Teva UK)	4070200	Opioid Analgesics
Alfentanil hydrochloride	Alfentanil 5mg/1ml solution for injection ampoules	15010403	Opioid Analgesics (in Anaesthesia)
Codeine phosphate	Codeine 15mg/5ml linctus (Thornton & Ross)	3090100	Cough Suppressants
Tramadol hydrochloride	Zamadol SR 150mg capsules (Meda Pharmaceuticals)	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diagesil 10mg Injection (Berk Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg/5ml linctus (A A H Pharmaceuticals)	3090100	Cough Suppressants
Codeine phosphate	Codeine 15mg/5ml Oral solution (Approved Prescription Services)	03090100/04070200	Cough Suppressants/Opioid Analgesics
Methadone hydrochloride	Methadose 10mg/ml oral solution concentrate (Rosemont Pharmaceuticals)	4105200	Drugs Used In Substance Dependence - Opioid Dependence
Methadone hydrochloride	Methadose 20mg/ml oral solution concentrate (Rosemont Pharmaceuticals)	4105200	Drugs Used In Substance Dependence - Opioid Dependence
Tramadol hydrochloride	Tramake Insts 100mg sachets (Galen)	0	Unknown
Methadone hydrochloride	Methodex 1mg/ml Mixture (Link Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Morphine Sulphate	Morcap sr 100mg Modified-release capsule (Faulding Pharmaceuticals (Dbl))	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone 50mg/2ml solution for injection ampoules	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Diamorphine Hydrochloride	Diaphine 100mg Injection (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Hydromorphone hydrochloride	Hydromorphone 24mg modified-release capsules	4070200	Opioid Analgesics

Alfentanil Hydrochloride	Alfentanil 500micrograms/ml injection	15010403	Opioid Analgesics (in Anaesthesia)
Morphine Sulphate	Morphine sulphate 20mg/ml Injection	4070200	Opioid Analgesics
Pethidine Hydrochloride/levallorphan	Pethidine with levallorphan tartrate injection	4070200	Opioid Analgesics
Fentanyl citrate	Fentanyl 1.6mg lozenges	4070200	Opioid Analgesics
Fentanyl Citrate	Sublimaze 50microgram/ml Injection (Janssen-Cilag)	04070200/15010403	Opioid Analgesics/Opioid Analgesics (in Anaesthesia)
Fentanyl citrate	Actiq 600microgram lozenges with integral oromucosal applicator (Teva UK)	4070200	Opioid Analgesics
Morphine Anhydrous	Nepenthe 8.4mg/ml Injection (Celltech Pharma Europe)	4070200	Opioid Analgesics
Codeine Phosphate	Codeine phosphate with other ingredient pastilles	3090100	Cough Suppressants
Dextromoramide Tartrate	Palfium 10mg/ml Injection (Roche Products)	4070200	Opioid Analgesics
Pentazocine lactate	Fortral 50mg suppositories (Sterwin Medicines)	0	Unknown
Dextropropoxyphene napsylate	Doloxene 60mg Capsule (Eli Lilly and Company)	4070200	Opioid Analgesics
Fentanyl citrate	Actiq 1.6mg lozenges with integral oromucosal applicator (Teva UK)	4070200	Opioid Analgesics
Methadone hydrochloride	Physeptone 1mg/ml mixture (Martindale Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Morphine sulfate	Filnarine SR 10mg tablets (Teva UK)	4070200	Opioid Analgesics
Morphine sulfate	Filnarine SR 100mg tablets (Teva UK)	4070200	Opioid Analgesics
Tramadol hydrochloride	Dromadol XL 300mg tablets (IVAX Pharmaceuticals UK)	4070200	Opioid Analgesics
Fentanyl citrate	Actiq 800microgram lozenges with integral oromucosal applicator (Teva UK)	4070200	Opioid Analgesics
Tramadol hydrochloride	Zamadol 24hr 200mg modified-release tablets (Meda Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	Filnarine SR 60mg tablets (Teva UK)	4070200	Opioid Analgesics
	OXYCODONE	0	Unknown
Tramadol hydrochloride	Zamadol 24hr 150mg modified-release tablets (Meda Pharmaceuticals)	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate 24 150mg Modified-release capsule	4070200	Opioid Analgesics
Fentanyl	Tilofyl 100micrograms/hour transdermal patches (Tillomed Laboratories)	4070200	Opioid Analgesics
Methadone hydrochloride	Metharose 1mg/ml oral solution sugar free (Rosemont Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Morphine Sulphate	Moraxen 35mg Rectal tampon (Schwarz Pharma)	4070200	Opioid Analgesics
Alfentanil Hydrochloride	Rapifen 100microgram/ml Paediatric injection (Janssen-Cilag)	15010403	Opioid Analgesics (in Anaesthesia)
Diamorphine Hydrochloride	Diamorphine hydrochloride bpc 1973 3mg/5ml oral solution	4070200	Opioid Analgesics
Tramadol hydrochloride	Zamadol 24hr 300mg modified-release tablets (Meda Pharmaceuticals)	4070200	Opioid Analgesics
Dextromoramide Tartrate	Dextromoramide 10mg suppository	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diaphine 10mg Injection (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	Morphine 200mg modified-release granules sachets sugar free	4070200	Opioid Analgesics
Methadone hydrochloride	Physeptone 10mg/1ml solution for injection ampoules (Martindale Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Tramadol hydrochloride	Dromadol SR 75mg tablets (IVAX Pharmaceuticals UK)	0	Unknown
Pethidine Hydrochloride	Pethidine 50mg/ml Injection (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 5mg/5ml oral solution	4070200	Opioid Analgesics
Fentanyl citrate	Actiq 1.2mg lozenges with integral oromucosal applicator (Teva UK)	4070200	Opioid Analgesics

Methadone hydrochloride	Methadone 2mg/5ml Oral solution (Martindale Pharmaceuticals)	3090100	Cough Suppressants
Tramadol hydrochloride	Tramadol 50mg capsules (IVAX Pharmaceuticals UK)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate powder	04070200/50030000	Opioid Analgesics/Extemporaneous Item
Methadone hydrochloride	Methadone 2mg/5ml linctus (Thornton & Ross)	3090100	Cough Suppressants
Morphine Sulphate	Morphine sulphate rapiject 1mg/ml Injection (International Medication Systems (UK))	4070200	Opioid Analgesics
Morphine Anhydrous	Morphine 8.4mg/ml elixir	4070200	Opioid Analgesics
Pethidine Hydrochloride	Pethidine powder	50000000	Ingredients
Diamorphine Hydrochloride	Diaphine 30mg Injection (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone 1mg/ml oral solution sugar free (Rosemont Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Levorphanol Tartrate	Levorphanol 1.5mg Tablet	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diagesil 500mg Injection (Berk Pharmaceuticals)	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diamorphine 10mg/5ml Oral solution (Manufacturer unknown)	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diamorphine hydrochloride 3mg/5ml oral solution	4070200	Opioid Analgesics
Fentanyl	Tilofyl 25micrograms/hour transdermal patches (Tillomed Laboratories)	4070200	Opioid Analgesics
Tramadol hydrochloride	Dromadol XL 200mg tablets (IVAX Pharmaceuticals UK)	4070200	Opioid Analgesics
Tramadol hydrochloride	Dromadol XL 150mg tablets (IVAX Pharmaceuticals UK)	4070200	Opioid Analgesics
Pethidine Hydrochloride	Pethidine 50mg/ml Injection (Auden McKenzie (Pharma Division))	4070200	Opioid Analgesics
Codeine phosphate	Codeine 30mg tablets (Wockhardt UK)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Pentazocine lactate	Pentazocine 30mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Pentazocine lactate	Pentazocine 60mg/2ml solution for injection ampoules	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulfate 30mg/30ml solution for infusion vials	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg tablets (Actavis UK)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Tramadol hydrochloride	Dromadol XL 400mg tablets (IVAX Pharmaceuticals UK)	4070200	Opioid Analgesics
Pethidine hydrochloride	Pethidine 100mg/10ml solution for injection ampoules	4070200	Opioid Analgesics
Pethidine hydrochloride	Pethidine 50mg Tablet (Roche Products)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 30mg tablets (IVAX Pharmaceuticals UK)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 15mg/5ml oral solution	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg Capsule (Generics (UK))	4070200	Opioid Analgesics
Methadone hydrochloride	Methex 1mg/ml Mixture (Generics (UK))	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Alfentanil hydrochloride	Rapifen 5mg/ml Concentrate for solution for infusion (Janssen-Cilag)	15010403	Opioid Analgesics (in Anaesthesia)
Oxycodone hydrochloride	OxyNorm 10mg/1ml solution for injection ampoules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 3mg/5ml linctus paediatric (Thornton & Ross)	0	Unknown
Tramadol hydrochloride	Zamadol 24hr 400mg modified-release tablets (Meda Pharmaceuticals)	4070200	Opioid Analgesics
Morphine anhydrous	Opium tincture	0	Unknown
Diamorphine Hydrochloride	Diagesil 5mg Injection (Berk Pharmaceuticals)	4070200	Opioid Analgesics
Pethidine Hydrochloride	Pethidine 100mg/2ml Injection (Roche Products)	4070200	Opioid Analgesics

Diamorphine hydrochloride	Diamorphine 5mg powder for solution for injection ampoules (Novartis)	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone 10mg/1ml solution for injection ampoules	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Methadone Hydrochloride	Methadone 35mg/ml Injection	4105200	Drugs Used In Substance Dependence - Opioid Dependence
Codeine phosphate	Codeine 15mg/5ml linctus sugar free (A A H Pharmaceuticals)	3090100	Cough Suppressants
Dihydrocodeine tartrate	Dihydrocodeine 30mg tablets (Wockhardt UK)	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone 1mg/ml oral solution (Martindale Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Pethidine Hydrochloride/ Promethazine Hydrochloride	Promethazine hydrochloride 50mg with pethidine 100mg/2ml injection	03040102/04070200	Sedating Antihistamines/Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 30mg tablets (IVAX Pharmaceuticals UK)	4070200	Opioid Analgesics
Tramadol Hydrochloride	Tramadol sr 150mg Modified-release tablet (Winthrop Pharmaceuticals)	4070200	Opioid Analgesics
Ethylmorphine hydrochloride	Collins 1.5mg/5ml elixir (Collins Elixir Co)	03090100/04070200	Cough Suppressants/Opioid Analgesics
Codeine phosphate	Codeine Oral solution (Berk Pharmaceuticals)	03090100/04070200	Cough Suppressants/Opioid Analgesics
Codeine phosphate	Codeine 15mg/5ml linctus sugar free (Pinewood Healthcare)	3090100	Cough Suppressants
Codeine phosphate	Codeine 15mg/5ml Oral solution (Celltech Pharma Europe)	03090100/04070200	Cough Suppressants/Opioid Analgesics
Codeine phosphate	Codeine 15mg/5ml linctus sugar free (Thornton & Ross)	3090100	Cough Suppressants
Codeine phosphate	Codeine 15mg/5ml Oral solution (William Ransom)	03090100/04070200	Cough Suppressants/Opioid Analgesics
Codeine phosphate	Codeine 15mg/5ml Oral solution (Rusco)	03090100/04070200	Cough Suppressants/Opioid Analgesics
Tramadol hydrochloride	Tramadol sr 100mg Modified-release tablet (Winthrop Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol Hydrochloride	Tramadol sr 200mg Modified-release tablet (Winthrop Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg tablets (A A H Pharmaceuticals)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Codeine phosphate	Codeine Oral solution (Co-operative)	03090100/04070200	Cough Suppressants/Opioid Analgesics
Codeine phosphate	Codeine 30mg tablets (A A H Pharmaceuticals)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg capsules (Actavis UK)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg/5ml Oral solution (Nucare Plc)	03090100/04070200	Cough Suppressants/Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 30mg tablets (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg tablets (Wockhardt UK)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg/5ml oral solution (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diamorphine hydrochloride 10mg Injection (Hillcross Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg capsules (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 30mg tablets (Actavis UK)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg capsules (Teva UK)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 30mg tablets (Actavis UK)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg capsules (Genus Pharmaceuticals)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 30mg tablets (Mylan)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 30mg Tablet (Berk Pharmaceuticals)	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate 30mg/ml Injection (Celltech Pharma Europe)	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 10mg powder for solution for injection ampoules (Novartis)	4070200	Opioid Analgesics

Diamorphine hydrochloride	Diamorphine 30mg powder for solution for injection ampoules (Novartis)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 30mg tablets (Kent Pharmaceuticals)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg capsules (PLIVA Pharma)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyNorm 20mg/2ml solution for injection ampoules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxycodone 20mg/2ml solution for injection ampoules	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulfate 50mg/50ml solution for infusion vials	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Temgesic 300micrograms/1ml solution for injection ampoules (RB Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Fentanyl citrate	Fentanyl 100micrograms/2ml solution for injection ampoules	04070200/15010403	Opioid Analgesics/Opioid Analgesics (in Anaesthesia)
Oxycodone hydrochloride	Oxycodone 10mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Tramadol Hydrochloride	Tramadol 24 Modified-release tablet	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramquel SR 100mg capsules (Beechmere Pharmaceuticals)	4070200	Opioid Analgesics
Alfentanil hydrochloride	Alfentanil 1mg/2ml solution for injection ampoules	15010403	Opioid Analgesics (in Anaesthesia)
Methadone hydrochloride	Methadone 20mg/2ml solution for injection ampoules	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Tramadol hydrochloride	Tradorec XL 200mg tablets (Paladin Labs Europe)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tradorec XL 100mg tablets (Paladin Labs Europe)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 25mg/5ml oral solution (Thornton & Ross)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Tramadol hydrochloride	Larapam SR 100mg tablets (Sandoz)	4070200	Opioid Analgesics
Fentanyl citrate	Fentanyl 500micrograms/10ml solution for injection ampoules	04070200/15010403	Opioid Analgesics/Opioid Analgesics (in Anaesthesia)
Fentanyl	Matrifen 25micrograms/hour transdermal patches (Teva UK)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tradorec XL 300mg tablets (Paladin Labs Europe)	4070200	Opioid Analgesics
Fentanyl	Matrifen 100micrograms/hour transdermal patches (Teva UK)	4070200	Opioid Analgesics
Alfentanil hydrochloride	Alfentanil 5mg/10ml solution for injection ampoules	15010403	Opioid Analgesics (in Anaesthesia)
Fentanyl	Matrifen 50micrograms/hour transdermal patches (Teva UK)	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone 50mg/5ml solution for injection ampoules	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Tramadol hydrochloride	Mabron 200mg modified-release tablets (Morningside Healthcare)	4070200	Opioid Analgesics
Tramadol Hydrochloride	Tramadol 50mg modified-release tablets	4070200	Opioid Analgesics
Tramadol hydrochloride	Zydol SR 50mg tablets (Grünenthal)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramquel SR 50mg capsules (Beechmere Pharmaceuticals)	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone 5mg/ml oral solution	0	Unknown
Tramadol hydrochloride	Tramadol 150mg modified-release tablets	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 200mg modified-release tablets	4070200	Opioid Analgesics
Alfentanil hydrochloride	Alfentanil 0.1% nasal spray	4070200	Opioid Analgesics
Methadone hydrochloride	Physeptone 50mg/1ml solution for injection ampoules (Martindale Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Methadone hydrochloride	Physeptone 50mg/1ml solution for injection ampoules (Martindale Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Methadone hydrochloride	Methadone 35mg/3.5ml solution for injection ampoules	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Pethidine hydrochloride	Pethidine 50mg/1ml solution for injection ampoules (AMCo)	4070200	Opioid Analgesics

Fentanyl	Fentalis Reservoir 100micrograms/hour transdermal patches (Sandoz)	4070200	Opioid Analgesics
Fentanyl	Fentalis Reservoir 25micrograms/hour transdermal patches (Sandoz)	4070200	Opioid Analgesics
Tramadol hydrochloride	Mabron 100mg modified-release tablets (Morningside Healthcare)	4070200	Opioid Analgesics
Tramadol Hydrochloride	Tramadol (roi) Tablet	4070200	Opioid Analgesics
Fentanyl	Fentalis Reservoir 50micrograms/hour transdermal patches (Sandoz)	4070200	Opioid Analgesics
Fentanyl	Matrifen 12micrograms/hour transdermal patches (Teva UK)	4070200	Opioid Analgesics
Fentanyl	Mezolar Matrix 12micrograms/hour transdermal patches (Sandoz)	4070200	Opioid Analgesics
Fentanyl	Osmach 50micrograms/hour transdermal patches (Teva UK)	4070200	Opioid Analgesics
Fentanyl	Fentanyl 40micrograms/dose transdermal system	4070200	Opioid Analgesics
Pethidine hydrochloride	Pethidine 50mg capsules	4070200	Opioid Analgesics
Fentanyl	Mezolar Matrix 25micrograms/hour transdermal patches (Sandoz)	4070200	Opioid Analgesics
Pentazocine Lactate	Pentazocine 30mg/ml Injection (Sterwin Medicines)	4070200	Opioid Analgesics
Pethidine Hydrochloride	Pethidine 25mg Tablet (Roche Products)	4070200	Opioid Analgesics
Remifentanyl hydrochloride	Remifentanyl 1mg powder for solution for injection vials	15010403	Opioid Analgesics (in Anaesthesia)
Tramadol hydrochloride	Larapam SR 200mg tablets (Sandoz)	4070200	Opioid Analgesics
Buprenorphine Hydrochloride/ Naloxone Hydrochloride	Naloxone hc 2mg + 8mg Tablet	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Fentanyl	Mezolar Matrix 75micrograms/hour transdermal patches (Sandoz)	4070200	Opioid Analgesics
Fentanyl	Matrifen 75micrograms/hour transdermal patches (Teva UK)	4070200	Opioid Analgesics
Fentanyl	Fentalis Reservoir 75micrograms/hour transdermal patches (Sandoz)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 30mg tablets (Teva UK)	4070200	Opioid Analgesics
Alfentanil hydrochloride	Rapifen 1mg/2ml solution for injection ampoules (Janssen-Cilag)	15010403	Opioid Analgesics (in Anaesthesia)
Tramadol hydrochloride	Tramadol 50mg Capsule (Tillomed Laboratories)	4070200	Opioid Analgesics
Fentanyl	Mezolar Matrix 100micrograms/hour transdermal patches (Sandoz)	4070200	Opioid Analgesics
Tramadol hydrochloride	Zamadol 100mg/2ml solution for injection ampoules (Meda Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramquel SR 200mg capsules (Beechmere Pharmaceuticals)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	DF 118 Forte 40mg tablets (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Galcodine 3mg/5ml linctus paediatric (Thornton & Ross)	3090100	Cough Suppressants
Fentanyl	Osmach 100micrograms/hour transdermal patches (Ratiopharm UK)	4070200	Opioid Analgesics
Fentanyl	Mezolar Matrix 50micrograms/hour transdermal patches (Sandoz)	4070200	Opioid Analgesics
Fentanyl	Osmach 25micrograms/hour transdermal patches (Teva UK)	4070200	Opioid Analgesics
Dextromoramide tartrate	Palfium 5mg Tablet (IDIS World Medicines)	4070200	Opioid Analgesics
Methadone hydrochloride	Eptadone 1mg/ml oral solution (Dee Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Ibuprofen/Codeine phosphate	Solpadeine Migraine Ibuprofen & Codeine tablets (Omega Pharma)	04070200/10010100	Opioid Analgesics/Non-steroidal Anti-inflammatory Drugs
Fentanyl citrate	Fentanyl 100microgram sublingual tablets sugar free	4070200	Opioid Analgesics
Naloxone Hydrochloride/ oxycodone Hydrochloride	Oxycodone 10mg / Naloxone 5mg modified-release tablets	4070200	Opioid Analgesics

Naloxone Hydrochloride/ oxycodone Hydrochloride	Targinact 10mg/5mg modified-release tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Naloxone hydrochloride/ Oxycodone hydrochloride	Targinact 20mg/10mg modified-release tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Naloxone hydrochloride /Oxycodone hydrochloride	Oxycodone 20mg / Naloxone 10mg modified-release tablets	4070200	Opioid Analgesics
Tramadol hydrochloride	Marol 100mg modified-release tablets (Morningside Healthcare)	4070200	Opioid Analgesics
Fentanyl citrate	Abstral 100microgram sublingual tablets (ProStrakan)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 30mg tablets (Zentiva)	4070200	Opioid Analgesics
Fentanyl citrate	Fentanyl 200microgram sublingual tablets sugar free	4070200	Opioid Analgesics
Tramadol hydrochloride	Marol 200mg modified-release tablets (Morningside Healthcare)	4070200	Opioid Analgesics
Fentanyl Citrate	Fentanyl 100microgram buccal tablets sugar free	4070200	Opioid Analgesics
Fentanyl citrate	Effentora 100microgram buccal tablets (Teva UK)	4070200	Opioid Analgesics
Tramadol hydrochloride	Marol 150mg modified-release tablets (Morningside Healthcare)	4070200	Opioid Analgesics
Fentanyl citrate	Abstral 200microgram sublingual tablets (ProStrakan)	4070200	Opioid Analgesics
Tramadol hydrochloride	Nobligan retard 100mg tablets (Grunenthal)	4070200	Opioid Analgesics
Fentanyl citrate	Abstral 800microgram sublingual tablets (ProStrakan)	4070200	Opioid Analgesics
Tramadol hydrochloride	Maxitram SR 200mg capsules (Chiesi)	4070200	Opioid Analgesics
Meptazinol hydrochloride	Meptid 200mg tablets (Almirall)	4070200	Opioid Analgesics
Fentanyl citrate	Effentora 200microgram buccal tablets (Teva UK)	4070200	Opioid Analgesics
Fentanyl citrate	Abstral 400microgram sublingual tablets (ProStrakan)	4070200	Opioid Analgesics
Fentanyl citrate	Fentanyl 200microgram buccal tablets sugar free	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramulief SR 100mg tablets (AMCo)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramulief SR 200mg tablets (AMCo)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramulief SR 150mg tablets (AMCo)	4070200	Opioid Analgesics
Fentanyl Citrate	Fentanyl 400microgram sublingual tablets sugar free	4070200	Opioid Analgesics
Fentanyl Citrate	Effentora 400microgram buccal tablets (Teva UK)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 10mg/5ml oral solution (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg capsules (Niche Generics)	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Buprenorphine 2mg sublingual tablets sugar free (Teva UK)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Buprenorphine hydrochloride	Buprenorphine 8mg sublingual tablets sugar free (Teva UK)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Pethidine hydrochloride	Pethidine 50mg tablets (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol hydrochloride	Maxitram SR 100mg capsules (Chiesi)	4070200	Opioid Analgesics
Tramadol hydrochloride	Maxitram SR 50mg capsules (Chiesi)	4070200	Opioid Analgesics
Alfentanil Hydrochloride	Rapifen 500microgram/ml Injection (Janssen-Cilag)	15010403	Opioid Analgesics (In Anaesthesia)
Fentanyl citrate	Effentora 600microgram buccal tablets (Teva UK)	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Buprenorphine 300micrograms/1ml solution for injection ampoules	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence

Fentanyl citrate	Abstral 600microgram sublingual tablets (ProStrakan)	4070200	Opioid Analgesics
Morphine sulfate	Morphine 30mg modified-release capsules	4070200	Opioid Analgesics
Fentanyl Citrate	Fentanyl 400microgram buccal tablets sugar free	4070200	Opioid Analgesics
Naloxone Hydrochloride/ Oxycodone Hydrochloride	Oxycodone 5mg / Naloxone 2.5mg modified-release tablets	4070200	Opioid Analgesics
Naloxone Hydrochloride/ Oxycodone Hydrochloride	Targinact 5mg/2.5mg modified-release tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone Hydrochloride	Oxycodone 50mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg capsules (Almus Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyNorm 50mg/1ml solution for injection ampoules (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride/ Naloxone hydrochloride/ Tramadol hydrochloride	Oxycodone 40mg / Naloxone 20mg modified-release tablets	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramquel SR 150mg capsules (Beechmere Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol hydrochloride	Maxitram SR 150mg capsules (Chiesi)	4070200	Opioid Analgesics
Tramadol hydrochloride	Larapam SR 150mg tablets (Sandoz)	4070200	Opioid Analgesics
Fentanyl Citrate	Fentanyl 300microgram sublingual tablets sugar free	4070200	Opioid Analgesics
Fentanyl citrate	Effentora 800microgram buccal tablets (Teva UK)	4070200	Opioid Analgesics
Oxycodone hydrochloride/ Naloxone hydrochloride/ Fentanyl citrate	Targinact 40mg/20mg modified-release tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Fentanyl	Fentanyl 50micrograms/dose nasal spray	4070200	Opioid Analgesics
Fentanyl	Osmach 75micrograms/hour transdermal patches (Teva UK)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg/5ml Oral solution (Thornton & Ross)	03090100/04070200	Cough Suppressants/Opioid Analgesics
Fentanyl Citrate	Abstral 300microgram sublingual tablets (ProStrakan)	4070200	Opioid Analgesics
Fentanyl Citrate	Fentanyl 600microgram sublingual tablets sugar free	4070200	Opioid Analgesics
Codeine phosphate	Codeine 60mg tablets (Wockhardt UK)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Codeine phosphate	Codeine Oral solution (Family Health)	03090100/04070200	Cough Suppressants/Opioid Analgesics
Codeine phosphate	Codeine 30mg tablets (Teva UK)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Pethidine Hydrochloride	Pethidine 100mg/2ml Injection (C P Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg tablets (Teva UK)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Methadone hydrochloride	Methadone 1mg/ml oral solution (Rosemont Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Morphine hydrochloride	Morphine hcl 15mg Suppository (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulphate 10mg Suppository (Aurum Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulphate 15mg Suppository (Celltech Pharma Europe)	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone 1mg/ml Mixture (Macarthy Medical)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Methadone hydrochloride	Methadone 1mg/ml Mixture (Macarthy Medical)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Diamorphine hydrochloride	Diamorphine 30mg powder for solution for injection ampoules (Wockhardt UK)	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 30mg powder for solution for injection ampoules (Wockhardt UK)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg/1ml solution for injection ampoules (Martindale)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 100mg modified-release tablets (A H H Pharmaceuticals)	4070200	Opioid Analgesics
Fentanyl	Victanyl 100micrograms/hour transdermal patches (Actavis UK)	4070200	Opioid Analgesics

Buprenorphine Hydrochloride/ Naloxone Hydrochloride	Naloxone hc 500micrograms + 2mg Tablet	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Pentazocine lactate	Fortral 30mg/1ml solution for injection ampoules (Zentiva)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Df118 30mg Tablet (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol hydrochloride/ Paracetamol	Tramadol 37.5mg / Paracetamol 325mg effervescent tablets sugar free	4070200	Opioid Analgesics
Tramadol hydrochloride/ Paracetamol	Tramacet 37.5mg/325mg effervescent tablets (Grunenthal)	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate 10mg Modified-release capsule	4070200	Opioid Analgesics
Fentanyl citrate	Fentanyl 800microgram sublingual tablets sugar free	4070200	Opioid Analgesics
Fentanyl citrate	Fentanyl 600microgram buccal tablets sugar free	4070200	Opioid Analgesics
Fentanyl	Victanyl 75micrograms/hour transdermal patches (Actavis UK)	4070200	Opioid Analgesics
Fentanyl	Osmanil 75micrograms/hour transdermal patches (Zentiva)	4070200	Opioid Analgesics
Fentanyl	Osmanil 25micrograms/hour transdermal patches (Zentiva)	4070200	Opioid Analgesics
Pethidine Hydrochloride	Pethidine 50mg/ml intramuscular injection (Roche Products)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg/5ml Oral solution (Actavis UK)	03090100/04070200	Cough Suppressants/Opioid Analgesics
Tramadol hydrochloride	Tramadol 150mg modified-release tablets (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 10mg powder for solution for injection ampoules (Wockhardt UK)	4070200	Opioid Analgesics
Fentanyl Citrate	Instanyl 100micrograms/dose nasal spray (Takeda UK)	4070200	Opioid Analgesics
Fentanyl	Osmanil 50micrograms/hour transdermal patches (Zentiva)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol sr 50mg Capsule (Hillcross Pharmaceuticals)	4070200	Opioid Analgesics
Methadone Hydrochloride	Methadone Oral solution	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg/1ml suspension for injection vials	4070200	Opioid Analgesics
Alfentanil hydrochloride	Rapifen Intensive Care 5mg/1ml solution for injection ampoules (Janssen-Cilag)	15010403	Opioid Analgesics (in Anaesthesia)
Codeine phosphate	Codeine phosphate Oral solution (William Ransom)	01040200/04070200	Antimotility Drugs/Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg capsules (Zentiva)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg tablets (Ranbaxy (UK))	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Fentanyl Citrate	Instanyl 200micrograms/dose nasal spray (Takeda UK)	4070200	Opioid Analgesics
Morphine sulfate	Morphine 100mg modified-release capsules	4070200	Opioid Analgesics
Morphine sulfate	Morphine 200mg modified-release capsules	4070200	Opioid Analgesics
Alfentanil hydrochloride	Rapifen 5mg/10ml solution for injection ampoules (Janssen-Cilag)	15010403	Opioid Analgesics (in Anaesthesia)
Methadone hydrochloride	Eptadone 5mg/ml oral solution (Dee Pharmaceuticals)	0	Unknown
Fentanyl citrate	Sublimaze 500micrograms/10ml solution for injection ampoules (Janssen-Cilag)	04070200/15010403	Opioid Analgesics/Opioid Analgesics (in Anaesthesia)
Fentanyl citrate	Sublimaze 500micrograms/10ml solution for injection ampoules (Janssen-Cilag)	04070200/15010403	Opioid Analgesics/Opioid Analgesics (in Anaesthesia)
Tramadol hydrochloride	Mabron 150mg modified-release tablets (Morningside Healthcare)	4070200	Opioid Analgesics
Fentanyl	Osmanil 12micrograms/hour transdermal patches (Zentiva)	4070200	Opioid Analgesics
Fentanyl	Victanyl 50micrograms/hour transdermal patches (Actavis UK)	4070200	Opioid Analgesics
Pentazocine lactate	Fortral 60mg/2ml solution for injection ampoules (Zentiva)	4070200	Opioid Analgesics
Fentanyl Citrate	Fentanyl 200micrograms/dose nasal spray	4070200	Opioid Analgesics

Pethidine Hydrochloride	Pethidine injection	4070200	Opioid Analgesics
Fentanyl Citrate	PecFent 100micrograms/dose nasal spray (ProStrakan)	4070200	Opioid Analgesics
Fentanyl	Osmanil 100micrograms/hour transdermal patches (Zentiva)	4070200	Opioid Analgesics
Fentanyl	Victanyl 25micrograms/hour transdermal patches (Actavis UK)	4070200	Opioid Analgesics
Fentanyl citrate	Instanyl 50micrograms/dose nasal spray (Takeda UK)	4070200	Opioid Analgesics
Morphine sulfate	Morphine 60mg modified-release capsules	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyContin 30mg modified-release tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyContin 60mg modified-release tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyContin 15mg modified-release tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxycodone 15mg modified-release tablets	4070200	Opioid Analgesics
Tapentadol hydrochloride	Tapentadol 200mg modified-release tablets	4070200	Opioid Analgesics
Tapentadol hydrochloride	Tapentadol 50mg tablets	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxycodone 30mg modified-release tablets	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyContin 120mg modified-release tablets (Napp Pharmaceuticals)	4070200	Opioid Analgesics
Fentanyl Citrate	Fentanyl 100micrograms/dose nasal spray	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxycodone 60mg modified-release tablets	4070200	Opioid Analgesics
Tapentadol hydrochloride	Palexia 50mg tablets (Grünenthal)	4070200	Opioid Analgesics
Tapentadol hydrochloride	Palexia SR 50mg tablets (Grünenthal)	4070200	Opioid Analgesics
Tapentadol Hydrochloride	Tapentadol 100mg modified-release tablets	4070200	Opioid Analgesics
Tapentadol Hydrochloride	Tapentadol 150mg modified-release tablets	4070200	Opioid Analgesics
Tapentadol Hydrochloride	Palexia SR 100mg tablets (Grünenthal)	4070200	Opioid Analgesics
Tapentadol Hydrochloride	Tapentadol 50mg modified-release tablets	4070200	Opioid Analgesics
Tapentadol hydrochloride	Palexia 75mg tablets (Grünenthal)	4070200	Opioid Analgesics
Tapentadol Hydrochloride	Palexia SR 150mg tablets (Grünenthal)	4070200	Opioid Analgesics
Oxycodone Hydrochloride	Oxycodone 120mg modified-release tablets	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 200mg modified-release capsules (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Fentanyl citrate	PecFent 400micrograms/dose nasal spray (ProStrakan)	4070200	Opioid Analgesics
Tapentadol hydrochloride	Tapentadol 75mg tablets	4070200	Opioid Analgesics
Fentanyl citrate	Fentanyl 800microgram buccal tablets sugar free	4070200	Opioid Analgesics
Fentanyl	Fencino 12micrograms/hour transdermal patches (DB Ashbourne)	4070200	Opioid Analgesics
Fentanyl	Fencino 50micrograms/hour transdermal patches (DB Ashbourne)	4070200	Opioid Analgesics
Methadone hydrochloride	Physeptone 20mg/2ml solution for injection ampoules (Martindale Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Tramadol Hydrochloride	Tramadol 100mg/ml oral drops	4070200	Opioid Analgesics
Tramadol hydrochloride	Zeridame SR 150mg tablets (Actavis UK)	4070200	Opioid Analgesics
Fentanyl	Fencino 75micrograms/hour transdermal patches (DB Ashbourne)	4070200	Opioid Analgesics
Fentanyl	Fencino 100micrograms/hour transdermal patches (DB Ashbourne)	4070200	Opioid Analgesics

Tapentadol hydrochloride	Palexia SR 200mg tablets (Grünenthal)	4070200	Opioid Analgesics
Fentanyl	Fencino 25micrograms/hour transdermal patches (DB Ashbourne)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 60mg tablets (Ranbaxy (UK))	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Papaveretum	Omnopon 15.4mg/ml Injection (Roche Products)	4070200	Opioid Analgesics
Morphine sulfate	Filnarine SR 200mg tablets (Teva UK)	4070200	Opioid Analgesics
Tapentadol Hydrochloride	Tapentadol 250mg modified-release tablets	4070200	Opioid Analgesics
Fentanyl	Fentanyl 75micrograms/hr Transdermal patch (Sandoz)	4070200	Opioid Analgesics
Tapentadol hydrochloride	Palexia SR 250mg tablets (Grünenthal)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg/10ml solution for injection Minijet pre-filled syringes (UCB)	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diamorphine hydrochloride 10mg Injection (Approved Prescription Services)	4070200	Opioid Analgesics
Diamorphine Hydrochloride	Diamorphine hydrochloride 30mg Injection (Hillcross Pharmaceuticals)	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone 1mg/ml oral solution sugar free (Martindale Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Morphine sulfate	Morphine 90mg modified-release capsules	4070200	Opioid Analgesics
Fentanyl Citrate	Fentanyl 400micrograms/dose nasal spray	4070200	Opioid Analgesics
Tramadol Hydrochloride	Tramadol (roi) Tablet	4070200	Opioid Analgesics
Morphine sulfate	Morphine 150mg modified-release capsules	4070200	Opioid Analgesics
Codeine phosphate	Codeine phosphate 15mg Tablet (Wockhardt UK)	01040200/04070200	Antimotility Drugs/Opioid Analgesics
Morphine sulfate	Morphine 120mg modified-release capsules	4070200	Opioid Analgesics
Codeine phosphate	Codeine phosphate 30mg Tablet (Wockhardt UK)	01040200/04070200	Antimotility Drugs/Opioid Analgesics
Morphine sulfate	M-eslon 10mg Capsule (Trinity Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 30mg tablets (Ranbaxy (UK))	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Codeine Phosphate	Codeine phosphate oral solution	01040200/03090100	Antimotility Drugs/Cough Suppressants
Tramadol hydrochloride	Tramadol 200mg modified-release tablets (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Pethidine hydrochloride	Pethidine 100mg/2ml solution for injection ampoules (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 30mg tablets (Almus Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg tablets (Almus Pharmaceuticals)	0	Unknown
Pethidine hydrochloride	Pethidine 100mg/2ml solution for injection ampoules (Actavis UK)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 60mg tablets (Actavis UK)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 5mg powder for solution for injection vials (Teva UK)	4070200	Opioid Analgesics
Fentanyl citrate	Fentanyl 100micrograms/2ml solution for injection ampoules (Martindale Pharma)	04070200/15010403	Opioid Analgesics/Opioid Analgesics (in Anaesthesia)
Diamorphine hydrochloride	Diamorphine 5mg powder for solution for injection ampoules	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 5mg powder for solution for injection vials	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 10mg powder for solution for injection ampoules	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 30mg powder for solution for injection ampoules	4070200	Opioid Analgesics
Fentanyl	Durogesic DTrans 50micrograms transdermal patches (Waymade Healthcare Plc)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg/1ml solution for injection ampoules	4070200	Opioid Analgesics

Diamorphine hydrochloride	Diamorphine 10mg powder for solution for injection vials	4070200	Opioid Analgesics
Diamorphine	Diamorphine 30mg powder for solution for injection vials	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 100mg powder for solution for injection ampoules	4070200	Opioid Analgesics
Diamorphine	Diamorphine 100mg powder for solution for injection vials	4070200	Opioid Analgesics
Codeine phosphate	Codeine 3mg/5ml linctus paediatric	0	Unknown
Tramadol hydrochloride	Marol 150mg modified-release tablets (Teva UK)	4070200	Opioid Analgesics
Tramadol hydrochloride	Marol 100mg modified-release tablets (Teva UK)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyContin 5mg modified-release tablets (DE Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyContin 20mg modified-release tablets (Lexon (UK))	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyNorm 20mg/2ml solution for injection ampoules (Waymade Healthcare Plc)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyNorm 5mg capsules (Lexon (UK))	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg/1ml solution for injection ampoules (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyNorm 5mg capsules (DE Pharmaceuticals)	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Subutex 2mg sublingual tablets (Lexon (UK))	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Codeine phosphate	Codeine phosphate 15mg Tablet (Celltech Pharma Europe)	01040200/04070200	Antimotility Drugs/Opioid Analgesics
Codeine phosphate	Codeine 15mg tablets (Alliance Healthcare (Distribution))	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg/1ml solution for injection ampoules (UCB Pharma)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 30mg tablets (Bristol Laboratories)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 60mg tablets (A A H Pharmaceuticals)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Fentanyl	Fentanyl 12micrograms/hour transdermal patches (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyNorm 10mg/1ml solution for injection ampoules (Waymade Healthcare Plc)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyContin 10mg modified-release tablets (Mawdsley-Brooks & Company)	4070200	Opioid Analgesics
Tramadol hydrochloride	Marol 200mg modified-release tablets (Teva UK)	4070200	Opioid Analgesics
Fentanyl	Durogesic DTrans 12micrograms transdermal patches (Mawdsley-Brooks & Company)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 100mg modified-release capsules (Alliance Healthcare (Distribution))	4070200	Opioid Analgesics
Fentanyl	Fentanyl 25micrograms/hour transdermal patches (Phoenix Healthcare Distribution)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 30mg tablets (Alliance Healthcare (Distribution))	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Oxycodone hydrochloride	OxyNorm 20mg capsules (DE Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyNorm 10mg/1ml solution for injection ampoules (Mawdsley-Brooks & Company)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 30mg tablets (Bristol Laboratories)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Oxycodone hydrochloride	OxyNorm 10mg capsules (Waymade Healthcare Plc)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyContin 80mg modified-release tablets (Mawdsley-Brooks & Company)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg tablets (Bristol Laboratories)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Fentanyl citrate	Fentanyl 100micrograms/2ml solution for injection ampoules (AMCo)	04070200/15010403	Opioid Analgesics/Opioid Analgesics (in Anaesthesia)
Oxycodone hydrochloride	Longtec 5mg modified-release tablets (Qdem Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Longtec 10mg modified-release tablets (Qdem Pharmaceuticals)	4070200	Opioid Analgesics

Oxycodone hydrochloride	Longtec 40mg modified-release tablets (Qdem Pharmaceuticals)	4070200	Opioid Analgesics
Pethidine hydrochloride	Pethidine 100mg/10ml solution for injection ampoules (Alliance Healthcare)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg capsules (Bristol Laboratories)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyNorm 10mg capsules (DE Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg capsules (Accord Healthcare)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyContin 10mg modified-release tablets (Lexon (UK))	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg tablets (Kent Pharmaceuticals)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Codeine phosphate	Codeine 25mg/5ml oral solution (A A H Pharmaceuticals)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Codeine phosphate	Codeine 15mg tablets (Sigma Pharmaceuticals Plc)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Tramadol hydrochloride	Tramadol 100mg modified-release capsules (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Hydromorphone hydrochloride	Hydromorphone 10mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 5mg/5ml solution for injection ampoules	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyContin 10mg modified-release tablets (DE Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Longtec 20mg modified-release tablets (Qdem Pharmaceuticals)	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 10mg powder for solution for injection vials (Teva UK)	4070200	Opioid Analgesics
Morphine hydrochloride	Morphine hydrochloride 10mg/5ml oral solution (Special Order)	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 10mg powder for solution for injection ampoules (Actavis UK)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 60mg tablets (Alliance Healthcare (Distribution))	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Ibuprofen/Codeine phosphate	Ibuprofen and codeine 200mg+12.8mg Tablet (Almus Pharmaceuticals)	04070200/10010100	Opioid Analgesics/Non-steroidal Anti-inflammatory Drugs
Morphine sulfate	Morphine 10mg modified-release tablets (Sigma Pharmaceuticals Plc)	4070200	Opioid Analgesics
Pethidine Hydrochloride	Pethidine oral liquid	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg/1ml solution for injection ampoules (Hameln Pharmaceuticals)	4070200	Opioid Analgesics
Pethidine hydrochloride	Pethidine 50mg/1ml solution for injection ampoules (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Codeine phosphate 60mg Tablet (Wockhardt UK)	01040200/04070200	Antimotility Drugs/Opioid Analgesics
Morphine Sulphate	Morphine sulphate Capsule	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg modified-release capsules (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Pethidine Hydrochloride	Pethidine capsule	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 30mg tablets (Kent Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 30mg suppositories (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate Oral solution	4070200	Opioid Analgesics
Oxycodone hydrochloride	Longtec 80mg modified-release tablets (Qdem Pharmaceuticals)	4070200	Opioid Analgesics
Pethidine hydrochloride	Pethidine 50mg tablets (Actavis UK)	4070200	Opioid Analgesics
Buprenorphine	Transtec 52.5micrograms/hour transdermal patches (DE Pharmaceuticals)	4070200	Opioid Analgesics
Fentanyl	Fentanyl 50micrograms/hour transdermal patches (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	Morcap SR 50mg capsules (Hospira UK)	0	Unknown
Morphine sulfate	Morphine 20mg modified-release capsules	0	Unknown

Diamorphine hydrochloride	Diamorphine 500mg powder for solution for injection ampoules	4070200	Opioid Analgesics
Nalbuphine hydrochloride	Nubain 10mg/1ml solution for injection ampoules (Bristol-Myers Squibb Pharmaceuticals)	0	Unknown
Codeine phosphate	Codeine 15mg tablets (Phoenix Healthcare Distribution)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Morphine sulfate	Morphine sulfate 50mg/50ml solution for infusion vials (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Dihydrocodeine Tartrate	Dihydrocodeine 10mg tablets	03090100/04070200	Cough Suppressants/Opioid Analgesics
Diamorphine	Diamorphine 500mg powder for solution for injection vials	4070200	Opioid Analgesics
Fentanyl	Fentanyl 100micrograms/hour transdermal patches (Phoenix Healthcare Distribution)	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone 1mg/ml oral solution sugar free (Thornton & Ross)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Morphine sulfate	Morphine sulphate 15mg/ml Injection (Celltech Pharma Europe)	4070200	Opioid Analgesics
Pethidine Hydrochloride	Pethidine 50mg/ml Injection (Roche Products)	4070200	Opioid Analgesics
Pethidine Hydrochloride	Pethidine 10mg/ml Injection (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Pethidine hydrochloride	Pethidine 50mg Capsule (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 60mg/1ml solution for injection ampoules (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Morphine Sulphate	Morphine sulphate Injection	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg/2ml solution for injection ampoules	4070200	Opioid Analgesics
Tramadol hydrochloride	Zamadol SR 200mg capsules (Lexon (UK))	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 50mg/50ml solution for infusion vials (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 30mg tablets (Phoenix Healthcare Distribution)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Alfentanil Hydrochloride	Alfentanil 5mg/5ml buccal spray	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxylan 10mg modified-release tablets (Chanelle Medical UK)	4070200	Opioid Analgesics
Fentanyl	Fentanyl 25micrograms/hour transdermal patches (Sigma Pharmaceuticals Plc)	4070200	Opioid Analgesics
Buprenorphine	BuTrans 5micrograms/hour transdermal patches (Waymade Healthcare Plc)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg/5ml oral solution (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg tablets (Almus Pharmaceuticals)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Pethidine hydrochloride	Pethidine 50mg tablets (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxylan 10mg modified-release tablets (Actavis UK)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxylan 20mg modified-release tablets (Actavis UK)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 60mg tablets (Teva UK)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Buprenorphine hydrochloride	Prefibin 8mg sublingual tablets (Sandoz)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Codeine phosphate	Codeine 30mg tablets (Waymade Healthcare Plc)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Morphine sulfate	Morphine sulfate 15mg/1ml solution for injection ampoules (UCB Pharma)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 15mg/1ml solution for injection ampoules (Wockhardt UK)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 10mg/5ml oral solution	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Oxycodone hydrochloride	Oxycodone 5mg/5ml oral solution	4070200	Opioid Analgesics
Oxycodone hydrochloride	Lynlor 20mg capsules (Actavis UK)	4070200	Opioid Analgesics
Tramadol hydrochloride	Zeridame SR 100mg tablets (Actavis UK)	4070200	Opioid Analgesics

Codeine phosphate	Codeine 15mg/5ml linctus sugar free (DE Pharmaceuticals)	3090100	Cough Suppressants
Pethidine hydrochloride	Pethidine 50mg/5ml solution for injection ampoules (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Lynlor 5mg capsules (Actavis UK)	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Buprenorphine 2mg sublingual tablets sugar free (A A H Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Diamorphine hydrochloride	Diamorphine 10mg tablets (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg suppositories (Martindale Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg modified-release capsules (DE Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxylan 20mg modified-release tablets (Chanelle Medical UK)	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 3mg/5ml oral solution	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 1mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Pethidine hydrochloride	Pethidine 50mg tablets (Alliance Healthcare (Distribution))	4070200	Opioid Analgesics
Buprenorphine	BuTrans 10micrograms/hour transdermal patches (Waymade Healthcare Plc)	4070200	Opioid Analgesics
	Generic Migravele tablets	04070200/04070401	Opioid Analgesics/Treatment Of Acute Migraine
Methadone sulfate	Morphine sulfate 5mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Oxycodone hydrochloride	Lynlor 10mg capsules (Actavis UK)	4070200	Opioid Analgesics
Morphine hydrochloride	Morphine hydrochloride 10mg/5ml oral solution	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg/5ml linctus sugar free (Kent Pharmaceuticals)	3090100	Cough Suppressants
Fentanyl citrate	Fentanyl 400microgram buccal films sugar free	4070200	Opioid Analgesics
	BuTrans 20micrograms/hour transdermal patches (Waymade Healthcare Plc)	4070200	Opioid Analgesics
Methadone	Methadone 100mg capsules	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Buprenorphine	Hapoctasin 70micrograms/hour transdermal patches (Actavis UK)	4070200	Opioid Analgesics
Fentanyl	Fentanyl 200microgram buccal films sugar free	4070200	Opioid Analgesics
Buprenorphine	Hapoctasin 52.5micrograms/hour transdermal patches (Actavis UK)	4070200	Opioid Analgesics
Fentanyl	Fentanyl 37.5microgram/hour transdermal patches	4070200	Opioid Analgesics
Fentanyl	Mezolar Matrix 37.5microgram/hour transdermal patches (Sandoz)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg/5ml oral solution (Alliance Healthcare (Distribution))	4070200	Opioid Analgesics
Buprenorphine	Transtec 35micrograms/hour transdermal patches (Mawdsley-Brooks & Company)	4070200	Opioid Analgesics
Fentanyl citrate	Fentanyl 100micrograms/2ml solution for injection ampoules (A A H Pharmaceuticals)	04070200/15010403	Opioid Analgesics/Opioid Analgesics (in Anaesthesia)
Oxycodone hydrochloride	Shortec 10mg capsules (Qdem Pharmaceuticals)	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Buprenorphine 2mg sublingual tablets sugar free (Actavis UK)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Dihydrocodeine tartrate	Dihydrocodeine 30mg tablets (Waymade Healthcare Plc)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 30mg tablets (Ranbaxy (UK))	4070200	Opioid Analgesics
Bucilzine hydrochloride/ Paracetamol/Codeine	Generic Migravele Pink tablets	04070200/04070401	Opioid Analgesics/Treatment Of Acute Migraine
Buprenorphine hydrochloride	Tephine 200microgram sublingual tablets (Sandoz)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Alfentanil hydrochloride	Alfentanil 500micrograms/1ml solution for injection ampoules	04070200/15010403	Opioid Analgesics/Opioid Analgesics (in Anaesthesia)
Morphine sulfate	Morphine sulfate 5mg/10ml solution for injection ampoules	4070200	Opioid Analgesics

Tramadol hydrochloride	Tramadol 50mg modified-release capsules (Waymade Healthcare Plc)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Shortec 5mg capsules (Qdem Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Shortec 20mg capsules (Qdem Pharmaceuticals)	4070200	Opioid Analgesics
Buprenorphine	Hapoctasin 35micrograms/hour transdermal patches (Actavis UK)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxylan 40mg modified-release tablets (Chanelle Medical UK)	4070200	Opioid Analgesics
Remifentanyl hydrochloride	Remifentanil 5mg powder for solution for injection vials	15010403	Opioid Analgesics (in Anaesthesia)
Fentanyl	Fentanyl 25micrograms/hour transdermal patches (A A H Pharmaceuticals)	4070200	Opioid Analgesics
	Codeine 30mg suppositories	4070200	Opioid Analgesics
	Morphine 0.1% in Intrasite gel	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 500micrograms/5ml oral solution	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg tablets (Waymade Healthcare Plc)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 5mg powder for solution for injection ampoules (Actavis UK)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tilodol SR 200mg tablets (Sandoz)	4070200	Opioid Analgesics
	Tapentadol 20mg/ml oral solution sugar free	4070200	Opioid Analgesics
Fentanyl	Fentanyl 25micrograms/hour transdermal patches (Waymade Healthcare Plc)	4070200	Opioid Analgesics
Buprenorphine	Transtec 35micrograms/hour transdermal patches (Sigma Pharmaceuticals Plc)	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone 5mg capsules	03090100/04070200/04105200	Cough Suppressants/Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Morphine sulfate	Morphine sulfate 5mg/5ml oral solution	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg tablets (DE Pharmaceuticals)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Codeine phosphate	Codeine 15mg/5ml linctus (Waymade Healthcare Plc)	3090100	Cough Suppressants
	Opiodur 12micrograms/hour transdermal patches (Pfizer)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 60mg tablets (Waymade Healthcare Plc)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Buprenorphine hydrochloride	Tephine 400microgram sublingual tablets (Sandoz)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Fentanyl	Fentanyl 12micrograms/hour transdermal patches (Waymade Healthcare Plc)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 50mg/50ml solution for infusion vials (Alliance Healthcare Distribution)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg capsules (Phoenix Healthcare Distribution)	4070200	Opioid Analgesics
Fentanyl	Mylafent 75micrograms/hour transdermal patches (Mylan)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 30mg/1ml solution for injection ampoules (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	Morphine 30mg modified-release tablets (Sigma Pharmaceuticals Plc)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg/1ml solution for injection ampoules (Wockhardt UK)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 50mg/50ml solution for infusion vials (Torbay Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg capsules (Morningside Healthcare)	4070200	Opioid Analgesics
	Recivit 267microgram sublingual tablets (Grünenthal)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 100mg/50ml solution for infusion vials (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Tapentadol hydrochloride	Palexia 20mg/ml oral solution (Grünenthal)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg capsules (Sigma Pharmaceuticals Plc)	4070200	Opioid Analgesics

Oxycodone hydrochloride	Reltebon 40mg modified-release tablets (Actavis UK)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Reltebon 20mg modified-release tablets (Actavis UK)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 20mg/2ml solution for injection ampoules	4070200	Opioid Analgesics
Oxycodone hydrochloride	Reltebon 10mg modified-release tablets (Actavis UK)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Reltebon 5mg modified-release tablets (Actavis UK)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 2.5mg/5ml solution for injection ampoules	4070200	Opioid Analgesics
Codeine phosphate	Codeine 30mg tablets (DE Pharmaceuticals)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Oxycodone hydrochloride	Reltebon 80mg modified-release tablets (Actavis UK)	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Buprenorphine 200microgram sublingual tablets sugar free (A A H Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Morphine hydrochloride	Morphine hydrochloride 1mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Methadone hydrochloride	Methadone hydrochloride powder	50030000	Extemporaneous Item
Buprenorphine hydrochloride	Buprenorphine 4mg sublingual tablets sugar free	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Tramadol hydrochloride/Paracetamol	Tramacet 37.5mg/325mg tablets (Waymade Healthcare Plc)	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Buprenorphine 6mg sublingual tablets sugar free	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Buprenorphine hydrochloride	Buprenorphine 8mg sublingual tablets sugar free (Zentiva)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Tramadol hydrochloride	Tramadol 100mg modified-release capsules (Waymade Healthcare Plc)	4070200	Opioid Analgesics
Fentanyl	Fentanyl 12micrograms/hour transdermal patches (Phoenix Healthcare Distribution)	4070200	Opioid Analgesics
Pethidine hydrochloride	Pethidine 50mg/1ml solution for injection ampoules (Alliance Healthcare Distribution)	4070200	Opioid Analgesics
Oxycodone hydrochloride	OxyContin 40mg modified-release tablets (DE Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Reltebon 30mg modified-release tablets (Actavis UK)	4070200	Opioid Analgesics
Fentanyl	Fentanyl 133microgram sublingual tablets sugar free	4070200	Opioid Analgesics
Fentanyl citrate	Fentanyl 2.5mg/50ml solution for infusion vials	04070200/15010403	Opioid Analgesics/Opioid Analgesics (In Anaesthesia)
Morphine sulfate	Morphine sulfate 10mg/1ml solution for injection ampoules (DE Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 1mg suppositories	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 10mg/5ml oral solution (Actavis UK)	4070200	Opioid Analgesics
Codeine phosphate	Codeine phosphate powder (Martindale Pharmaceuticals)	50030000	Extemporaneous Item
Buprenorphine hydrochloride	Subutex 2mg sublingual tablets (DE Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Oxycodone hydrochloride	Reltebon 60mg modified-release tablets (Actavis UK)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg modified-release capsules (J M McGill)	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 10mg/5ml oral solution (Waymade Healthcare Plc)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 15mg tablets (Crescent Pharma)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Oxycodone hydrochloride	Oxylan 5mg modified-release tablets (Chanelle Medical UK)	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Buprenorphine 400microgram sublingual tablets sugar free (Teva UK)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Oxycodone hydrochloride	Reltebon 15mg modified-release tablets (Actavis UK)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Longtec 30mg modified-release tablets (Qdem Pharmaceuticals)	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 2mg/5ml oral solution	4070200	Opioid Analgesics

Oxycodone hydrochloride	Longtec 15mg modified-release tablets (Qdem Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol	Tramadol 37.5mg / Paracetamol 325mg tablets (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 100mg modified-release capsules (Ennogen Healthcare)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Longtec 60mg modified-release tablets (Qdem Pharmaceuticals)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 100mg modified-release capsules (Icarus Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 60mg/1ml solution for injection ampoules (Alliance Healthcare (Distribution))	4070200	Opioid Analgesics
Codeine phosphate	Codeine 30mg tablets (Sigma Pharmaceuticals Plc)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Morphine sulfate	Morphine sulfate 50mg/1ml solution for injection ampoules	4070200	Opioid Analgesics
Morphine sulfate	Morphine sulfate 50mg/5ml solution for injection ampoules	4070200	Opioid Analgesics
	Longtec 120mg modified-release tablets (Qdem Pharmaceuticals)	4070200	Opioid Analgesics
Buprenorphine hydrochloride	Gabup 8mg sublingual tablets (Martindale Pharmaceuticals)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
Morphine sulfate	Morphine sulfate 10mg/10ml solution for injection ampoules	4070200	Opioid Analgesics
Tramadol hydrochloride	Maneo 100mg modified-release tablets (Mylan)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Oxycodone 5mg/5ml oral solution sugar free (Wockhardt UK)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 30mg tablets (Crescent Pharma)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Buprenorphine hydrochloride	Buprenorphine 2mg sublingual tablets sugar free (Sigma Pharmaceuticals Plc)	04070200/04105200	Opioid Analgesics/Drugs Used In Substance Dependence - Opioid Dependence
	Mylafent 12micrograms/hour transdermal patches (Mylan)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 30mg tablets (Mawdsley-Brooks & Company)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg capsules (Kent Pharmaceuticals)	4070200	Opioid Analgesics
Codeine phosphate	Codeine 60mg tablets (DE Pharmaceuticals)	01040200/03090100/04070200	Antimotility Drugs/Cough Suppressants/Opioid Analgesics
Fentanyl	Mylafent 50micrograms/hour transdermal patches (Mylan)	4070200	Opioid Analgesics
Diamorphine hydrochloride	Diamorphine 5mg powder for solution for injection ampoules (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Abtard 30mg modified-release tablets (DB Ashbourne)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Abtard 20mg modified-release tablets (DB Ashbourne)	4070200	Opioid Analgesics
Fentanyl	Fentanyl 100micrograms/hour transdermal patches (A A H Pharmaceuticals)	4070200	Opioid Analgesics
Fentanyl	Fentanyl 267microgram sublingual tablets sugar free	4070200	Opioid Analgesics
Dihydrocodeine tartrate	Dihydrocodeine 30mg/5ml oral solution	4070200	Opioid Analgesics
Oxycodone hydrochloride	Abtard 40mg modified-release tablets (DB Ashbourne)	4070200	Opioid Analgesics
Oxycodone hydrochloride	Abtard 80mg modified-release tablets (DB Ashbourne)	4070200	Opioid Analgesics
Tramadol hydrochloride	Tramadol 50mg modified-release capsules (Cubic Pharmaceuticals)	4070200	Opioid Analgesics
Z-drugs			
Zopiclone	Zopiclone 7.5mg tablets	4010100	Hypnotics
Zopiclone	Zopiclone 3.75mg tablets	4010100	Hypnotics
Zolpidem tartrate	Zolpidem 5mg tablets	4010100	Hypnotics
Zolpidem tartrate	Stilnoct 5mg tablets (Sanofi)	4010100	Hypnotics
Zopiclone	Zimovane 7.5mg tablets (Sanofi)	4010100	Hypnotics

Zolpidem tartrate	Stilnoct 10mg tablets (Sanofi)	4010100	Hypnotics
Zopiclone	Zimovane LS 3.75mg tablets (Sanofi)	4010100	Hypnotics
Zopiclone	Zileze 3.75 tablets (Opus Pharmaceuticals)	4010100	Hypnotics
Zaleplon	Sonata 10mg capsules (Meda Pharmaceuticals)	4010100	Hypnotics
Zaleplon	Zaleplon 10mg capsules	4010100	Hypnotics
Zolpidem tartrate	Zolpidem 10mg tablets	4010100	Hypnotics
Zaleplon	Zaleplon 5mg capsules	4010100	Hypnotics
Zaleplon	Sonata 5mg capsules (Meda Pharmaceuticals)	4010100	Hypnotics
Zopiclone	Zopiclone 3.75mg/5ml oral suspension	4010100	Hypnotics
Zopiclone	Zileze 7.5 tablets (Opus Pharmaceuticals)	4010100	Hypnotics
Zopiclone	Zopiclone 7.5mg tablets (Actavis UK)	4010100	Hypnotics
Zopiclone	Zopiclone 3.75mg tablets (Actavis UK)	4010100	Hypnotics
Zolpidem tartrate	Zolpidem 5mg Tablet (Winthrop Pharmaceuticals)	4010100	Hypnotics
Zopiclone	Zopiclone 3.75mg tablets (IVAX Pharmaceuticals UK)	4010100	Hypnotics
Zopiclone	Zopiclone 3.75mg tablets (Mylan)	4010100	Hypnotics
Zolpidem tartrate	Zolpidem 10mg tablets (A A H Pharmaceuticals)	4010100	Hypnotics
Zolpidem tartrate	Zolpidem 5mg tablets (A A H Pharmaceuticals)	4010100	Hypnotics
Zopiclone	Zopiclone 7.5mg tablets (IVAX Pharmaceuticals UK)	4010100	Hypnotics
Zopiclone	Zopiclone 7.5mg tablets (Mylan)	4010100	Hypnotics
Zolpidem tartrate	Zolpidem 10mg tablets (Mylan)	4010100	Hypnotics
Zopiclone	Zopiclone 7.5mg tablets (PLIVA Pharma)	4010100	Hypnotics
Zopiclone	Zopiclone 3.75mg tablets (A A H Pharmaceuticals)	4010100	Hypnotics
Zopiclone	Zopiclone 3.75mg tablets (Teva UK)	4010100	Hypnotics
Zopiclone	Zopiclone 7.5mg tablets (Teva UK)	4010100	Hypnotics
Zopiclone	Zopiclone 7.5mg tablets (Kent Pharmaceuticals)	4010100	Hypnotics
Zopiclone	Zopiclone 3.75mg tablets (Kent Pharmaceuticals)	4010100	Hypnotics
Zolpidem tartrate	Zolpidem 10mg tablets (IVAX Pharmaceuticals UK)	4010100	Hypnotics
Zolpidem tartrate	Zolpidem 5mg tablets (Teva UK)	4010100	Hypnotics
Zolpidem tartrate	Zolpidem 5mg tablets (IVAX Pharmaceuticals UK)	4010100	Hypnotics
Zolpidem tartrate	Zolpidem 10mg Tablet (Winthrop Pharmaceuticals)	4010100	Hypnotics
Zopiclone	Zopiclone 7.5mg tablets (A A H Pharmaceuticals)	4010100	Hypnotics
Zolpidem tartrate	Zolpidem 10mg tablets (Teva UK)	4010100	Hypnotics
Zopiclone	Zopiclone 7.5mg tablets (Sandoz)	4010100	Hypnotics
Zopiclone	Zopiclone 3.75mg/5ml oral solution	4010100	Hypnotics
Zopiclone	Zimovane 7.5mg tablets (Lexon (UK))	4010100	Hypnotics
Zopiclone	Zopiclone 3.75mg tablets (Almus Pharmaceuticals)	4010100	Hypnotics

Zopiclone	Zopiclone 7.5mg/5ml oral suspension	4010100	Hypnotics
Zopiclone	Zopiclone 7.5mg/5ml oral solution	4010100	Hypnotics
Zopiclone	Zopiclone 7.5mg tablets (Sigma Pharmaceuticals Plc)	4010100	Hypnotics
Zolpidem tartrate	Zolpidem 10mg tablets (Zentiva)	4010100	Hypnotics
Zopiclone	Zopiclone 7.5mg tablets (Phoenix Healthcare Distribution)	4010100	Hypnotics